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ABSTRACT 
Pharmacokinetic variability is an important consideration in pharmacotherapy to 
ensure safety and efficacy of medications, thus the understanding of the sources of 
variability in drug concentrations in the body is imperative.  The goals of this 
dissertation were: (1) To use in vitro drug metabolism tools to characterize the 
influence of non-alcoholic fatty liver disease (NAFLD) on Cytochrome P450 2B6 
(CYP2B6)-mediated hydroxylation of bupropion in human liver microsomes; and (2) 
To use population pharmacokinetics to characterize the pharmacokinetics of PF-
5190457, an inverse agonist of the growth hormone secretagogue receptor (hGHS-
R1a).  This work has been organized in two parts. Part one is made up of manuscripts 
I-III; and addresses the first objective. Part two, on the other hand, is made up of 
manuscript IV, and addresses the second objective.  The manuscripts are briefly 
described below: 
Manuscript I:  Non-alcoholic fatty liver disease (NAFLD) is a spectrum of liver 
disorders.  It is defined by the presence of steatosis in more than 5 % of hepatocytes 
with little or no alcohol consumption.  The physiological and biochemical changes 
associated with NAFLD may result in altered expression and activity of drug 
metabolizing enzymes (DMEs) or transporters.  Existing evidence suggests that the 
effect of NAFLD on CYP3A4, CYP2E1 and MRP3 are more consistent across rodent 
and human studies.  CYP3A4 activity is down-regulated in NASH whereas the activity 
of CYP2E1 and the efflux transporter MRP3 are up-regulated.  However, it is not clear 
how the majority of CYPs, UGTs, SULTs and transporters are influenced by NAFLD 
 
 
either in vivo or in vitro.  The alterations associated with NAFLD could be a potential 
source of drug variability in patients and could have serious implications for the safety 
and efficacy of xenobiotics.  In the first manuscript, we reviewed the effects of 
NAFLD on the regulation, expression and activity of major drug metabolizing 
enzymes and transporters.  We also discussed the potential mechanisms underlying 
these alterations. 
Manuscript II:  Diabetes is strongly associated with NAFLD.  However, tools for 
predicting the diabetic status of human liver tissues (HLTs) is lacking.  Manuscript II 
was aimed to establish a model-based approach for predicting the diabetic status of 
donors of HLTs.  The liver tissue as well as demographic and anthropometric 
information were supplied by Xenotech LLC.  Histopathological examination was 
conducted to characterize NAFLD lesions.  HLTs were homogenized and levels of 
feeding-related hepatic neuroendocrine peptides (active amylin, insulin, c-peptide, 
glucagon, ghrelin, active GLP-1, GIP, PP, PYY, leptin and MCP-1) determined.  The 
association between diabetes, and these covariates was modeled using multiple logistic 
regression.  The statistically validated model was used to predict new diabetic classes 
of HLTs.  A multiple logistic regression model adequately described the association 
between diabetes, NAFLD lesions and the neuroendocrine peptides.  Liver weight, c-
peptide, leptin, PYY, Amylin (active) and steatosis were significant predictors of 
diabetes.  The final model had an AROC curve of 0.89, accuracy of 80%, sensitivity of 
82.4% and specificity of 77%.  The new diabetic classes showed that hepatic GLP-1 
(active) level was 1.4 higher in non-diabetic livers compared to diabetic ones.  In 
addition, the logistic regression model can be used as a tool to verify the diabetic 
 
 
status of HLTs which are used for drug metabolism studies.  
 
Manuscript III:  Despite the initial belief that Cytochrome P450 (CYP) 2B6 is of 
minor significance, it is now recognized as a clinically relevant drug metabolizing 
enzyme.  The impact of non-alcoholic fatty liver disease (NAFLD) on drug 
metabolism has been identified; however, it is still unclear how it influences CYP2B6. 
We used in vitro approaches in human liver microsomes (HLM) and HepaRG cells to 
investigate the effect of NAFLD on CYP2B6-mediated formation of 
hydroxybupropion.  The presence of NAFLD increased the km significantly (p < 0.04) 
and reduced CYP2B6 intrinsic clearance by 2-fold.  The results from the HepaRG 
cells qualitatively recapitulated findings in the HLMs.  Fatty acid accumulation in 
hepatocytes seems to be involved with the alteration.  This investigation contributes to 
our current knowledge on the influence of NAFLD on CYP2B6 in vitro kinetics and 
offers a basis for clinical trial in this patient population. 
 
Manuscript IV:  PF-5190457 is an inverse agonist of the growth hormone 
secretagogue receptor (hGHS-R1a), that is undergoing clinical trial for treatment of 
alcohol use disorder.  The purpose of this study was to describe the population 
pharmacokinetics (PK) of PF-5190457 and to identify demographic and biochemical 
characteristics that influence its PK variability.  Data on drug dosage, sampling times 
and plasma concentrations were collected retrospectively from two studies: Phase 1a 
and Phase 1b.  Thirty five (35) healthy volunteers were enrolled in the Phase 1a, and 
12 non-treatment seeking alcoholic subjects in the Phase 1b trial.  The log-transformed 
concentration and time points were modeled in NONMEM.  The influence of patients' 
 
 
demographic and biochemical characteristics were evaluated; and the accuracy and 
precision of the model parameters determined using bootstrapping.  The predictive 
performance of the final model was checked using percentile visual predictive checks. 
The pharmacokinetics of PF-5190457 was best described by a one-compartmental 
model with first order absorption after oral administration.  The estimated typical 
pharmacokinetic parameters included the absorption rate constant (ka, 3.6 h-1), oral 
clearance (CL/F, 80 Lh-1) and apparent volume of distribution (V/F, 575 L).  Inclusion 
of body weight and serum albumin as covariates on V/F reduced the interindividual 
variability (IIV) associated with V/F by ~28%.  Increasing body weight increased V/F, 
whereas increasing serum albumin levels reduced it.  We anticipate that this model 
would serve as a guide in designing dosage regimen for future clinical trials with PF-
5190457. 
Conclusion. This work demonstrates that in vitro drug metabolism in human liver 
microsome has the potential to explain the effect of NAFLD on CYP2B6-mediated 
hydroxybupropion formation.  Similarly, population pharmacokinetic modeling in 
NONMEM has the capability to elucidate the influence of body weight and serum 
albumin on the pharmacokinetics of PF-5190457. 
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PREFACE 
This dissertation titled “In Vitro Drug Metabolism and Population Pharmacokinetics 
as Tools for Elucidating Pharmacokinetic Variability” is presented in manuscript 
format.  
The first chapter is an introduction of general concepts in Pharmacokinetics and 
Pharmacokinetic variability. The next four chapters (2-5) are four manuscripts. 
Manuscript I was published in Drug Metabolism Review (Drug Metab Rev. 2017 
May;49(2):197-211). Manuscript II has been formatted for publication in 
Diabetes/Metabolism Research and Reviews Journal. Manuscript III has been 
prepared for submission to Diabetes, Obesity and Metabolism Journal. Finally, 
Manuscript IV has been prepared for submission to Clinical Pharmacokinetics 
Journal. 
In all four manuscripts, Dr. Fatemeh Akhlaghi, my major Professor is the 
corresponding author.  Any other contributors have been included as co-authors or 
acknowledged appropriately.  
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 BACKGROUND 
 
Introduction 
Pharmacokinetics is the study of the processes involved with the absorption (A), 
distribution (D), metabolism (M) and excretion (E) of drugs from the body.  Thus, the 
body interacts with the drug to absorb it from the site of administration and transport 
to the site of action to exert its effect before it is finally removed from the body.  The 
ADME processes control the concentration a drug achieves in body compartments 
after administration of a dose.  This implies that changes in the ADME properties can 
alter pharmacokinetic properties of a drug and ultimately the efficacy and toxicity.  To 
improve the safety and efficacy of drugs, the sources of pharmacokinetic variability 
must be characterized and applied to individualize dosing.  Pharmacokinetic 
variability results from inter-individual differences that alter pharmacokinetic 
parameters that control absorption, distribution, metabolism and excretion. 
Absorption.  
Drugs administered by extravascular route, are absorbed into the systemic circulation. 
Some drugs may undergo first pass metabolism in the enterocytes of the small 
intestines and the liver before they finally reach the systemic circulation.  The product 
of the fraction of the drug that is absorbed into the enterocytes (fa), the fraction that 
escapes metabolism in the enterocyte (fg) and the fraction that escapes first-pass 
hepatic metabolism (fh) is described by the bioavailability parameter, F. 
F = fa*fg*fh ................................................(1) 
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The rate of absorption of a drug usually follows a first-order kinetics.  The important 
pharmacokinetic parameters of absorption are the absorption rate constant (ka) and the 
overall bioavailability.  The absorption of a drug in the GIT may be affected by the 
motility of the GIT, pH changes, presence of food, concomitant medication, and 
transporters.  Consequently, these conditions can alter the magnitude of ka and the 
bioavailability (Rosenbaum, 2011). 
Distribution.  
The apparent volume of distribution (Vd) is the pharmacokinetic parameter that 
quantitatively describes the distribution of a drug in the body.  It is the ratio of the 
amount of drug in the body at equilibrium (Ab) and the drug plasma concentration 
(Cp).  Though this parameter does not have a physiological significance, it gives a 
general idea about the extent of drug distribution in the body.  The extent of the 
distribution of a drug depends on tissue binding and plasma protein binding.  The 
magnitude of Vd depends on whether the drug binds strongly to the plasma proteins or 
to tissues.  A high plasma protein binding may result in a small Vd, whereas a high 
tissue binding may yield a large Vd.  
The rate of drug distribution on the other hand, depends on tissue perfusion and 
diffusion into cells.  Drug distribution is faster in well-perfused tissues than in poorly-
perfused ones.  In addition, small lipophilic drugs are able to distribute into tissues 
faster through passive transcellular diffusion.  It must also be borne in mind that 
transporters like p-gp, MRP4 and BCRP play some role in drug distribution (Urquhart 
and Kim, 2009).  The extent of drug distribution is affected by conditions that affect 
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blood and tissue volume as well as the free fraction of drug in the plasma and tissues. 
It is anticipated that since tissue-perfusion and diffusion control the rate of 
distribution, conditions that affect perfusion and diffusion would also affect the rate of 
distribution.  
Elimination.  
Drugs are eliminated from the body through metabolism and excretion.  The primary 
organ for metabolism is the liver, whereas the kidney is the cardinal organ for 
excretion.  Metabolism is a process whereby drug molecules are biotransformed into 
their metabolites by addition of groups that make them more hydrophilic.  Drug 
metabolizing enzymes (cytochrome P450 enzyme, flavin monooxygenase, and UDP-
glucuronosyltransferases (UGTs)) and transporters (MRPs, OATPs etc) are involved 
in the metabolism of drugs.  
Renal excretion results from glomerular filtration, active tubular secretion and passive 
tubular reabsorption.  The capillaries of the glomerulus are very permeable and allows 
neutral molecules of less than 4 nm diameter to pass through into the renal tubules. 
The presence of transporters in the proximal tubular cells augment renal clearance 
through tubular secretion (Ho and Kim, 2005, Kusuhara, 2009, Choi and Song, 2008). 
The uptake transporters involved in this process include OAT1, OAT3 and OCT2 
whereas the efflux transporters include P-gp, MRP2 and MRP4.  At the distal tubule, 
drugs may be reabsorbed through passive diffusion depending on the lipophilicity, pH 
of the filtrate and the flow of the urine. 
Elimination incorporates the processes of metabolism and excretion.  The elimination 
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of most drugs follow first order kinetics.  The constant of proportionality between the 
rate of elimination and the plasma concentration is called clearance.  Clearance is the 
most important pharmacokinetic parameter and it is defined as the volume of blood 
that is completely cleared of the drug per unit time.  It is a function of blood flow and 
the efficiency with which the organs of elimination extract the drug that passes 
through them.  Hence, conditions that affect these organs and their function like 
diseases affect the clearance and eventually the pharmacokinetics of the drug. 
The elimination half-life of a drug.  
The ratio of the clearance (Cl) and the volume of distribution (Vd) is called the 
elimination rate constant (ke).  Closely related to the elimination rate constant is the 
half-life of a drug.  It is the time required for the amount of drug in the body to fall by 
half, and it is estimated as:  
t1/2 = 0.693/ke ......................................................(2) 
The elimination rate constant and the half-life are derived parameters and depend on 
the volume of distribution and clearance which are independent of each other.  
The half-life of a drug is particularly important because it helps to determine the time 
it takes a drug to reach steady state.  It also guides the selection of dosing interval in 
multiple dosing.  Since t1/2 depends on clearance and volume of distribution, any factor 
that alters the distribution or clearance of a drug may alter its half-life.  This would 
alter the dosing interval, the time to reach steady state and the time it will take to clear 
the drug from the body. 
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Elucidating the sources of pharmacokinetic variability. 
To understand the sources of pharmacokinetic variability, pharmacokinetic parameters 
are investigated under various conditions to elucidate how those conditions influence 
their magnitude.  These conditions include food, gender, lifestyle, genetic 
polymorphisms, diseases and co-administered drugs.  
In this work, two methodologies were employed to investigate pathological and non-
pathological sources of PK variability.  In the first part of the study (manuscripts I, II 
and III), the influence of non-alcoholic fatty liver disease was investigated in vitro 
using both human liver microsomes (HLM) and steatosis-induced HepaRG cell lines. 
By incubating each of the two in vitro systems with a CYP2B6 probe substrate, 
bupropion, we were able to estimate parameters related to the in vitro clearance of 
bupropion via the CYP2B6 drug metabolizing enzyme pathway.  Comparing the 
values obtained among the control and treatment groups enabled us to establish the 
influence of NAFLD on CYP2B6-mediated clearance of bupropion.  NAFLD was 
chosen as the disease of interest mainly because it affects the liver, the major organ of 
clearance; and also because NAFLD is prevalent in the population. 
In the second part of the study (manuscript IV), population pharmacokinetics using 
nonlinear mixed effect modeling was employed to determine the pharmacokinetic 
parameters of a ghrelin inverse agonist, PF-5190457, administered to healthy and non-
treatment seeking alcoholic adults.  The influence of various covariates including 
demographic (age, BMI, and Gender, etc.), and biochemical (albumin, serum 
creatinine, etc.) variables were examined on the pharmacokinetic parameters - ka, CL 
and Vd.   
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By employing these two methodologies, we were able to demonstrate the effect of 
NAFLD on CYP2B6-mediated formation of hydroxybupropion and the factors that 
influence the disposition of PF-5190457. 
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1 MANUSCRIPT I 
Abstract  
Non-alcoholic fatty liver disease (NAFLD) is a spectrum of liver disorders. It is 
defined by the presence of steatosis in more than 5 % of hepatocytes with little or no 
alcohol consumption. Insulin resistance, the metabolic syndrome or type 2 diabetes 
and genetic variants of PNPLA3 or TM6SF2 seem to play a role in the pathogenesis of 
NAFLD. The pathological progression of NAFLD follows tentatively a ‘three-hit’ 
process namely steatosis, lipotoxicity and inflammation. The presence of steatosis, 
oxidative stress and inflammatory mediators like TNF-α and IL-6 have been 
implicated in the alterations of nuclear factors such as CAR, PXR, PPAR-α in 
NAFLD. These factors may result in altered expression and activity of drug 
metabolizing enzymes (DMEs) or transporters. 
Existing evidence suggests that the effect of NAFLD on CYP3A4, CYP2E1 and 
MRP3 are more consistent across rodent and human studies.  CYP3A4 activity is 
down-regulated in NASH whereas the activity of CYP2E1 and the efflux transporter 
MRP3 are up-regulated.  However, it is not clear how the majority of CYPs, UGTs, 
SULTs and transporters are influenced by NAFLD either in vivo or in vitro.  The 
alterations associated with NAFLD could be a potential source of pharmacokinetic 
variability in patients and could have serious implications for the safety and efficacy 
of xenobiotics. In this manuscript, we summarize the effects of NAFLD on the 
regulation, expression and activity of major drug metabolizing enzymes and 
transporters.  We also discuss the potential mechanisms underlying these alterations. 
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Age, ALT, Triglycerides;  BCRP - Breast cancer resistance protein;  BMI - Body 
Mass Index;  C/EBPs  - CCAAT-enhancer-binding proteins (or C/EBPs);  CAR - 
Constitutive androstane receptor;  chREBP - Carbohydrate-responsive element-
binding protein;  CT - Computerized tomographic;  CYP - Cytochrome P450;  DAGs - 
Diacyl glycerols;  DME - Drug metabolizing enzyme;  ER - Endoplasmic Reticulum;  
FAT/CD36 - Fatty acid translocase;  FATPs - Fatty acid transport proteins;  FGF21-
Fibroblast growth factor 21;  GR - Glucocorticoid receptor;  GSTs - Glutathione -S-
transferases;  HAIR - Hypertension, ALT, Insulin resistance;  HDL - High-density 
lipoprotein;  HFD - High fat diet;  HNF-4 - Hepatic nuclear factors 4;  IL-1β - 
Interleukin-1 β;  IL-6 - Interleukin-6;  JAK/STAT - Janus kinase / Signal Transducer 
and Activator of Transcription;  keapl - Kelch-like ECH-associated protein 1;  LPS - 
Lipopolysaccharide;  LXRα - Liver X receptor alpha;  MAPK - Mitogen-activated 
protein kinase;  MCD - Methionine choline deficient;  MRI - Magnetic resonance 
imaging;  MRP - Multidrug resistance-associated protein;  NADPH - Nicotinamide 
adenine dinucleotide phosphate (reduced);  NAFL - Non-alcoholic fatty liver;  
NAFLD - Non-alcoholic fatty liver disease;  NAS - NAFLD activity score;  NASH - 
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Non-alcoholic steatohepatitis;  NASH CRN - NASH Clinical Research Network;  
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National Institute of Diabetes & Digestive & Kidney Disease;  Nrf2 - Nuclear factor 
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PPAR-γ - Peroxisome proliferator-activated receptor gamma;  PUFA - 
Polyunsaturated fatty acids;  PXR - Pregnane X receptor;  QUICKI - Quantitative 
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member 2;  TNF-α - Tumor necrosis factor - alpha;  UGTs - Uridine diphosphate;  
(UDP) - glucuronosyl transferases 
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1.1 Introduction 
Non-alcoholic fatty liver disease (NAFLD) is a spectrum of liver disorders (Figure 
1.1).  It is a condition defined by the presence of steatosis in more than 5 % of 
hepatocytes (Sanyal et al., 2011) with little or no alcohol consumption.  NAFLD 
consists of the benign non-alcoholic fatty liver (NAFL), and the more severe non-
alcoholic steatohepatitis (NASH).  NASH is a more progressive form of NAFLD and 
is characterized by steatosis, hepatocellular ballooning, lobular inflammation and 
almost always fibrosis (Kleiner and Makhlouf, 2016).  In an effort to regenerate new 
cells, NASH progresses (Argo and Caldwell, 2009, Starley et al., 2010) to cirrhosis 
with the hepatocytes replaced by scar tissues of type I collagen produced by stellate 
cells.  Cirrhosis is an end stage organ failure that require liver transplantation or may 
lead to hepatocellular carcinoma (Sorensen et al., 2003, Yasui et al., 2011).  With 
progression of NASH to full-blown cirrhosis, some of the histological characteristics 
of NASH might be lost (Yoshioka et al., 2004). 
The metabolic syndrome, formerly known as Syndrome X, underlies both non-
alcoholic fatty liver disease (NAFLD) and diabetes.  It is defined by the presence of at 
least three of the following (Figure 1.2): abdominal obesity, increased triglycerides, 
reduced high density lipoprotein (HDL) cholesterol, increased blood pressure and 
hyperglycemia (Alberti et al., 2009).  Insulin resistance appears to explain almost all 
situations of metabolic syndrome (Eckel et al., 2010); and hence diabetes (Groop, 
1999) and NAFLD (Marchesini et al., 1999). 
Though NAFLD is more prevalent in obese and diabetic patients, it is also present in 
lean and non-diabetic individuals (Vos et al., 2011, Younossi et al., 2012).  It is the 
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most common cause of cryptogenic cirrhosis (Clark and Diehl, 2003) and 
approximately 30 -50 % of NASH patients may progress to cirrhosis within 10 years 
(Jou et al., 2008).  NAFLD is not only prevalent in industrialized countries, but also in 
developing ones.  Global prevalence of NAFLD has been reviewed and ranges from 6 
- 35 % (Fazel et al., 2016, Sayiner et al., 2016, Bellentani, 2017); and approximately 
30% of the population of United States (90 million persons) are estimated to be 
affected by NAFLD (Fazel et al., 2016).  About 70% Americans with diagnosed type 
2 diabetes are believed to have NAFLD while 63–87% of patients having both 
diabetes and NAFLD may have NASH.  (Bazick et al., 2015, Corey et al., 2016).  The 
economic burden of NAFLD in four European countries (Germany, France, Italy and 
the United Kingdom) was projected to be ~35 billion US dollars compared to the 
approximately 103 billion dollars in the United States (Younossi et al., 2016). 
Pharmacotherapy of NAFLD or NASH is an unmet clinical need.  To date, no drug 
has received FDA approval for NASH (Sanyal et al., 2015), thus a clinical or 
regulatory pathway has not yet been established.  Current therapies like vitamin E 
(Rinella and Sanyal, 2016), pentoxifylline (Zein et al., 2011) and insulin sensitizers 
such as pioglitazone in patients with diabetes (Cusi, 2016) have been used.  Therapies 
in development include obeticholic acid, a semi-synthetic bile acid analogue 
undergoing development by Intercept Pharmaceuticals and elafibranor (formerly 
GFT505) a Peroxisome proliferator-activated receptor (PPAR) alpha and gamma 
agonist (Rinella and Sanyal, 2016).  In view of the lack of standard therapy, 
international guidelines on NAFLD (European Association for the Study of the Liver 
(EASL), 2016) recommend lifestyle modifications particularly diet and exercise as 
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treatment options.  Recently, the role of Mediterranean diet in prevention and 
treatment of NAFLD has been proposed (Abenavoli et al., 2014, Godos et al., 2017). 
The main clearance mechanisms of xenobiotics from the body are hepatic, renal and 
biliary.  It has been reported that more than 60 % of commonly prescribed drugs in the 
United States are cleared hepatically (Williams et al., 2004), indicating the crucial role 
of the liver in drug metabolism.  Hepatic clearance of drugs is achieved through the 
activities of drug metabolizing enzymes (DMEs) and transporters and hence factors 
that affect their regulation and activities eventually alter drug disposition. 
In this manuscript, we summarize the effects of NAFLD on the regulation, expression 
and activity of major drug metabolizing enzymes and transporters.  In addition, we 
discuss the various classification systems of NAFLD and the potential mechanisms 
underlying these alterations.  This work however does not include a discussion on 
models of NAFLD and most findings published before 2011 since these have been 
reviewed by other groups (Merrell and Cherrington, 2011, Naik et al., 2013). 
 
1.2 Pathogenesis of NAFLD 
The mechanisms leading to NAFLD is unclear to date.  Several mechanisms have 
been proposed, but insulin resistance seems to be pivotal in the pathogenesis of both 
NAFLD and type 2 diabetes (Shulman, 2000, Tarantino and Finelli, 2013).  The 
genetic variant of PNPLA3 (patatin-like phospholipase domain-containing protein 3), 
an enzyme encoding I148M (rs738409 C/G) and involved in the hydrolysis of 
triacylglycerols in adipocytes, has been reported to be associated with NAFLD 
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independent of the metabolic syndrome (Romeo et al., 2008, Sookoian and Pirola, 
2011).  Similarly, the genetic variant of the lipid transporter located on ER 
(endoplasmic reticulum) and ER-Golgi compartments, TM6SF2 (transmembrane 6 
superfamily member 2), encoding E167K (rs58542926 C/T), causes loss of function of 
the protein and increases hepatic deposition of triglycerides (Dongiovanni et al., 
2015).  The pathological progression of NAFLD follows tentatively a ‘three-hit’ 
process (Jou et al., 2008) namely steatosis, lipotoxicity and inflammation. 
Steatosis results from the interplay between diet, gut microbiota (Jiang et al., 2015, 
Kirpich et al., 2015), genetic factors (Romeo et al., 2008), and de novo lipogenesis via 
up-regulation of lipogenic transcription factors like sterol regulatory binding protein-
1c (SREBP1c), carbohydrate-responsive element-binding protein (chREBP), and 
peroxisome proliferator-activated receptor gamma (PPAR-γ) (Anderson and Borlak, 
2008).  Primarily, fatty acid (FA) is stored in the adipose tissue as TAG 
(triacylglycerol).  However, in obese subjects, fatty acids seem to be misrouted from 
their primary storage site to ectopic sites like skeletal and hepatic tissues for re-
esterification into diacyl glycerols (DAGs), perhaps through increased adipocyte 
lipolysis.  The uptake of fatty acid by these organs probably is facilitated by fatty acid 
transport proteins (FATPs) and FAT/CD36 (fatty acid translocase) which have been 
shown to be elevated in obese subjects and NAFLD patients (Greco et al., 2008, 
Fabbrini et al., 2009). 
Steatosis leads to increased signaling of the transcription factor NF-κβ (nuclear factor 
– kappaβ) through the upstream activation of IKKβ (inhibitor of nuclear factor kappaB 
(NF-κB)).  The activation of NF-κβ induces the production of pro-inflammatory 
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mediators like TNF-α (tumor necrosis factor - alpha), IL-6 (interleukin-6) and IL-1β 
(interleukin-1 β).  These cytokines contribute to the recruitment and activation of 
Kupffer cells (resident hepatic macrophages) (Anderson and Borlak, 2008) to mediate 
inflammation in NASH (Ramadori and Armbrust, 2001, Joshi-Barve et al., 2007). 
Additionally, TNF- α and IL-6 have been reported to play a role in hepatic insulin 
resistance through the up-regulation of SOCS3 (suppressor of cytokine signaling 3) 
(Persico et al., 2007, Torisu et al., 2007). 
The excess fat in the liver causes lipotoxicity and leads to organelle failure mainly 
mitochondrial dysfunction and endoplasmic reticulum stress (Browning and Horton, 
2004, Bell et al., 2008 ).  A dysfunctional mitochondrion has an elevated capacity to 
oxidize FA resulting in the production of ROS (reactive oxygen species) and causing 
oxidative stress due to an imbalance between the production of ROS and protective 
oxidants.  Oxidative stress in NAFLD patients (Sanyal et al., 2001, Tiniakos et al., 
2010) is regarded as the third insult that eventually leads to hepatocyte death.  The 
pathogenesis of NAFLD seem to be a vicious cycle of steatosis, lipotoxicity and 
inflammation resulting in intricate alterations in the histopathological and biochemical 
features of the liver. 
1.3 Diagnosis and Classification of NAFLD 
The diagnosis of NAFLD is challenging, as the current available routine techniques 
(serological tests and imaging techniques) are unable to distinguish between steatosis 
and NASH.  Liver biopsy is considered the gold standard in defining NAFLD and is 
capable of differentiating steatosis and NASH.  It is however, not recommended for 
routine use due to increased risk of bleeding and complications.  In the last decades, 
 
16 
 
many diagnostic non-invasive tools have been described (Table 1.1).  Accurate 
diagnosis of NAFLD is important for its classification.  Some of the classification 
systems available include the scoring systems by Matteoni (Matteoni et al., 1999 ), 
Brunt  (Brunt et al., 1999), NASH CRN (Clinical Research Network) system (Kleiner 
et al., 2005), and the SAF (steatosis, activity and fibrosis) system (Bedossa et al., 
2012).  The different classification systems of NAFLD may thus yield different results 
and hence introduce variability into scientific investigations. 
One of the pioneering works with the largest number of patients and longest follow-up 
for the stratification of NAFLD patients was carried out  (Matteoni et al., 1999 ).  The 
Matteoni's system was based on fat accumulation, inflammation, ballooning 
degeneration, Mallory hyaline and fibrosis.  NAFLD patients were put into four 
groups: Type I (simple fatty liver), Type II (steatohepatitis), Type III (steatonecrosis) 
and Type IV (steanecrosis plus either Mallory hyaline or fibrosis).  Type I was 
relatively benign whereas the necrotic forms were considered aggressive.  The 
aggressive forms have higher risk of cirrhosis and liver-related death.  Though this 
system helps to identify patients at risk of cirrhosis and liver-related death, it does not 
take into account NAFLD in children. 
The system developed by Brunt  (Brunt et al., 1999, Brunt et al., 2004) is semi-
quantitative and evaluates the unique lesions of NASH.  It unifies steatosis and 
steatohepatitis into a ‘grade’ and fibrosis into a ‘stage’(Angulo, 2002).  Steatosis is 
graded on a scale of 1 to 3 depending on the percentage of hepatocytes affected (<33% 
=1; 33-66% = 2; >66% = 3).  Steatohepatitis was similarly graded on a scale of 1 to 3 
(1 = mild; 2 = moderate; 3 = severe) but based on the severity and extent of steatosis, 
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ballooning, lobular inflammation and portal inflammation.  Fibrosis on the other hand 
was staged on a scale of 1 to 4.  Brunt’s system does not cover the entire spectrum of 
NAFLD as defined by Matteoni's system.  Additionally, it was not designed to 
evaluate NAFLD in children (Kleiner et al., 2005). 
In 2005, the Pathology Committee of the NASH Clinical Research Network (NASH 
CRN) of the National Institute of Diabetes & Digestive & Kidney Disease (NIDDK) 
came up with a scoring system and NAFLD activity score (NAS) for use in clinical 
trial (Kleiner et al., 2005).  The scoring system was intended to address the full 
spectrum of lesions of NAFLD.  The histological features considered were grouped 
into five broad categories each with a scoring scale.  These features, which were 
independently associated with NASH, included steatosis (0-3), lobular inflammation 
(0-3), hepatocellular injury (0-2), fibrosis (0-4) and miscellaneous features like 
Mallory’s hyaline and glycogenated nuclei. The NAS is the unweighted sum of 
steatosis, lobular inflammation, and hepatocellular ballooning scores.  NAS of ≥ 5 was 
found to correlate with the diagnosis of NASH and biopsies with scores of less than 3 
were classified as “not NASH”.  Notwithstanding, not all biopsies with NAS ≥ 5 meet 
the diagnostic criteria of definite NASH and should be used carefully in establishing 
the presence or absence of NASH (Brunt et al., 2011).  In a number of experimental 
work involving humans and rodents, a NAS score of at least 4 was considered as 
NASH (Canet et al., 2014, Ferslew et al., 2015). 
Recently, the SAF (steatosis, activity and fibrosis) system has been proposed. The 
SAF considers steatosis, lobular inflammation and ballooning in defining NAFL and 
NASH.  The activity is defined as the sum of the grades of lobular inflammation and 
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ballooning and ranges from 0-4.  The presence of NAFLD is defined by steatosis in 
the presence of any degree of activity.  This implies that the definition of either NAFL 
or NASH requires the presence of steatosis (1-3) and varying degree of activity 
(NAFL: steatosis (1-3) + lobular inflammation (0) + ballooning (0-2), or steatosis (1-
3) + lobular inflammation (1-2) + ballooning (0); and NASH: steatosis (1-3) + 
lobular inflammation (1) + ballooning (1-2) or steatosis (1-3) + lobular inflammation 
(2) + ballooning (1-2)) (Bedossa et al., 2012, Kleiner and Makhlouf, 2016). 
Clinicobiological scores have also been used in relation to NAFLD for several reasons 
including selection of patients needing biopsy and prediction of advanced forms of 
NASH.  These clinicobiologial scores make use of indices like body mass index 
(BMI), Age, AST/ALT ratio, albumin, platelet count, diabetes, hyperglycemia, insulin 
resistance index, triglycerides, hypertension and others (Angulo et al., 1999, Dixon et 
al., 2001, Harrison et al., 2003).  For instance, ‘BAAT’ scoring (Ratziu et al., 2000 ) 
uses BMI, age, ALT, and serum triglycerides. The BAAT score is calculated as the 
sum of categorical variables with a scale of 0 to 4.  A score of 0 or 1 on the BAAT 
scale would indicate absence of septal fibrosis.  ‘HAIR’ scoring (Dixon et al., 2001) 
on the other hand utilizes hypertension, ALT and insulin resistance as an index with a 
scale of 0 to 3.  A score of ≥2 is suggestive of NASH. 
1.4 Mechanisms of the alteration of DMEs and Transporters in 
NAFLD 
The influence of diseases on DMEs and transporters is complex due to the associated 
physiological and pathological changes.  For instance, inflammatory conditions have 
been reported to cause the release of circulating pro-inflammatory cytokines like TNF-
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α, IL-1β, and IL-6 which act as signaling molecules to mediate the down-regulation of 
drug metabolizing enzymes partly through the suppression of transcription (Aitken et 
al., 2006, Aitken and Morgan, 2007).  The inflammation models, bacteria 
endotoxemia (lipopolysaccharide (LPS)) and turpentine have been employed in 
rodents and hepatocytes to gain some insight into the role of cytokines on the 
regulation of DMEs and transporters.  It seems that in majority of cases, inflammation 
and the associated cytokines down-regulate the expression and activity of DMEs and 
some transporters as described  in these reviews (Aitken et al., 2006, Morgan, 2009). 
Oxidative stress in NAFLD and diabetes causes activation of Nrf2 (nuclear factor 
erythroid 2-related factor 2) in both experimental (Fisher et al., 2008) and clinical 
studies (Hardwick et al., 2010).  Nrf2 is a specific transcription factor that controls the 
antioxidant response.  It is released from keapl (Kelch-like ECH-associated protein 1) 
and is translocated to the nucleus where it binds to antioxidant response element 
(ARE) within promoters of target genes, and induces expression of DMEs and 
transporters central to the maintenance of oxidative stress inducing molecules 
(Jaiswal, 2004, Nakata et al., 2006, Zhang, 2006). 
Fatty acids regulate gene expression by controlling the activity or expression of key 
nuclear receptors.  In vitro studies have identified many transcription factors as 
possible targets for fatty acid regulation, including hepatic nuclear factors (HNF-4α 
and γ), PPARα, β, γ1, and γ2, SREBP-1c, retinoid X receptor (RXRα), liver X 
receptor (LXRα), and others.  Some nuclear receptors, PPAR, HNF4 (hepatic nuclear 
factor), RXRα, and LXRα, bind directly to non-esterified fatty acids (NEFA), but 
others like SREBP-1c and NF-κB are regulated by fatty acids through indirect 
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mechanisms (Jump et al., 2005, Jump, 2008).  In rodents, SREBP-1c inhibits PXR 
(pregnane X receptor) and CAR (constitutive androstane receptor) (Roth et al., 2008), 
and has been shown to be up-regulated in obese insulin-resistant patients (Pettinelli et 
al., 2009). The modulation of the activity of CAR and PXR by polyunsaturated fatty 
acids (PUFA) has also been reported (Finn et al., 2009).  
In addition, changes in the architecture of the liver in hepatic cirrhosis have been 
reported to cause reduced liver blood flow, reduced functional hepatocytes and 
diminished functional capacity of the liver to synthesize serum proteins including 
albumin (Elbekai et al., 2004, Edginton and Willmann, 2008, Johnson et al., 2010). 
Collectively, the changes mediated by excess fatty acids, cytokines, oxidative stress, 
and other mechanisms in NAFLD and diabetes may affect the hepatic metabolism of 
certain drugs possibly through the alteration of the expression and activity of DMEs 
and transporters.  This could result from host defense mechanisms at the 
transcriptional as well as pre- and post-translational levels (George et al., 1995, 
Renton, 2004, Aitken et al., 2006).  These aberrant signals disrupt the normal hepatic 
signaling pathways and eventually dysregulate major drug-metabolism-associated 
nuclear factors  leading to altered drug metabolism in NAFLD and diabetic patients 
(Naik et al., 2013). 
1.5 Hepatic Drug Metabolism 
Phase I reactions are mainly oxidative processes and are predominantly carried out by 
the cytochrome P450 (CYP) enzyme system (Guengerich and MacDonald, 1990, 
Guengerich, 2008, Guengerich and Munro, 2013).  Of the 18 known families of CYP 
enzymes (Zanger and Schwab, 2013), only a few of the members belonging to families 
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1, 2 and 3 appear to be relevant to biotransformation of xenobiotics (Cholerton et al., 
1992, Zanger and Schwab, 2013).  These include CYP1A1, CYP1A2, CYP2A6, 
CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP2J2, CYP3A4, and 
CYP3A5.  Non-CYP enzymes involved in phase I reactions include monoamine 
oxidase, flavin-containing monooxygenase (Rettie et al., 1995, Fisher et al., 2002) and 
aldehyde oxidase (Johns, 1967 ). 
Phase II biotransformation on the other hand are primarily conjugation reactions and it 
includes glucuronidation (Meech and Mackenzie, 1997), sulfation (Negishi et al., 
2001), and glutathione conjugation (Sofia et al., 1997).  The enzymes responsible for 
these processes are Uridine diphosphate (UDP) - glucuronosyl transferases (UGTs), 
Sulfotransferases (SULT1A), Glutathione -S-transferases (GSTs) respectively.  
Drug transporters are crucial for metabolism of drugs and have been reviewed by 
several groups (Giacomini et al., 2010).  Hepatic transporters are classified into uptake 
and efflux transporters (Mizuno and Sugiyama, 2002, Mizuno et al., 2003).  The main 
uptake transporters belong to the solute carrier (SLC) superfamily and facilitate the 
movement of drugs into cells.  These include OATPs (organic anion transporting 
polypeptides), OCTs (organic cation transporter), and OATs (organic anion 
transporter).  The efflux transporters on the other hand belong to the ABC (ATP-
binding cassette) superfamily and help move drugs out of cells (Mizuno et al., 2003, 
Sugiura et al., 2006).  Examples include P-gp (P-glycoprotein), BCRP (Breast cancer 
resistance protein) and MRPs (Multidrug resistance-associated protein). 
Several factors have been reported to affect DMEs and transporters.  These include 
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genetic polymorphisms, epigenetic factors, and non-genetic factors.  Genetic 
polymorphisms result in alterations in DNA sequence of genes that regulate the 
expression of DMEs and transporters; and have led to loss-of-function or gain-of-
function variants.  The association between genetic polymorphisms and variation of 
plasma concentration levels of drugs as well as response has been extensively studied 
(Koren et al., 2006, Elens et al., 2011).  Epigenetic influences on drug metabolism 
have also been reported.  These are heritable changes in gene function that are not 
based on DNA sequence variation, but covalent modification of DNA, modification of 
histones or microRNA regulation (Pan et al., 2009, Mohri et al., 2010).  In addition to 
the above, non-genetic factors like sex (Schmidt et al., 2001, Wolbold et al., 2003), 
age (Cotreau et al., 2005, Stevens et al., 2008) and disease state like diabetes 
(Dostalek et al., 2011 , Dostalek et al., 2012a, Dostalek et al., 2012b) affect the 
expression and activity of DMEs and transporters. 
 
1.6 Effect of NAFLD on Phase I Drug Metabolizing Enzymes 
(DMEs) 
1.6.1 CYP3A 
This gene is part of a cluster of cytochrome P450 genes on chromosome 7q21.1 and 
includes four genes - 3A4, 3A5, 3A7 and 3A43 (Zanger and Schwab, 2013).  It is the 
most abundant human cytochrome P450 isoform in the liver and is involved in the 
metabolism of about half of clinically useful drugs (Guengerich, 1999).  The CYP3A5 
isoform is expressed mostly in Africans (Diczfalusy et al., 2011).  It also exhibits wide 
inter-individual variability in its expression and activity through polymorphisms, 
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epigenetic and non-genetic influences. 
The influence of NAFLD on the expression and activity of CYP3A has been studied 
using animal and cell culture models, human hepatic tissues, and human subjects 
(Woolsey et al., 2015).  Previous studies in rats and mice models are conflicting. 
However, a more consistent result have been emerging showing down-regulation of 
the mRNA and protein expressions, and the corresponding CYP3A activity in NAFLD 
(Table 1.2 ).  This is perhaps due the use of models that are able to simulate better the 
metabolic and histological lesions of NAFLD.  The activity of CYP3A decreased with 
severity of steatosis (Kolwankar et al., 2007) and with the progression of NAFLD 
(Woolsey et al., 2015).  Dostalek et al. (2011) observed significantly lower protein 
levels, reduced enzymatic activity of CYP3A4 and unchanged mRNA levels in 
microsomal fractions of human diabetes mellitus livers (Dostalek et al., 2011).  Again, 
the plasma levels of atorvastatin, a substrate of CYP3A4 (Lennernäs, 2003), has been 
reported to be elevated in patients with diabetes mellitus (Dostalek et al., 2012b).  In 
view of the high prevalence of NAFLD in the diabetic population, it is likely that 
NAFLD could be involved in the down-regulation of CYP3A4 activity in the diabetic. 
CYP3A genes seem to be regulated by a multiplicity of signaling pathways via 
CCAAT-enhancer-binding proteins (C/EBP) (Martínez-Jiménez et al., 2005), HNF4 
(Jover et al., 2009), PXR (Liu et al., 2008), and CAR (Timsit and Negishi, 2007).  A 
reduced CYP3A4 luciferase reporter activity in steatotic mice suggested a reduced 
CYP3A4 transcription in NAFLD (Woolsey et al., 2015).  The cytokine-mediated 
down-regulation of CYP3A4 (Werk and Cascorbi, 2014) in the course of the 
inflammatory response via the JAK/STAT (Janus kinase / Signal Transducer and 
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Activator of Transcription) pathway (Jover et al., 2002 ) seem to be clinically relevant 
in NAFLD and diabetic patients due to circulating cytokines.  Additionally, it has been 
suggested that the hepatic CYP3A4 expression is probably down-regulated by FGF21 
(fibroblast growth factor 21) through the receptor-mitogen-activated protein kinase 
(MAPK) pathway which leads to reduced gene transcription (Woolsey et al., 2016). 
1.6.2 CYP2 
The CYP2 family contains several of the most important drug metabolizing CYPs 
including CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2D6.  Some of 
these members are highly polymorphic (Zanger and Schwab, 2013).  The regulation of 
the subfamilies of CYP2 appears to involve nuclear factors like PXR, CAR, GR, and 
HNF4α.  Conflicting results have been reported in NAFLD and diabetic models.  This 
is perhaps due to differences in models used.  Additionally, the polymorphic nature of 
some of the members of this family could be a source of discrepancy in findings 
especially where the genotypes involved are not considered.  Several groups have 
studied the effect of NAFLD on CYP2 enzymes.  Reduced activity and mRNA 
expression of CYP2A6, CYP2B6, CYP2C9 and CYP2D6 have been reported in 
primary human cultured hepatocytes exposed to increasing concentrations (0.25 to 3 
mM) of mixture (2:1) of oleic and palmitic acids (Donato et al., 2006).  This study 
suggested probable alterations in some of the CYP2 enzymes in steatosis. 
1.6.3 CYP2A6 
CYP2A6 is clinically relevant for the hydroxylation of coumarin.  The murine 
ortholog of CYP2A6, Cyp2a5, was found to be elevated in the presence of steatosis 
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(Li et al., 2013, Cui et al., 2016) similar to the observations made in human hepatic 
tissues (Fisher et al., 2009). These observations however contradict the observations 
made by another group (Donato et al., 2006). 
1.6.4 CYP2B6 
CYP2B6 is an emerging enzyme with significant importance.  It is involved in the 
biotransformation of several clinically relevant drugs like bupropion, efavirenz and 
cyclophosphamide.  It also plays a role in the inactivation of environmental toxins. 
Recently, in vivo and in vitro studies using male Sprague Dawley rats and rat hepatic 
tissues respectively showed down-regulation of rat Cyp2b1(rat ortholog of human 
CYP2B6) activity, mRNA and protein expressions.  This observation was made in 
both steatotic (HF diet) and NASH (MCD-diet) models with pronounce effect in 
NASH.  It appears progression of NAFLD to hepatocellular carcinoma aggravates the 
decrease in CYP2B6 activity (Gao et al., 2016).  Notwithstanding, Fisher and 
colleagues (Fisher et al., 2009) observed a slight increase in the mRNA levels, but did 
not observe any change in the protein level and activity of CYP2B6 in steatotic and 
NASH human liver tissues.  Since CYP2B6 is less abundant and highly variable, 
evaluating the effect of heterogeneous NAFLD on its expression and activity poses a 
challenge. 
1.6.5 CYP2C 
The CYP2C family of CYPs are responsible for the metabolism of about 12 % (Wang 
and Tompkins, 2008) of clinically useful drugs.  These include CYP2C8 (paclitaxel, 
amodiaquine), CYP2C9 (warfarin, tolbutamide) and CYP2C19 (phenytoin, 
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omeperazole).  There seems to be very little information about the CYP2Cs since the 
last reviews on NAFLD and DMEs (Merrell and Cherrington, 2011, Naik et al., 2013). 
The available reports suggest alterations of CYP2C in NAFLD. However, the 
direction of change is not clear, as both increasing and decreasing trends have been 
observed (Fisher et al., 2009, Li et al., 2016).  The AUC of rosiglitazone, an insulin 
sensitizer and a substrate of CYP2C8 and CYP2C9 (Baldwin et al., 1999), was found 
to be significantly increased in male mice after high fat and high fructose NAFLD 
induction (Kulkarni et al., 2016).  Nevertheless, it is not clear whether this increase 
was mediated through down-regulation of the CYP2C8/9 or alteration in transport 
mechanisms. 
1.6.6 CYP2D6 
CYP2D6 constitutes about 4 % of total CYP content, yet it is involved in the 
biotransformation of more than 25 %  (Wang and Tompkins, 2008) of clinically useful 
drugs including dextromethorphan and bufuralol.  It is highly polymorphic (Ingelman-
Sundberg, 2005) and the few reports are conflicting.  In leptin-deficient (ob/ob) mice, 
the protein levels of Cyp2d22 (rat ortholog of human CYP2D6) (Li et al., 2016) were 
decreased.  Similarly, in human liver tissues, CYP2D6 protein levels and activity 
showed a decreasing trend in NASH (Fisher et al., 2009). 
1.6.7 CYP2E1 
CYP2E1 is the most studied CYP enzyme in relation to NAFLD.  CYP2E1 is involved 
in the biotransformation of acetaminophen, ethanol, acetone and fatty acid oxidation. 
It is known for the generation of ROS like hydrogen peroxide, and superoxide anion 
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radicals (Aubert et al., 2011) due to uncoupling of oxygen consumption with NADPH 
(Nicotinamide adenine dinucleotide phosphate) oxidation and as a by-product of lipid 
peroxidation (Robertson et al., 2001).  It is therefore considered to probably worsen 
the oxidative stress associated with diabetes and NAFLD, and may play a key role in 
the progression of NAFLD (Aubert et al., 2011).  In fact, it is suspected to be a 
contributor to acetaminophen-induced liver injury in obesity and NAFLD  (Michaut 
A1, 2014). There seem to be an increasing number of findings in the literature to 
support the enhancement of expression and activity of CYP2E1 in NAFLD in both 
humans and rodents (Chalasani et al., 2003, Abdelmegeed et al., 2012, Aljomah et al., 
2015). Results in rat studies have shown a consistent trend of increase in Cyp2e1 
expression and activity in MCD (Methionine choline deficient) diet fed rats (Weltman 
et al., 1996).  Diabetes has also been reported to increase the mRNA and protein 
expressions of CYP2E1 (Lucas et al., 1998, Wang et al., 2003), and perhaps 
generating tissue-damaging hydroxyl radical in patients (Caro and Cederbaum, 2004). 
1.7 CYP1A 
The CYP1A subfamily has two functional members oriented head-to-head on 
chromosome 15q24.1.  These are CYP1A1 and CYP1A2 (Zanger and Schwab, 2013). 
The two are highly inducible by ligands of CAR and AhR (aryl hydrocarbon receptor) 
(Zanger and Schwab, 2013).  CYP1A2 constitutes approximately 15 % of total hepatic 
CYP enzymes (Wang and Tompkins, 2008).  Its substrates include anticoagulants, 
antidepressants, antihistamines and anticancer agents (Zanger and Schwab, 2013). 
Reports from different groups about the down-regulation of CYP1A2 in NAFLD 
appears to be one of the most consistent despite some discrepancies (Merrell and 
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Cherrington, 2011). The levels of expression of mRNA and protein are decreased in 
different rodent models of NAFLD (Zhang et al., 2007, Hanagama et al., 2008).  In 
human related tissues, down-regulation of mRNA, protein and activity have been 
observed (Donato et al., 2006, Fisher et al., 2009). 
Significant increases in the systemic clearance of antipyrine and protein levels of 
hepatic CYP1A2 were observed in diabetic rats possibly due to the enhancement of 
hepatic CYP1A2-mediated metabolism (Ueyama et al., 2007).  Similarly, the 
metabolism of antipyrine was observed to be increased in patients with type 1 diabetes 
(Matzke et al., 2000).  The hepatic metabolism of theophylline into 1, 3- dimethyluric 
acid (3-DMU) by CYP1A2 and CYP2E1 were studied using diabetes mellitus rat 
models (alloxan-induced and streptozotocin-induced).  A significant increase in the 
AUC of 1, 3-DMU was observed in the diabetic rats compared to the controls.  Based 
on in vitro rat hepatic microsomal studies, the increased clearance of theophylline was 
confirmed in the diabetic rats (Kim et al., 2005).  Other studies in similar diabetic 
models have reported similar findings (Bae et al., 2006, DY et al., 2007). 
1.8 Effect on Phase II Drug Metabolizing Enzymes (DMEs) 
1.8.1 UDP-glucuronosyltransferases (UGTs) 
Glucuronidation is the major route for phase II reactions catalyzed by the UDP-
glucuronosyltransferases (UGTs).  UGTs have been reported to be involved in the 
glucuronidation of more than 40 % of drugs in clinical use (Wells et al., 2004).  They 
are anchored in the endoplasmic reticulum.  Members of the UGT1A and 2B 
subfamilies appear relevant in humans due to their roles in the elimination of 
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xenobiotics.  In some reports, there was no change in Ugtb1 protein (rat) and UGT2B7 
activity (humans) in NASH (Dzierlenga et al., 2015, Ferslew et al., 2015).  An earlier 
work utilizing human liver and kidney microsomes, however, observed a decrease in 
the activity as well as reduction in the mRNA and protein expression of UGT2B7 in 
diabetes compared to control (Dostalek et al., 2011 ).  Again, it is not clear whether 
the presence of NASH in the diabetic livers contributed to this observation.  Limited 
literature on this subject matter does not allow a clear understanding of how the 
expression and activities of UGTs are modified by diabetes and NAFLD. 
1.8.2 Sulfotransferases 
Sulfotransferases (SULTs) are cytosolic enzymes that catalyze the sulfonation reaction 
of xenobiotics and endogenous compounds by adding a sulfonate moiety to a 
compound to increase its water solubility and decrease its biological activity.  In 
humans three SULT families, SULT1, SULT2, and SULT4 have been reported 
PPARα mediates the induction of human SULTs, thus implicating a role for fatty acids 
as endogenous regulators of hepatic sulfonation in humans (Runge-Morris and 
Kocarek, 2005).  In human patients, SULT1A2 was found to be down-regulated in 
NASH (Younossi et al., 2005); and resulted in decreased plasma levels of 
acetaminophen-sulfate (Canet et al., 2015).  Yalcin and colleagues  (Yalcin et al., 
2013) also observed that sulfotransferase activity decreased significantly with severity 
of liver disease from steatosis to cirrhosis.  Available reports therefore suggest that the 
activities of SULT1A1 and SULT1A3 were lower in disease states compared to non-
steatotic tissues. 
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1.8.3 Glutathione-S-transferases 
The Glutathione-S-transferases are present as different isoforms -  α (A=alpha), μ 
(M=mu), π (P=pi), ϴ (T=theta), and ζ (Z=zeta) (Hayes et al., 2005).  They are 
involved in the conjugation of glutathione (GSH) to reactive drug metabolites, though 
this reaction can be spontaneous without GST (Dragovic et al., 2010).  A number of 
studies into GST activity in NAFLD and diabetes have found decreased enzymatic 
activity in ob/ob mice (Barnett et al., 1992, Roe et al., 1999) and human liver samples 
(Hardwick et al., 2010).  GSTM2, M4 and M5 expressions were higher in African 
Americans with NASH than in Caucasians (Stepanova et al., 2010). 
1.9 Effect of NAFLD on efflux and uptake transporters 
The down-regulation of uptake and up-regulation of efflux transporters in obese and 
NAFLD have been observed in studies involving rodents and human samples (Canet 
et al., 2014, Canet et al., 2015).  Though interspecies variation limits the use of 
rodents in modeling human NAFLD, concordance analysis has suggested that both 
mouse and rat MCD models, as well as mouse ob/ob and db/db NASH models show 
some similarity to human transporter mRNA and protein expression, and hence may 
be useful for predicting altered drug disposition (Canet et al., 2014).  Canet et al. 
(2014) observed mainly up-regulation of mRNA and protein expressions of Mdr1 
(multidrug resistance protein), Mrp1-4 (multidrug resistance-associated protein) and 
Bcrp (Breast cancer resistance protein) in rat and mouse NASH models.  Conversely, 
the Oatps (organic anion transporting polypeptides) mainly showed a down-regulation 
(Canet et al., 2014).  The plasma concentrations of metformin, an anti-hyperglycemic 
agent, were slightly increased in the WT/MCD and ob/Control groups.  In ob/MCD 
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mice compared to Wild Type, the plasma concentrations were 4.8-fold higher. These 
changes were attributed to decreases in the kidney mRNA expression of Oct2 and 
Mate1, the primary mediators of metformin elimination (Clarke et al., 2015). 
In the literature, the influence of NAFLD on MRP2-3 appears more obvious compared 
to other transporters (Hardwick et al., 2012, Canet et al., 2015).  Table 1.3 shows 
some of the published work on the effect of NAFLD on MRP3.  In MCD diet-induced 
NASH male Sprague-Dawley rats, mislocalization of Mrp2, the canaliculi efflux 
transporter, was observed.  Mrp2 appeared to pocket inward, resulting in a diminished 
function of effluxing substrates into bile.  On the other hand, the sinusoidal Mrp3 
efflux transporter increased with respect to protein expression leading to increased 
efflux of substrates into plasma (Dzierlenga et al., 2015).  These findings were 
consistent with human clinical studies involving MRP3 and its morphine glucuronide 
(morphine 3 and 6 glucuronides) substrate in NASH subjects (Ferslew et al., 2015). 
The AUC of morphine glucuronide was 58 % higher in NASH subjects compared to 
healthy subjects.  The Cmax also was also significantly higher in NASH subjects.  In 
addition, fasting levels of total bile acids, glycocholate and taurocholate were also 
elevated in NASH subjects suggesting up-regulation of the basolateral efflux MRP-3 
(Ferslew et al., 2015). Clinical impact of NAFLD/NASH on pharmacotherapy 
Though very few clinical studies have reported the impact of NAFLD on 
pharmacotherapy, they strongly highlight the potential of NAFLD to cause variable 
drug response, adverse drug reaction and eventually toxicity through alteration of 
pharmacokinetic profile.  Midazolam (Woolsey et al., 2015), morphine (Ferslew et al., 
2015) and acetaminophen (Canet et al., 2015) have been evaluated in both healthy and 
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NAFLD patients.  NAFLD seem to increase the AUC of midazolam by reducing the 
activity of CYP3A4; and similarly increase the AUC of the glucuronide metabolites of 
morphine and acetaminophen via the up-regulation of the MRP3 efflux transporter. 
Perhaps, the available evidence in the literature is the main motivation behind the 
emerging interest in drug disposition in NAFLD patients.  Hopefully, additional 
clinical studies would be conducted to gain more insight into the nature and extent of 
impact of NAFLD on pharmacotherapy. 
 
1.10 Challenges to studying the effect of NAFLD on DMEs and 
Transporters 
Studying the effect of NAFLD on DMEs and transporters is challenging.  First, the 
pathogenesis of NAFLD is not clearly understood, and is usually asymptotic requiring 
biopsy for definitive diagnosis. Due to ethical reasons, researchers are unable to 
routinely obtain biopsies from patients for studies. Also, the presence of co-
morbidities particularly diabetes, which is highly prevalent in NAFLD patients, is not 
accounted for.  For instance, it has been demonstrated that antipyrine elimination rate 
was dependent on the type of diabetes (type 1 versus type 2) and gender (Sotaniemi et 
al., 2002).  It was observed that insulipenia enhanced hepatic microsomal enzyme 
activity (probably through increased ketone bodies), whereas relative insulin 
deficiency was associated with decreased metabolic activity (Sotaniemi et al., 2002). 
Since the presence of diabetes and other demographic characteristics could confound 
the effect of NAFLD on DMEs and transporters, it may be necessary to account for 
them.  Finally, the absence of consensus on NASH models and NAFLD classification 
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system to use for experiments has permitted the use of different NASH models and 
classification systems.  For instance, a mice diabetic model of NASH only 
recapitulated human CYP alterations in NAFLD partially (Li et al., 2016); and hence 
may be inadequate for all CYPs.  This has made comparison of results from some 
groups difficult.  It is hoped that as research advance in this earlier, these procedures 
would be harmonized to allow comparability of results. 
1.11 Conclusion 
NAFLD and diabetes are gradually becoming pandemic globally.  Limited options are 
available for the treatment of NASH; hence, several pharmaceutical companies are 
trying to develop new molecules for this condition.  However, lack of knowledge on 
the effect of NAFLD or NASH on the expression and activity of hepatic DMEs and 
transporters can impede drug development in this area.  Current research findings, 
though limited and sometimes conflicting, suggest alterations in DMEs and 
transporters in NAFLD.  Few of the results however are consistent across studies and 
species and includes the down-regulation of CYP3A; and up-regulation of CYP2E1 
and MRP3.  Results from other DMEs and transporters are either lacking or 
conflicting.  Investigating the influence of NAFLD on DMEs and transporters is 
challenging because NAFLD is heterogeneous and involves a spectrum of hepatic 
lesions.  The challenges introduce another layer of variability to NAFLD experimental 
studies.  The presence of steatosis, oxidative stress and inflammatory mediators like 
TNF-α and IL-6 have been implicated in the alterations of nuclear factors in NAFLD.  
Consequently, the regulation of transcription factors like CAR, PXR, PPAR-α, etc. 
may change and eventually alter the expression of DMEs and transporters.  These 
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alterations could be potential sources of drug variability in patients and could have 
serious consequences on safety and efficacy.  We recommend more studies in this area 
to augment our understanding on the effect of NAFLD on drug metabolism. 
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1.13 Tables 
 
Table 1.1 Biomarkers and imaging techniques employed in diagnosis of NAFLD. 
 
Diagnosis 
Tools 
Technique / Principle Features References 
 
Serological 
Tests 
Aspartate 
aminotransferase (AST) 
Raised levels not indicative of 
NAFLD because AST and 
ALTs are normal in some 
NAFLD patients. 
 (Mofrad et 
al., 2003, 
Browning 
et al., 2004, 
Bugianesi 
et al., 2004) 
Alanine 
aminotransferase (ALT) 
AST/ALT > 1 is predictive of fibrosis 
Imaging 
Techniques 
Ultrasonography Sensitive when steatosis is > 
30 % of hepatocytes;                                                                           
Does not distinguish between 
steatosis and NASH 
  
(Wieckows
ka and 
Feldstein, 
2008) 
  
Computerized 
Tomographic (CT) 
Scanning                                              
Magnetic Resonance 
Imaging (MRI) 
More sensitive than 
ultrasonography 
Cannot distinguish between 
steatosis and NASH 
Expensive 
Transient Elastography Can detect fibrosis but 
expensive 
 
Liver Biopsy Histological evaluation 
of hepatic tissues.    
Hepatic lesions like 
steatosis, inflammation 
and ballooning are 
graded; and fibrosis is 
staged. 
Gold Standard but invasive 
and may be involved with 
complications and sampling 
variability                                                  
Able to detect steatosis and 
inflammation                                                    
 (Ratziu et 
al., 2005, 
Wieckowsk
a and
Feldstein, 
2008)
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Table 1.2 The effect of NAFLD on CYP3A4/CYP3A5. 
Overall, NAFLD progression seem to reduce the activity of CYP3A. 
 
Study NAFLD 
Model 
NAFLD 
category 
mRNA Protein Activity Activity 
Probe 
(Kolwankar 
et al., 2007) 
Human 
liver 
tissues 
(Ex vivo) 
 
Steatosis Decreased Slight 
decrease 
Decreased Testosterone 
(Fisher et 
al., 2009) 
Human 
liver 
tissues 
(Ex vivo) 
Steatosis No 
change 
Slight 
increase 
Decreased Testosterone 
NASH 
(fatty) 
No 
change 
Decreased Decreased 
NASH (not 
fatty) 
No 
change 
Decreased Decreased 
(Woolsey et 
al., 2015) 
Human 
Subjects 
(in vivo) 
Steatosis Not 
Reported 
Not 
reported 
 
Decreased 
(2.4 fold) 
Midazolam 
NASH Decreased 
(2.5 fold) 
Human 
liver 
tissues 
(Ex vivo) 
Steatosis Decreased 
(60 %) 
 Not 
reported 
 
  
Not 
reported 
 
  
  
NASH Decreased 
(69 %) 
Female 
Mice  (In 
vivo) 
HFD 
Steatosis  Not 
reported 
 
 Not 
reported 
 
 Not 
reported 
 
CYP3A4 
Luciferase 
Reporter 
plasmid 
Huh7 
hepatoma 
cells (In 
vitro) 
 
Steatosis Decreased 
(80 %) 
 Not 
reported 
 
Decreased 
(38 %) 
Midazolam 
(Li et al., 
2016) 
ob/ob 
male 
Mouse 
(In vivo) 
(MCD) 
 
Diabetic Increase Slight 
decrease 
Slight 
decrease 
Midazolam 
Diabetic 
NASH 
Increase Decreased Slight 
decrease 
 
61 
 
 
Table 1.3 The effect of NAFLD on MRP3. 
Overall, NAFLD progression seem to increase the expression and activity of MRP3 
 
Study Species Ref/NAF
LD 
Endpoi
nt 
Change Probe 
Substrate 
(Hardwick et 
al., 2012) 
Rats (male 
Sprague-
Dawley) 
Control/N
ASH 
mRNA 
level 
Significantly 
increased  
  
Protein Significantly 
increased  
  
Plasma  
Concent
ration 
Significantly 
increased  
Ezetimibe 
glucuronide 
(Dzierlenga et 
al., 2015) 
Rats (male 
Sprague-
Dawley) 
Control/N
ASH 
AUC 150 % 
increase 
Morphine 
glucuronide 
Protein Significantly 
increased  
  
Activity Significantly 
increased  
  
(Ferslew et 
al., 2015) 
Human Healthy/N
ASH 
Cmax 52 % increase 
in NASH 
Morphine 
glucuronide 
AUC 58 % increase 
in NASH 
Morphine 
glucuronide 
(Canet et al., 
2015) 
Human 
(Children) 
Healthy/S
teatosis 
/NASH 
AUC Increased Acetaminophen 
glucuronide 
Human Liver 
Tissues 
Healthy/S
teatosis 
/NASH 
MRP3 
Protein 
Significantly 
increased  
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1.14 Figures 
 
 
 
 
Figure 1.1 The progressive stages of NAFLD (non-alcoholic fatty liver disease) 
The benign form of NAFLD, NAFL (non-alcoholic fatty liver), progresses to NASH (non-alcoholic 
steatohepatitis) with or without fibrosis.  Subsequently, NASH leads to cirrhosis and eventually 
hepatocellular carcinoma. 
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Figure 1.2 Major components of the metabolic syndrome. 
Major components of the metabolic syndrome.  The presence of at least three of these 
components define the presence of metabolic syndrome. 
 
 
 
 
64 
 
MANUSCRIPT II 
 
(For submission to Diabetes/Metabolism Research and Reviews Journal) 
Hepatic neuroendocrine peptides and fatty liver strongly predict the diabetic 
status of donors of human liver tissues 
 
Enoch Cobbina1, Suzanne M. de la Monte2, Fatemeh Akhlaghi1* 
1 Clinical Pharmacokinetics Research Laboratory, Department of Biomedical and 
Pharmaceutical Sciences, University of Rhode Island, Kingston, RI, USA 
2 Departments of Medicine, Pathology, Neurology, and Neurosurgery, Rhode Island 
Hospital and the Warren Alpert Medical School of Brown University, Providence, RI 
02903, USA. 
 
Running Title: Prediction of the diabetic status of human liver tissues (HLTs) 
 
Address for correspondence: Fatemeh Akhlaghi; Clinical Pharmacokinetics 
Research Laboratory; University of Rhode Island; Office 495 A, Avedisian Hall; 7 
Greenhouse Road; Kingston; RI 02881, USA.  Phone: (401) 874 9205; Fax: (401) 874 
5787; Email: fatemeh@uri.edu 
 
Departmental Website URI: http://web.uri.edu/pharmacy/research/akhlaghi/ 
Laboratory Website URI:  http://akhlaghilab.com/ 
Website Brown University: https://vivo.brown.edu/display/fakhlagh 
Google Scholar:
 https://scholar.google.com/citations?user=wdnBYOAAAAAJ&hl=en 
LinkedIn site:   http://www.linkedin.com/in/akhlaghi 
ORCID ID:  orcid.org  0000-0002-3946-7615 
 
 
65 
 
2 MANUSCRIPT II 
Abstract 
Aims: Tools for determination of the diabetic status of human liver tissues (HLTs) 
used to study the effect of diabetes on drug metabolizing enzymes (DMEs) is lacking.  
This study is aimed to establish a model-based approach for predicting the diabetic 
status of donors of HLTs.  
Materials and Methods: HLTs, demographic and anthropometric information were 
supplied by Xenotech LLC.  Histopathological examination was conducted to 
characterize non-alcoholic fatty liver disease (NAFLD) lesions.  HLTs were 
homogenized and levels of feeding-related hepatic neuroendocrine peptides (amylin 
(active), insulin, c-peptide, glucagon, ghrelin, GLP-1 (active), GIP, PP, PYY, leptin 
and MCP-1) determined.  The association between diabetes, and these covariates was 
modeled using multiple logistic regression.  The statistically validated model was used 
to predict new diabetic classes of HLTs.  
Results: A multiple logistic regression model adequately described the association 
between diabetes, NAFLD lesions and the neuroendocrine peptides.  Liver weight, c-
peptide, leptin, PYY, Amylin (active) and steatosis were significant predictors of 
diabetes.  The final model had an AROC curve of 0.89, accuracy of 80%, sensitivity of 
82.4% and specificity of 77%.  The new diabetic classes showed that hepatic GLP-1 
(active) level was 1.4 higher in non-diabetic livers compared to diabetic ones. 
Conclusions: Hepatic neuroendocrine peptides and steatosis strongly predicted the 
diabetic status of HLT donors.  The logistic regression model describing this 
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relationship can be used as a tool to predict the diabetic status of HLTs.  
Key Words:  
Diabetes, liver, model, neuroendocrine, non-alcoholic fatty liver disease 
 
List of abbreviations 
AIC: Akaike information criterion;  AROC: Area under ROC curve;  BAPP: Bias-
adjusted predicted probabilities;  BMI: Body mass index;  DMEs: Drug metabolizing 
enzymes;  FBG: Fasting blood glucose;  GIP: Glucose-dependent insulinotropic 
peptide;  GLP-1: Glucagon-like peptide-1;  HbA1c: Hemoglobin A1c;  HLTs: Human 
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PP: Pancratic polypeptide;  PYY: Peptide YY;  ROC: Receiver operating 
characteristics;  T2D: Type 2 Diabetes 
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2.1 Introduction 
The liver is an important organ involved in the metabolism of many drugs 1.  
Consequently, many drug metabolism studies are performed using human liver tissues 
(HLT) or human hepatocytes 2,3.  Subcellular fractions, mainly microsomes and 
cytosol, derived from HLTs have been used to study the metabolic pathways of new 
drugs and also to investigate the influence of demography, polymorphisms and 
diseases on drug metabolizing enzymes (DMEs) particularly Cytochrome P450 
enzymes 4,5.  Unlike primary human hepatocytes and cell lines, human liver tissues are 
scarce and may not be well characterized with respect to demographic differences, 
disease conditions, medication use and environmental exposures.  Despite these 
limitations, certain investigations including disease effect on the expression and 
activity of DMEs, are preferentially conducted in vitro using human liver tissues 6,7.  
In recent times, efforts have been made to study the effect of non-alcoholic fatty liver 
disease on DMEs using HLTs 6,7.  Nonalcoholic fatty liver disease (NAFLD) is a 
common liver disease with global prevalence ranging from 6-35 % 8-10.  It progresses 
from simple non-alcoholic fatty liver (NAFL) or steatosis to non-alcoholic 
steatohepatitis (NASH), cirrhosis, and eventually hepatocellular carcinoma 11.  To 
delineate the effects of NAFLD on DMEs, HLTs are characterized with respect to 
steatosis and other NAFLD lesions (inflammations, ballooning, fibrosis, etc.) using 
histopathological techniques.  NAFLD is strongly associated with Type 2 diabetes 
(T2D) via the metabolic syndrome 12,13. Unlike NAFLD however, methods to 
characterize HLTs with respect to T2D is still lacking. 
Type 2 diabetes affects over 400 million people globally 14, and like NAFLD, may 
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influence the expression and activity of DMEs.  However, this influence is not clearly 
understood.  To study the influence of diabetes on DMEs, it is similarly important to 
correctly classify the HLTs with respect to the presence or absence of diabetes.  This 
is important because information on the diabetic status of human livers may be lacking 
or unreliable.  For instance, liver donors with prediabetes or undiagnosed diabetes may 
be identified as non-diabetic, although their biochemical profile may be diabetic.  
Conversely, well-managed diabetic donors may be labeled as "diabetic" but may have 
a more non-diabetic biochemical profile.  The mismatch between diabetic labels and 
the biochemical profile of donor livers can adversely affect the reliability of 
investigations aimed at studying the effect of disease state on protein expression or 
enzyme activity.  To predict the diabetic status of HLTs, we propose a novel approach 
that combines vendor-provided information and the biochemical state of the liver 
tissues to confirm the diabetic status of donors.  
In this study, we measured the hepatic concentrations of neuroendocrine peptides 
associated with feeding and diabetes 15.  They included amylin (active), insulin, c-
peptide, glucagon, ghrelin, GLP1-active, GIP (Glucose-dependent insulinotropic 
peptide), PP (pancreatic polypeptide), PYY (peptide YY), leptin, and MCP-1 
(monocyte chemoattractant protein 1).  These peptides are essential to glucose 
homeostasis and some others such as GLP1 and ghrelin, etc. have been targeted for the 
treatment of diabetes 16,17.  Together with anthropometric information and NAFLD 
lesions, a multiple logistic regression model was developed and used to predict new 
diabetic status of the HLT.  It is hoped that findings in this study would help in future 
prediction of HLTs with unknown diabetic status; and pave the way for further 
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investigations to advance approaches to characterizing the true diabetic status of HLTs 
used for drug metabolism studies. 
 
2.2 Materials and Methods 
2.2.1 Human Liver Tissues Characterization.  
Diabetic (n = 51) and non-diabetic (n = 52) human livers were obtained from 
XenoTech LLC (Lenexa, KS, USA) and were carefully selected based on their 
similarity in demographic data.  The NAFLD lesions were determined at the Liver 
Research Center of Brown University Medical School according to a previously 
described scoring system 18.  This scoring system comprises a semi-quantitative 
grading of steatosis (0-3), lobular inflammation (0-2), hepatocellular ballooning (0-2), 
and fibrosis stage (0-4).  These grades generated a NAFLD Activity Score (NAS) 
ranging from 0 to 8 excluding the score from fibrosis that is less reversible.  Using 
established algorithms for NAFLD classification (Kleiner et al., 2005, Kleiner and 
Makhlouf, 2016) the livers were grouped into NoNAFLD (n=29), NAFL (n=34) and 
NASH (n=27). 
2.2.2 Biochemical Analysis.  
The concentration of amylin (active), insulin, c-peptide, glucagon, ghrelin, GLP1-
active, GIP, PP, PYY, leptin and MCP-1 in liver homogenate were determined using 
the Milliplex MAP Kit, HMHEMAG-34K, (EMD Millipore Corporation, Billerica, 
MA) according to manufacturer's instructions with slight modification to the sample 
preparation.  Briefly, liver homogenate was prepared from 200 mg human liver in 
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phosphate buffer containing recommended protease inhibitors at pH=7.4 using Omni 
Bead Ruptor 24 (NW Kennesaw, GA, US).  The homogenate was first centrifuged to 
remove debris and the concentration determined on a MagPix (Luminex, Chicago). 
The concentration of the peptides were expressed in nanogram per gram of liver tissue 
(ng.g-1).  
2.2.3 Statistical methods 
Statistical analyses. Descriptive statistics was used to summarize the demographic and 
anthropometric information, NAFLD lesions and neuroendocrine data. Correlation 
between hepatic neuroendocrine peptides was also obtained.  Graphs were generated 
using GraphPad Prism version 7.0 (GraphPad Software Inc., La Jolla, CA).  All 
statistical analyses and modeling were done in SAS version 9.3 (SAS Institute, Cary, 
NC).  Differences between groups were evaluated using Mann-Whitney U and 
Kruskal-Wallis tests (PROC NPAR1WAY) for groups with two and greater than two 
categories respectively.  Both tests are nonparametric and were used because they do 
not require the normality distribution assumption of data required by parametric 
approaches like T-test and ANOVA (analysis of variance).  Statistical differences 
were considered significant at the P < 0.05 level. 
Dependent variable. The vendor-provided information about the diabetic status of the 
HLTs were used.  Hence, livers were identified as either diabetic or non-diabetic with 
no additional information about the type of diabetes.  The diabetic status (Y) of the 
livers was thus a dichotomous variable as shown below:  
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The dependent variable was modeled as the logit of (Y), i.e., the logit of a diabetic 
liver.  This is summarized below: 
logit =   1 −  
 
Independent variables. Demographic (age, ethnicity) and anthropometric information 
(body weight, body mass index (BMI), liver weight) from Xenotech LLC, the NAFLD 
lesions and concentration levels of the neuroendocrine peptides were used as 
covariates to examine their effect on the probability of the liver donated by a diabetic 
individual.  Categorical variables were included as dummy variables (0 or 1), whereas 
continuous variables were modeled without transformation.  The continuous variables 
included the hepatic levels of all the neuroendocrine peptides, age, body weight, BMI 
and liver weight.  The remaining variables - ethnicity, NAFLD lesions were all 
considered as categorical. 
 
2.2.4 Modeling.  
A multiple logistic model was implemented using PROC LOGISTIC to establish the 
association between the logit of a diabetic liver and the covariates.  The model was of 
the form: 
logit = 
 + 1 1 + ⋯ +     
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Where "a" is the intercept; 'b1" and "bn" are coefficients associated with the 1st and 
nth covariate "X1" and "Xn".  A logistic model was used because the dependent 
variable was dichotomous.  Model results are presented as odds ratios (OR) with 95% 
confidence intervals. 
Model selection and validation. Parsimonious logistic regression models were 
selected using forward, backward and stepwise procedures in SAS.  The adequacy of 
the logistic model was examined using multiple criteria: residuals from the diagnostics 
statistics, the model fit statistics (Akaike Information Criterion (AIC)), and the 
Hosmer-Lemeshow goodness-of-fit test.  This approach was intended to minimize the 
criterion-bias associated with each technique on the model selection. 
The model was validated by classification using bias-adjusted predicted probabilities 
(BAPP) implemented using the CTABLE option of the PROC LOGISTIC model 
statement 19.  The cut-off probability for deciding whether an HLT donor is diabetic or 
not was established using a decision probability.  Decision rule probabilities ranging 
from 0.40 to 0.95 were explored.  The optimal decision probability was chosen based 
on accuracy, sensitivity and specificity of the classification.  This approach 
approximates the unbiased method where a training dataset is modeled and the 
resulting model is used to classify a validation set 19.  The area under the receiver 
operating characteristic (AROC) curve, accuracy, sensitivity, and specificity of the 
final models were computed. 
Prediction of the new diabetic status of the HLTs. Using the final validated logistic 
model, and the optimal decision rule from the BAPP validation, new diabetic classes 
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of the human livers were predicted. 
Biological validation of model. The model-based diabetic classes of the HLTs were 
applied to investigate the differences between the concentration levels of GLP1 whose 
plasma concentration levels between diabetic and non-diabetic populations have been 
studied.  Secondly, the hepatic levels of leptin, PYY, amylin (active) and C-peptide 
between the diabetic and non-diabetic groups were compared with corresponding 
plasma levels reported in literature. 
 
2.3 Results 
2.3.1 Demographic, anthropometric and HLT characteristics.  
A total of 103 human liver tissues (Diabetic = 51, non-diabetic = 52) were used in this 
work.  The covariates included demographic information, NAFLD lesions 
characterization, and concentration of neuroendocrine peptides.  The covariates were 
grouped into categorical (Table 2.1) and continuous variables (Table 2.2 and Table 
2.4) for easy statistical description.  The median age of donors were similar; however, 
the median BMI and liver weight were significantly higher for the diabetic donors 
compared to the non-diabetic (p<0.06).  The median of all the neuroendocrine peptides 
were significantly higher in the non-diabetic group compared to the diabetic, except 
insulin, c-peptide and leptin.  Leptin level was significantly higher in the diabetic 
group.  The levels of insulin and c-peptide were however not different between the 
two groups. 
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2.3.2 Correlation among neuroendocrine peptides.  
With the exception of insulin, MCP-1 and leptin, the hepatic neuroendocrine peptides 
investigated in this work correlated with each other significantly Table 2.5.  PYY 
showed very strong correlation (correlation coefficient > 0.75, p-value <0.001) with 
ghrelin, GLP-1 (active), and GIP.  
2.3.3 Predictors of HLT diabetic status.  
The univariate analyses showed that weight, BMI and liver weight were predictive of 
the diabetic status of the HLTs (AROC curve = 0.60 and 0.64 respectively).  PYY and 
leptin were the most predictive neuroendocrine peptides (AROC curve = 0.73 and 0.69 
respectively).  The remaining neuroendocrine peptides were also predictive of diabetic 
status of the HLT, except c-peptide, and insulin.  None of the NAFLD lesions was 
statistically significant predictor of diabetes, though NAS gave a high AROC curve of 
0.56.  The bivariate analyses however showed that in the presence of PYY and c-
peptide, steatosis and NAS were significant predictors.  Similarly, steatosis was 
predictive in the presence of amylin (active), suggesting a dependence of NAS and 
steatosis on levels of PYY and amylin (active). 
2.3.4 Multiple logistic regression model.  
Two final multiple logistic regression models: model 1 and model 2 (Table 2.3) were 
selected.  In both models, liver weight, c-peptide and leptin had positive effect on the 
diabetic status of the HLTs.  PYY and amylin (active) on the other hand, had a 
negative influence, suggesting reduced risk of diabetes with raised hepatic levels.  
NAS and steatosis positively influenced the diabetic status of livers according to 
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models 1 and 2 respectively.  The AROC curve of model 1 was 0.87, Hosmer-
Lemeshow p-value, 0.80; AIC 106.60; and provided optimal classification at a 
decision probability of 0.55 (accuracy=75%, sensitivity=72.5%, and specificity=77%), 
Figure 2.1.  Model 2 on the other hand, had AROC curve of 0.89, a Hosmer-
Lemeshow p-value of 0.16; AIC 102.60; and a decision probability of 0.5 provided 
optimal classification (accuracy =  80 %, sensitivity = 82.4 % and specificity = 77 % ) 
of the liver tissues, Figure 2.1.  On the basis of a better AIC, AROC curve and 
classification indices (accuracy, sensitivity and specificity), model 2 was selected as 
the best model that adequately demonstrated the relationship between the logit of 
diabetes and the liver weight, c-peptide, leptin, PYY, amylin (active)  and steatosis.  
The graphical representation of ROC (receiver operating characteristic) curve of 
models 1 and 2 have been presented in Figure 2.1.  The cross tabulation of vendor-
supplied and predicted diabetic labels presented in Table 2.6, summarizes the number 
of livers correctly and incorrectly classified. 
2.3.5 Biological validation of model.  
GLP-1 is an incretin involved in postprandial insulin regulation 20.  The plasma levels 
in diabetic and non-diabetic subjects 21,22 have been reported; and hence was used as a 
marker to test the validity of the predicted classes.  We observed a 1.4 fold (non-
diabetic/diabetic: 0.58 ± 0.19 / 0.41 ± 0.20 ng/g of liver) decrease in the hepatic levels 
of GLP1 in diabetic compared to non-diabetic HLTs.  This reduction was similar to 
the 1.4 fold (control/T2D: Fasting levels = 2.87 ± 0.67 / 2.06 ± 0.43; Postprandial 
levels = 3.42 ± 0.85  / 2.49 ± 0.60  pg/mL) 21 and 1.6 fold (control/T2D: Fasting levels 
= 0.32 (0.18 - 0.53) / 0.20 (0.13-0.43) pM) 22 decrease in plasma GLP1 levels in T2D 
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diabetic human subjects.  
In the diabetic HLTs, leptin level was higher, whereas amylin (active), PYY, and c-
peptide were lower when compared to the non-diabetic HLTs.  Leptin plasma levels 
were elevated in Type 2 diabetes 23, and amylin (active) plasma was lower 24,25.  Pre-
prandial plasma level of PYY was reported to be higher in diabetic subjects, however 
after eating, it did not rise significantly compared to the non-diabetic group where 
there was a 63.6 % increase in plasma PYY 26.  Another group also showed reduced 
postprandial plasma PYY level in subjects with a strong history of Type 2 diabetes. 
These results suggested a defect in the functioning of PYY in diabetic subjects and 
corroborated with the hepatic levels shown in Figure 2.2.  Plasma c-peptide has been 
used as a measure of the current functioning of pancreatic β-cells, and also to 
distinguish between Type 1 from Type 2 diabetes 27.  The level we observed suggested 
a better functioning of pancreatic β-cells in the non-diabetic group compared to 
diabetic, however excessive increase may increase the risk of diabetes in accordance 
with the logistic model.  In addition, we detected c-peptide in all the livers suggesting 
that donors may not be Type I diabetic subjects.  Though the plasma levels of these 
peptides may fluctuate with fasting and food intake, the established effects on diabetes 
and glucose homeostasis 28,29 seem to be adequately described by the logistic 
regression model described in this work.   
 
2.4 Discussions 
Human liver tissues are important in vitro tools for drug metabolism studies 
particularly to investigate the influence of diseases like diabetes and NAFLD on drug 
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metabolizing enzymes.  The correct detection of the influence of each of these 
pathologies on DMEs depends on the accurate characterization of each HLT with 
respect to the disease.  Currently the techniques to predict or confirm the diabetic 
status of HLT is limited.  To our knowledge, this is the first study to investigate the 
hepatic levels of feeding-related neuroendocrine peptides, and to model the 
relationship between diabetes, liver weight, steatosis and the neuroendocrine peptides.  
In this study, we used vendor-provided information, hepatic neuroendocrine levels and 
NAFLD lesions to establish a logistic regression model for prediction of the diabetic 
classes of HLTs.  This study confirmed that neuroendocrine peptides: PYY, leptin, 
amylin (active) and c-peptides are significant predictors of diabetes.  Though steatosis, 
an important component of the NAFLD spectrum, and NAS were not significant 
predictors of the diabetic status of HLTs independently, they became significant in the 
presence of PYY and amylin (active), corroborating current knowledge about the 
intricate association of diabetes and NAFLD through the metabolic syndrome 10.  
Additionally, our findings showed that liver weight was also a significant predictor 
with or without the presence of neuroendocrine peptides.  This is not surprising since 
the liver weight is proportional to body weight 30 which is a predictor of diabetes.  
Overall, this study presented a multiple logistic regression model that was capable of 
predicting new diabetic classes of HLTs. 
The most common markers used in clinics for diagnosis and monitoring of diabetes 
include fasting blood glucose (FBG), oral glucose tolerance test (OGTT), hemoglobin 
A1c (HbA1c) and c-peptide 31-33.  The FBG, OGTT and HbA1c tests give indication 
about the plasma glucose concentration, where chronically elevated levels suggest 
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impaired glucose tolerance (IGT) resulting from defective insulin secretion or 
function.  Plasma c-peptide levels directly measures the functionality of the pancreatic 
β-cells, which secrete insulin and hence have been used to aid the differentiation 
between Type 1 and Type 2 diabetes.  C-peptide thus serves as a good surrogate for 
insulin secretion since insulin undergoes significant first pass metabolism 34, and in 
patients receiving exogenously administered insulin, levels may not be accurate as 
both exogenous and endogenous insulin are detected together by assays 27.  Our 
findings, at the hepatic level was in line with the use of c-peptide as a marker for 
diabetes.  
Furthermore, recent drug development efforts for T2D therapies have targeted the 
incretin system 35,36 and other feeding-related neuroendocrine peptides like amylin 37, 
leptin and PYY 38.  This is based on their effect on glucose homeostasis and hence 
association with diabetes.  More importantly is the GLP-1 receptor agonists like 
exenatide 17, liraglutide 16 and semaglutide 39,40, which have been successfully 
developed for the treatment of T2D.  The evidence available in literature thus support 
that our model is pharmacologically plausible.  
The choice of model 2 over model 1 was done on the basis of the improved accuracy, 
sensitivity and specificity when NALFD was incorporated as steatosis instead of NAS. 
Notwithstanding, both emphasize the strong association between diabetes, NAFLD 
and feeding-related neuropeptides at the hepatic level.  To prevent autocorrelation in 
the models, PYY which was a superior predictor was selected instead of GLP-(active), 
Ghrelin and GIP which correlated strongly.  Our model will thus be particularly useful 
for predicting the diabetic classes of HLT, particularly T2D (since we detected c-
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peptide in all the liver tissues), for studying effect of diabetes on DMEs.  This model 
is not meant to be used for clinical diagnosis but for in vitro experiments.  
Some of the limitations of this work include the lack of information about the presence 
of prediabetes and the type of diabetes of the liver donors.  Secondly, we were unable 
to ascertain whether the livers were donated preprandially or postprandially.  Finally, 
we did not have the full record of the medications taken by the donors. 
Notwithstanding, our model was adequate to recapitulate the known relationship 
between diabetes, feeding-related neuroendocrine peptides, NAFLD and liver weight.   
In conclusion, we have presented a pharmacologically plausible model that shows the 
intricate relationship between diabetes, steatosis and feeding-related peptides.  We 
have also demonstrated the ability of this model to predict the diabetic status of human 
liver tissues.  It is hoped that findings in this study would pave the way for further 
investigations to develop more approaches to characterizing the diabetic status of 
human liver tissues used for drug metabolism studies. 
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2.6 Tables 
 
Table 2.1 Description of Human Liver Tissue (HLT) donors. 
Categorical variables from demographic data (Gender and Ethnicity) and non-
alcoholic fatty liver disease characterization (NAFLD). 
 
Variable Definition Category 
Frequency 
 (D/ND) 
Diabetic status 
Diabetic (D) 0 52 
Non-diabetic (ND) 1 51 
Gender 
Female 0 49 (25/24) 
Male 1 54 (26/28) 
Ethnicity 
Caucasian (0) 0 88 (43/45) 
African American (1) 1 10 (5/5) 
Hispanics (2) 2 5 (3/2) 
Steatosis ( % of 
hepatocytes fatty) 
< 5   0 39 (19/20) 
5 – 33 1 24 (15/9) 
> 33 - 66  2 20 (8/12) 
> 66  3 20 (9/11) 
Lobular_inf (Overall 
assessment of all 
inflammatory foci) 
No foci 0 26 (11/15) 
2 foci per 200X field 1 60 (31/29) 
2-4 foci per 200X field 2 15 (9/6) 
> 4 foci per 200X field 3 2 (0/2) 
Hepatocyte_Ballooning 
Non 0 64 (28/36) 
Few balloon cells 1 30 (18/12) 
Prominent ballooning 2 9 (5/4) 
Fibrosis 
None 0 42 (19/23) 
Perisinusoidal or 
periportal 
1 45 (24/21) 
Perisinusoidal and 
portal/periportal 
2 10 (6/4) 
Bridging fibrosis 3 6 (2/4) 
NAFLD Activity Score 
(NAS) 
The unweighted sum of 
steatosis, lobular 
inflammation, and 
hepatocellular 
ballooning scores 
0 14 (4/10) 
1 24 (14/10) 
2 16 (10/6) 
3 15 (6/9) 
4 17 (9/8) 
5 9 (5/4) 
6 4 (1/3) 
7 4 (2/2) 
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Table 2.2 Description of characteristics of Human Liver Tissues (Continuous variables).  
Continuous variables from demographic (Age), anthropometric data (Weight, BMI, 
Liver weight) and hepatic concentration of neuroendocrine peptides (ng/g of liver). 
Data summarized according to diabetes category. 
 
Variable Diabetic Status N Median (min-max) p-value 
Age (years) 
D 51 51 (21-78) 
0.7 
ND 52 53.5 (21-76) 
Weight (kg) 
D 51 94 (51-213) 
0.06 
ND 52 85 (48-159) 
BMI (kg/m2) 
D 51 34 (18-89) 
0.008 
ND 52 28.5 (17-54) 
Liver Weight (g) 
D 51 1719 (1016-4375) 
0.04 
ND 52 1522 (884-3181) 
C-Peptide  
D 51 1.3 (0.5-2.7) 
0.09 
ND 52 1.6 (0.5-2.9) 
Ghrelin 
D 51 0.19 (0.09-0.39) 
0.0003 
ND 52 0.27 (0.1-0.62) 
GIP 
D 51 0.15 (0.03-0.32) 
0.004 
ND 52 0.19 (0.06-0.34) 
GLP1 (Active) 
D 51 0.4 (0.15-0.91) 
0.002 
ND 52 0.54 (0.09-1.02) 
Glucagon 
D 51 0.75 (0.36-2.1) 
0.005 
ND 52 1.1 (0.28-2.75) 
Insulin 
D 51 5.56 (1.33-24.68) 
0.9 
ND 52 5.5 (1.02-23.16) 
Leptin 
D 51 95.38 (28.04-276.98) 
0.0007 
ND 52 68.68 (15.46-183.5) 
MCP2 
D 51 1.67 (0.33-13.18) 
0.8 
ND 52 1.72 (0.42-22.38) 
PP 
D 51 0.22 (0.05-0.51) 
0.008 
ND 52 0.27 (0.1-0.66) 
PYY 
D 51 1.46 (0.76-2.17) 
0.0001 
ND 52 1.87 (1.04-2.83) 
Amylin_Active 
D 51 0.89 (0.27-1.66) 
0.007 
ND 52 1.14 (0.51-2.8) 
ND: Non-diabetic; D: Diabetic. 
*P-values were obtained using nonparametric Mann-Whitney U test.  
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Table 2.3 Multiple logistic regression model predicting the diabetic status of human 
liver tissues.  
Model 1 (NAFLD was incorporated as NAFLD activity score (ref=0, when NAS 
<2));  
and Model 2 (NAFLD was incorporated as steatosis, (ref=0, when steatosis <33 %)). 
 
MODEL1           
Parameter Beta 
Coefficient 
Standard 
Error 
p-value Odds 
Ratio 
95 % 
Confidence 
Limit 
Intercept 0.5481 1.7122 0.7489 
Liver Weight 0.00122 0.0006 0.0285 1.001 1.000 - 1.002 
PYY -4.2113 1.124 0.0002 0.015 0.002 - 0.134 
C-Peptide 2.8297 0.9721 0.0036 16.941 2.52 - 113.872 
Leptin 0.0166 0.00607 0.0061 1.017 1.005 - 1.029 
Amylin 
(active) 
-2.2311 0.8877 0.012 0.107 0.019 - 0.612 
NAS (ref=0) 1.8378 0.6558 0.0051 6.283 1.737 - 22.718 
MODEL 2           
Parameter Beta 
coefficient 
Standard 
error 
p-value Odds 
Ratio 
95 % CI 
Intercept 0.85 1.7982 0.6364   
Liver Weight 0.00137 0.0006 0.0206 1.001 1.000 -1.003 
PYY -4.7323 1.2311 0.0001 0.009 0.001 - 0.098 
C-Peptide 2.7635 0.9953 0.0055 15.855 2.254 - 111.53 
Leptin 0.0152 0.0059 0.0099 1.015 1.004 - 1.027 
Amylin 
(active) 
-2.2536 0.8892 0.0113 0.105 0.018 - 0.600 
Steatosis 
(ref=0) 
2.3874 0.7327 0.0011 10.885 2.589 - 45.766 
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2.7 Figures 
 
 
 
Figure 2.1 Classification indices of logistic regression models.  
Graphical representation of classification indices of logistic regression models used 
for predicting diabetic classes of human liver tissues.  Upper graphs: ROC curves for 
Models 1 and 2; Lower graphs : accuracy, sensitivity and specificity graphs for 
Models 1 and 2.  On the basis of accuracy, sensitivity and specificity a decision 
probability of 0.55 was selected for Model 1, and 0.5 for model 2.  The chosen 
decision probabilities are shown by arrows on respective graphs.  In model 1, NAFLD 
was incorporated as NAS whereas in Model 2 it was added as steatosis. 
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Figure 2.2 Comparison of hepatic levels of feeding related-neuroendocrine peptides.  
Feeding related-neuroendocrine peptides used for biological validation of the 
model (GLP1 (active), leptin, amylin (active), c-peptide and PYY).  The hepatic 
levels were statistically significant (p < 0.01) between the non-diabetic (n=42) and 
the diabetic group (n=40) 
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2.8 Supplementary Information 
 
Table 2.4  Description of characteristics of HLTs (Continuous variables).  
Continuous variables from demographic (Age), anthropometric data (Weight, BMI, 
Liver weight) and hepatic concentration of neuroendocrine peptides (ng/g of liver). 
Data summarized according to nonalcoholic fatty liver disease (NAFLD) grouping. 
 
Variable Category N Median (min - max) P-value 
Age 
NoNAFLD 39 49 (21 - 78) 
0.2 NAFL 35 54 (33 - 76) 
NASH 29 51 (33 - 74) 
Weight (kg) 
NoNAFLD 39 78 (55 - 213) 
0.1 NAFL 35 93 (48 - 191) 
NASH 29 91 (69 - 158) 
BMI (kg/m2) 
NoNAFLD 39 28 (18 - 89) 
0.2 NAFL 35 31 (17 - 70) 
NASH 29 32 (22 - 52) 
Liver Weight (g) 
NoNAFLD 39 1465 (884 - 2300) 
0.006 NAFL 35 1902 (1053 - 4375) 
NASH 29 1819 (1180 - 3685) 
C-Peptide 
NoNAFLD 39 1.7 (0.9 - 2.9) 
0.0001 NAFL 35 1.2 (0.5 - 1.9) 
NASH 29 1.1 (0.8 - 2) 
Ghrelin 
NoNAFLD 39 0.31 (0.17 - 0.51) 
0.0001 NAFL 35 0.19 (0.09 - 0.58) 
NASH 29 0.19 (0.09 - 0.62) 
GIP 
NoNAFLD 39 0.21 (0.09 - 0.34) 
0.001 NAFL 35 0.15 (0.03 - 0.29) 
NASH 29 0.15 (0.06 - 0.27) 
GLP (active) 
NoNAFLD 39 0.55 (0.27 - 1.02) 
0.0001 NAFL 35 0.39 (0.15 - 0.93) 
NASH 29 0.37 (0.09 - 0.81) 
Glucagon 
NoNAFLD 39 1.09 (0.4 - 2.17) 
0.03 NAFL 35 0.74 (0.36 - 2.75) 
NASH 29 0.83 (0.28 - 1.76) 
Insulin 
NoNAFLD 39 6.23 (1.96 - 23.16) 
0.2 NAFL 35 5.56 (1.33 - 24.68) 
NASH 29 4.77 (1.02 - 22.99) 
Leptin 
NoNAFLD 39 74.24 (15.46 - 191.78) 
0.3 
NAFL 35 81.01 (30.24 - 276.98) 
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NASH 29 96.62 (24.65 - 222.36) 
MCP1 
NoNAFLD 39 1.66 (0.33 - 9.09) 
0.6 NAFL 35 1.63 (0.51 - 13.18) 
NASH 29 2.42 (0.42 - 22.38) 
PP 
NoNAFLD 39 0.32 (0.18 - 0.66) 
0.0001 NAFL 35 0.22 (0.1 - 0.42) 
NASH 29 0.2 (0.05 - 0.41) 
PYY 
NoNAFLD 39 1.95 (1.35 - 2.68) 
0.0001 NAFL 35 1.45 (0.76 - 2.83) 
NASH 29 1.47 (0.92 - 2.47) 
Amylin (Active) 
NoNAFLD 39 1.19 (0.47 - 2.8) 
0.008 NAFL 35 0.87 (0.27 - 1.89) 
NASH 29 0.9 (0.55 - 1.52) 
*P-values were obtained using nonparametric Kruskal-Wallis test.  
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Table 2.5  Correlation between the hepatic neuroendocrine peptides.  
Correlation between the hepatic neuroendocrine peptide concentrations (ng/g of liver). 
  
C-
Peptide 
Ghrelin GIP 
GLP-1 
(Active) 
Glucagon Insulin Leptin 
MCP-
1 
PP PYY 
Amylin 
(active) 
C-Peptide 
1.00 
         
  
  
         
  
Ghrelin 
0.71 1.00 
        
  
<.0001   
        
  
GIP 
0.67 0.74 1.00 
       
  
<.0001 <.0001   
       
  
GLP-1 
(Active) 
0.71 0.74 0.63 1.00 
      
  
<.0001 <.0001 <.0001   
      
  
Glucagon 
0.33 0.60 0.52 0.48 1.00 
     
  
0.0007 <.0001 <.0001 <.0001   
     
  
Insulin 
0.09 0.11 0.04 0.20 0.05 1.00 
    
  
0.4 0.3 0.7 0.0 0.6   
    
  
Leptin 
-0.17 -0.28 -0.25 -0.25 -0.14 -0.06 1.00 
   
  
0.09 0.004 0.01 0.010 0.1 0.6   
   
  
MCP-1 
0.02 -0.04 -0.01 0.08 -0.12 0.03 -0.12 1.00 
  
  
0.9 0.7 0.9 0.4 0.2 0.7 0.2   
  
  
PP 
0.68 0.62 0.74 0.62 0.42 0.02 -0.23 -0.01 1.00 
 
  
<.0001 <.0001 <.0001 <.0001 <.0001 0.8533 0.0188 0.9002   
 
  
PYY 
0.68 0.83 0.79 0.75 0.59 0.10 -0.26 -0.12 0.72 1.00   
<.0001 <.0001 <.0001 <.0001 <.0001 0.3 0.01 0.2 <.0001     
Amylin 
(active) 
0.61 0.51 0.52 0.45 0.26 -0.08 -0.12 0.08 0.46 0.52 1.00 
<.0001 <.0001 <.0001 <.0001 0.007 0.4 0.2 0.4 <.0001 <.0001   
Correlation coefficient are aligned to the left (shaded rows); and p-values associated with correlation coefficients aligned to 
the right (unshaded rows).
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Table 2.6  Cross tabulation.  
Cross tabulation of vendor-provided diabetic labels and predicted diabetic classes. 
 
Vendor-provided 
Diabetic label 
Predicted Diabetic 
Class 
ND D Total 
ND 40 12 52 
D 9 42 51 
Total 49 54 103 
ND: Non-diabetic; D: Diabetic; Shaded cells are correctly predicted livers.  
40 out of 52 livers were predicted correctly as non-diabetic. 42 out of 51 liver tissues 
were predicted correctly as diabetic.
 
95 
 
CHAPTER 4: MANUSCRIPT III 
 
(For publication in Diabetes Obesity and Metabolism Journal) 
 
Nonalcoholic fatty liver disease (NAFLD) alters the in vitro kinetics of the 
CYP2B6-mediated formation of hydroxybupropion in human liver tissues and 
HepaRG cells. 
 
Enoch Cobbina1, Anitha Saravanakumar1, Fatemeh Akhlaghi1* 
1 Clinical Pharmacokinetics Research Laboratory, Department of Biomedical and 
Pharmaceutical Sciences, University of Rhode Island, Kingston, RI, USA 
 
Running Title: NAFLD alters CYP2B6-mediated hydroxylation of bupropion 
 
Address for correspondence: Fatemeh Akhlaghi; Clinical Pharmacokinetics 
Research Laboratory; University of Rhode Island; Office 495 A, Avedisian Hall; 7 
Greenhouse Road; Kingston; RI 02881, USA.  Phone: (401) 874 9205; Fax: (401) 874 
5787; Email: fatemeh@uri.edu 
 
Departmental Website URI: http://web.uri.edu/pharmacy/research/akhlaghi/ 
Laboratory Website URI:  http://akhlaghilab.com/ 
Website Brown University: https://vivo.brown.edu/display/fakhlagh 
Google Scholar:
 https://scholar.google.com/citations?user=wdnBYOAAAAAJ&hl=en 
LinkedIn site:   http://www.linkedin.com/in/akhlaghi 
ORCID ID:  orcid.org  0000-0002-3946-7615 
 
96 
 
3 MANUSCRIPT III 
Abstract 
Despite the initial belief that Cytochrome P450 (CYP) 2B6 is of minor significance, it 
is now recognized as a clinically relevant drug metabolizing enzyme.  The impact of 
non-alcoholic fatty liver disease (NAFLD) on drug metabolism has been identified; 
however, it is still unclear how it influences CYP2B6.  We used in vitro approaches in 
human liver microsomes (HLM) and HepaRG cells to investigate the effect of 
NAFLD on CYP2B6-mediated formation of hydroxybupropion. The presence of 
NAFLD increased the km significantly (p < 0.04) and reduced CYP2B6 intrinsic 
clearance 2-fold.  The results from the HepaRG cells qualitatively recapitulated 
findings in the HLMs.  Fatty acid accumulation in hepatocytes seems to be involved 
with the alteration.  This investigation is hoped to contribute to our current knowledge 
on the influence of NAFLD on CYP2B6 in vitro kinetics and offers the opportunity 
for further studies in a clinical trial.   
 
Keywords 
Bupropion, Hydroxybupropion, Cytochrome P450 2B6, fatty acids, NAFLD, NASH, 
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Abbreviations: 
AUC - Area Under (the plasma concentration) Curve 
BSA - Bovine Serum Albumin 
CAR/NR1I3 - Constitutive Androstane Receptor; nuclear factor subfamily 1, group I, 
member 3 
CLint - Intrinsic Clearance 
CYP - Cytochrome P450 
FAF - Fatty Acid Free 
EMEM -Eagle's Minimum Essential Medium 
HBUP - Hydroxy Bupropion 
HF - High-fat 
HLT - Human Liver Tissue 
HLM - Human Liver Microsome 
km - Michaelis-Menten constant 
MCD - Methionine-Choline Deficient 
MPPGL - Microsomal Protein Per Gram of Liver 
NAFLD - Non-Alcoholic Fatty Liver Disease 
NAS - NAFLD activity score 
NASH - Non-Alcoholic Steatohepatitis 
PBPK - Physiologically-based Pharmacokinetics 
PBS – Phosphate Buffer Saline 
PXR/NR1I2 - Pregnane X receptor; Nuclear factor subfamily 1, group I, member 2 
ROC - Receiver Operating Characteristic  
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UPLC/ MS/MS - Ultra Performance Liquid Chromatography tandem Mass 
Spectrometry 
Vmax - Maximum Velocity  
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3.1 Introduction 
Cytochrome P450 (CYP) 2B6 is one of the drug metabolizing enzymes (DMEs) 
mainly expressed in the liver (Mimura et al., 1993).  Though it is considered a minor 
DME, it is involved in the biotransformation of clinically relevant drugs like 
bupropion (Hesse et al., 2000), efavirenz (Ward et al., 2003), and cyclophosphamide 
(Xie et al., 2003).  Bupropion and efavirenz are also used as sensitive probe substrates 
for phenotyping CYP2B6 activity via the formation of hydroxybupropion (Hesse et 
al., 2000) and 8-hydroxyefavirenz (Ward et al., 2003) respectively.  
The expression and activity of CYP2B6 is highly variable among individuals.  The 
sources of variability include polymorphisms in the CYP2B6 gene, induction via  the 
constitutive androstane receptor (CAR, NR1I3) and pregnane X receptor (PXR, 
RN1I2) (Faucette et al., 2006), inhibition by potent agents like ticlopidine (Turpeinen 
et al., 2005), and disease state.  The study of hepatic diseases as a source of variability 
in DMEs is crucial because, hepatic clearance constitutes about 60% of major 
clearance mechanisms of clinically relevant  drugs (Williams et al., 2004).  
The effect of alcoholic liver disease (ALD) on the disposition of a single dose (200 
mg) bupropion was studied in human subjects (healthy (n=8) and ALD (n=8)) 
(DeVane et al., 1990).  Compared to healthy subjects, the ALD subjects had elevated 
AUC of bupropion (~57 %) and hydroxybupropion (~53 %).  The changes in the other 
metabolites of bupropion, erythrohydrobupropion (EB) and threohydrobupropion 
(TB), were however minimal.  The apparent clearance of bupropion reduced from 187 
to 145 L/hr in ALD subjects.  There was also a large intersubject variability in the 
pharmacokinetics of bupropion, especially in the ALD subjects, where bupropion half-
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life ranged from 2.2 - 29.9 hours.  Though the study was conducted in a limited 
number of subjects, the findings highlighted the potential influence of hepatic diseases 
on the disposition of bupropion, hence on CYP2B6 that is responsible for the 
formation of hydroxybupropion.  
Similar to ALD is nonalcoholic fatty liver disease (NAFLD) (Toshikuni et al., 2014). 
NAFLD is emerging as one of the commonest liver diseases worldwide.  Its global 
prevalence is estimated to range from 6-35 % (Bellentani, 2017, Cobbina and 
Akhlaghi, 2017).  NAFLD progresses from steatosis, also known as nonalcoholic fatty 
liver (NAFL), to fibrosis, non-alcoholic steatohepatitis (NASH), cirrhosis, and 
eventually hepatocellular carcinoma (HCC) (Angulo, 2002).  These lesions cause 
alterations in inflammatory and biochemical pathways which subsequently interfere 
with normal hepatic regulation of drug metabolism and glucose homeostasis (Cobbina 
and Akhlaghi, 2017).  NAFLD is strongly associated with the metabolic syndrome and 
is common in obesity (Bellentani et al., 2010), Type 2 diabetes (Anstee et al., 2013) 
and HIV/AIDs patients (Verna, 2017).  In view of the high prevalence of NAFLD in 
the population, several groups have evaluated the impact of NAFLD on drug 
metabolizing enzymes (Fisher et al., 2009, Woolsey et al., 2015, Canet et al., 2015, 
Ferslew et al., 2015). 
Though a number of the studies that examined the impact of NAFLD on DMEs did 
not observe alterations in the expression and activity of CYP2B6, others have 
highlighted the potential impact of NAFLD on CYP2B6 where the presence of NASH 
reduced gene expression (Yoneda et al., 2008, Stepanova et al., 2010).  In high-fat 
induced steatotic male C57/BL6 mice, the expression of Cyp2b10, (the mouse 
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ortholog of the human CYP2B6), was reduced (Kirpich et al., 2011).  Similarly, in 
human liver tissues the gene expression of CYP2B6 was reduced in the Non-NASH 
group (Stepanova et al., 2010, Yoneda et al., 2008).  A more recent study in 
Sprague−Dawley rats fed with a methionine/choline deficient (MCD) diet to induce 
NASH, showed marked reduction in activity, mRNA and protein expression of 
Cyp2b1 (rat ortholog of human CYP2B6) (Cho et al., 2016).  Additionally, the in vitro 
kinetic parameters determined using the rat liver microsomes showed 26 % reduction 
in Vmax and 2.4 fold reduction in Km of Cyp2b1.  Consequently, the bupropion AUC 
in the rat NASH model was about 1.9-fold higher compared to control.  Conversely, 
the same study reported no change in the activity, mRNA and protein expression of 
Cyp2b1 in high-fat diet induced steatotic rats (Cho et al., 2016).  Another key group 
observed increasing trend (p=0.003) in the relative mRNA expression of CYP2B6 in 
NAFLD human liver tissues compared to control.  Relative protein expression, 
however, showed a decreasing trend from steatosis to NASH (no longer fatty)  (Fisher 
et al., 2009).  The current evidence in the literature do not agree very well.  This lack 
of consensus may emanate from the variableness of the expression and activity of 
CYP2B6; and disparity in the different models used for the investigations (Li et al., 
2018).   
Despite the important contributions by other groups to this field, the activity together 
with  in vitro kinetics of CYP2B6 in human liver tissues have not been evaluated with 
respect to NAFLD.  Though, gene and protein expression information helps us gain 
mechanistic insight into the expression of enzymes, for the purposes of translational 
pharmacokinetics (in-vitro-in-vivo extrapolation (IVIVE)), information about the 
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activity and kinetics of an enzyme is more useful.  Hence, in this study, we 
investigated the influence of NALFD on the activity and kinetics of CYP2B6 using 
bupropion hydroxylation as probe.  To reduce the heterogeneity in the human liver 
tissues, the livers were characterized with respect to demography, genetic 
polymorphisms, and diabetes.  We examined further the effect of NAFLD on CYP2B6 
using fatty-acid-treated HepaRG cell lines.  With the aid of a physiologically-based 
pharmacokinetic (PBPK) model (Rowland et al., 2011) implemented in Simcyp 
simulator (Jamei et al., 2009), we simulated the potential effect of NAFLD on the 
biotransformation of bupropion to hydroxybupropion.  This investigation is hoped to 
contribute to our current knowledge on the influence of NAFLD on CYP2B6 in vitro 
kinetics and offers the opportunity for further studies in a clinical trial. 
3.2 Materials and Methods 
3.2.1 Chemicals and Reagents.  
Bupropion hydrochloride (BUP), hydroxybupropion (HBUP), hydroxybupropion-d6, 
chlorzoxazone (CZ), 6-hydroxy chlorzoxazone (6-OH CZ), and 6-hydroxy 
chlorzoxazone-d2 were purchased from Toronto Research Chemicals Inc. (North 
York, Canada); LC/MS-grade, acetonitrile, ammonium acetate and formic acid were 
from Fisher Scientific (Fair Lawn, NJ); potassium phosphate monobasic and 
potassium phosphate dibasic were purchased from Sigma-Aldrich (St. Louis, MO, 
USA).  Nicotinamide adenine dinucleotide phosphate (NADPH)-cytochrome P450 
reductase was obtained from EMD Millipore (Billerica, MA).  All other reagents and 
solvents were obtained from general commercial suppliers and used without further 
purification.  Solutions were prepared in accordance with manufacturers' instructions. 
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3.2.2 Experiments in Human Liver Tissues 
Characterization of human liver tissues (HLT). Human livers from donors with 
diabetes (n=53) and without diabetes (n=53) were obtained from XenoTech LLC 
(Lenexa, KS, USA).  These were matched based on age, gender and degree of liver 
fat.  The presence of NAFLD was established by histological evaluation of the livers 
in a blinded fashion.  A semi-quantitative grading of steatosis (0-3), lobular 
inflammation (0-2), hepatocellular ballooning (0-2), and fibrosis staging (0-4) 
permitted the classification of the livers into NoNAFLD, NAFL and NASH according 
to the SAF (steatosis, activity and fibrosis) algorithm (Bedossa et al., 2012, Kleiner 
and Makhlouf, 2016, Cobbina and Akhlaghi, 2017).  The diabetic status of livers were 
confirmed using a logistic regression model established by our lab [manuscript in 
preparation].  The model had an AROC curve of 0.89 and was accurate (80 %), 
sensitive (82.4%) and specific (77%).  Predicted probability of each liver being 
diabetic was determined.  Using a previously established decision probability of 0.5, 
liver was categorized nondiabetic if predicted probability was less than 0.5 and 
diabetic if greater than 0.5.  The predicted diabetic class was compared with the 
original vendor-provided labels to determine the correctly classified and the 
misclassified (false positives and negatives) livers.  This approach was carried out to 
reduce intrinsic experimental error due to misclassification of the diabetic status of 
HLTs.  Misclassified livers were removed from analyses when CYP2B6 activity and 
expression were compared between diabetic and nondiabetic groups. 
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Human liver microsome (HLM) isolation: The human liver microsomes were 
prepared by differential ultracentrifugation.  Briefly, 200 mg of HLT was 
homogenized in 100 mg liver tissue/ 300 uL of homogenization buffer (100 mM 
potassium phosphate buffer, pH=7.4; 1 mM EDTA; 0.1 mM potassium chloride; 8.55 
g of sucrose; and 0.02 mM butylated hydroxytoluene) using Omni Bead Ruptor 24 
(NW Kennesaw, GA, US).  Homogenate was centrifuged at 10,000g for 30 min at 4 
oC and the supernatant was collected and centrifuged at 100,000g for 60 min at 4 oC. 
The supernatant, cytosolic fraction, was collected and stored at -80°C.  The 
microsomal pellet was then washed with 100 mM potassium pyrophosphate buffer 
(pH=7.4) and re-suspended in 1000 mg liver tissue/ 660 uL of storage buffer (100 mM 
phosphate buffer, pH=7.4; 20% glycerol and 1 mM EDTA).  Prepared microsomes 
were stored at -80°C until analysis.  Total protein concentrations were determined 
using a bicinchoninic acid (BCA) assay in accordance with manufacturer's instructions 
(Pierce-Fisher, Rockford, IL, USA).  
 
Human Liver Microsomal Incubation: The activity of CYP2B6 was measured using 
bupropion hydroxylation, by examining varying concentrations of bupropion (0, 10, 
50, 100, 400, 800, 1600 uM) in an incubation buffer (100 mM potassium phosphate 
buffer (pH=7.4), and ~3 mM magnesium chloride, and 1 mM EDTA) containing 0.05 
mg.mL-1 of HLM.  All incubations were carried out in accordance with previously 
described methods with slight modification (Faucette et al., 2000, Walsky and Obach, 
2009).  The incubation mixture containing bupropion was pre-incubated for 5 mins in 
a water bath at 37 oC; and reaction initiated by addition of ~1.3 mM NADPH.  This 
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was incubated for 10 mins and then terminated with 20 uL of ice cold 5:92:3 
acetonitrile/water/formic acid containing hydroxy bupropion-d6 internal standard.  
The final incubation mixture was 200 uL.  After centrifugation at 3000 rpm for 10 
mins at 4 oC, the supernatant was collected and the amount of hydroxybupropion 
formed was quantified using liquid chromatography/ tandem mass spectrometry 
methodologies (UPLC-MS/MS).  The rate of hydroxybupropion formation was then 
calculated and the in vitro kinetics estimated.  
 
RNA Content determination using Reverse transcription-polymerase chain reaction 
(qRT-PCR): Total RNA was isolated from the HLTs using the RNeasy Mini Kit 
(Qiagen, Valencia, CA).  The total RNA was reverse-transcribed, and the single 
stranded DNA was used for real-time PCR.  The mRNA expression of hepatic CYP 
was quantified by real-time PCR using an Applied Biosystems 7500 Real-Time PCR 
system (Applied Biosystems) at least two times according to the manufacturer’s 
instructions.  Primer sequences for the CYP2B6, CAR, and PXR are reported in 
supplementary Table 3.5.  18S ribosomal RNA (rRNA) was also quantified as an 
internal control. 
 
CYP2B6 Genotyping of HLTs: Genomic DNA was isolated from the HLTs using 
QIAamp DNA Mini Kit (Qiagen, Valencia, CA) according to manufacturer’s 
instructions and genotyped for two single nucleotide polymorphisms (SNPs) in the 
P450 CYP2B6: CYP2B6*5 (rs3211371; 25505C>T) and CYP2B6*6 (rs3745274; 
15631G>T).  The CYP2B6 SNPs were determined by Taqman® Allelic 
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Discrimination Assays and Taqman Genotyping Mastermix (Applied Biosystems, 
Foster, CA) on ViiA™ 7 Real-Time PCR System (Applied Biosystems).  
3.2.3 Experiments in HepaRG Cell Lines  
Cell Culture: HepaRG cell lines have been used for drug metabolism studies because 
of its ability to express various Cytochrome P450 enzymes including CYP2B6 
(Kanebratt and Andersson, 2008).  The HepaRG cells (passages 2-5) were obtained 
from Biopredic International (Rennes, France), and were cultured and differentiated in 
accordance with manufacturer's instructions.  Steatosis was induced with 500 μM fatty 
acids (1:2 palmitate : oleate) conjugated to albumin in 30% essential fatty acid free 
(FAF) bovine serum albumin (BSA) solution (Invitrogen, Grand Island, NY) by 
modifying a previously described method (Brown et al., 2013).  The cells were treated 
for 72 h and media replenished after 48 h.  
Oil Red O Staining: Fatty-acid-treated and control HepaRG Cells were washed twice 
with PBS and fixed in 4% paraformaldehyde (Sigma-Aldrich, Saint Louis, MO) for 30 
min at room temperature.  Cells were washed with PBS and subsequently incubated 
with Oil Red O (Sigma-Aldrich, Saint Louis, MO) in PBS for 20 mins at room 
temperature.  After three washes, cells were incubated with hematoxylin (Sigma-
Aldrich, Saint Louis, MO) for 1 min to stain the nuclei and imaged to examine 
intracellular lipid accumulation using EVOS cells imaging systems (Life technologies, 
Foster City, CA).  Subsequently, the cells were examined spectrophotometrically in 
100% isopropanol using Spectromax (Molecular Devices, Sunnyvale, CA) at 492 nm. 
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RNA Extraction: For mRNA measurements, total RNA was isolated from both 
control and fatty-acid-treated HepaRG cells using the RNeasy Mini kit according to 
the manufacturer's instructions (Qiagen, Valencia, CA).  The quantity and quality of 
the RNA were determined using Nanodrop 1000 spectrophotometer (Thermo 
Scientific, Wilmington, DE).  The cDNA was prepared from 1 μg of total RNA using 
High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, 
CA) in accordance with the manufacturer’s instructions.  DNAse treatment (Qiagen, 
Valencia, CA) was included to avoid genomic DNA contamination. 
Real-Time PCR. Quantitative real-time PCR analyses of both fatty-acid-treated and 
control were performed with specific sets of Taqman primers and Taqman probes for 
CYP2B6 (Hs03044634_m1), PXR (Hs01114267_m1), CAR (Hs00901571_m1), 18S 
(Hs03003631_g1), GAPDH (Hs99999905_m1) and β-actin (Hs99999903_m1) using a 
ViiA™ 7 Real-Time PCR system in accordance with the manufacturer's instructions. 
GAPDH, 18 S and β-actin were used as endogenous controls to normalize the data.  
All runs were carried out in triplicate; and data analyzed using DataAssist software 
(Thermo Fisher Scientific, Waltham, MA). 
Insulin-stimulated phosphorylation of AKT: Following 72 h treatment, HepaRG cells 
were placed in serum free EMEM media for 12 h followed by stimulation with 
recombinant human insulin (Roche Diagnostics, Indianapolis, IN) at 1, 10 or 100 nM 
for 10 minutes at 37⁰C.  Samples were rinsed in PBS and lysed with RIPA buffer 
(150mM NaCl, 50mM Tris, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 1mM 
EDTA) supplemented with complete protease inhibitor cocktail (Roche Diagnostics) 
and HALTTM phosphatase inhibitor cocktail (Thermo Scientific, Waltham, MA) for 30 
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minutes at 4⁰C.  The lysate was run on sandwich ELISA kit that detected both pAkt 
(Ser473) and total Akt (Abcam, Cambridge, MA).  The assay was performed in 
accordance with the manufacturer’s protocol. 
Activity studies: Both control and fatty-acid-loaded HepaRG Cells were incubated 
with varying concentrations of bupropion (100, 250, 500, 750, 1000, 2500 uM), and 
chlorzoxazone (500, 750, 1000 μM) for 1 and 8 h in Williams' medium E in triplicates. 
The compounds were dissolved in DMSO in such a way that the final concentration 
was less than 0.1%.  The reaction was terminated with equal volume of ice-cold 
acetonitrile containing 0.1% formic acid and deuterated internal standards 
(hydroxybupropion-d6 for bupropion and chlorzoxazone-d2 for chlorzoxazone 
respectively).  The formation of hydroxybupropion and 6-hydroxy chlorzoxazone 
were determined using UPLC-MS/MS.  
3.2.4 UPLC-MS/MS measurements. 
Hydroxybupropion and 6-hydroxy chlorzoxazone were quantified using ACQUITY 
UPLC™ chromatographic system (Waters Corp., MA, USA) and an API 3200 triple 
quadrupole mass spectrophotometer (Applied Biosystems, Foster City, CA) with 
positive electrospray ionization.  Chromatographic separation was achieved using 
Waters ACQUITY C-18 column (50 × 2.1 mm; 1.7 μm particle size) and waters 
ACQUITY UPLC C-18 Vanguard pre-column.  Mobile phase A (10 mM aqueous 
ammonium acetate, 5% acetonitrile) and B (100% acetonitrile) were pumped at a flow 
rate of 0.45 mL.min-1 using a gradient ranging from 2% B at 0 to 0.5 mins, 32% B at 
2.4 to 2.7 mins, 2% B at 2.9 to 4.5 mins.  The column temperature was maintained at 
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32 oC.  
For hydroxybupropion, optimal conditions for the MRM scan in the positive 
ionization mode were: ion spray voltage, 5500 V; curtain gas, 35 L/h; ion source Gas1, 
55 L.h-1; ion source Gas2, 50 L.h-1; temperature, 450 oC; collision Gas, 6 L.h-1.  The 
MRM transitions of hydroxybupropion were m/z 256→238 and 256→130; and those 
of the hydroxy bupropion - d6 were 262 → 139 and 262 → 244. The assay was linear 
from 0.001 to 10 uM (R2 < 0.99), precise (Coefficient of variation = 1-8%) and 
accurate (94 - 105%). 
For 6-hydroxy chlorzoxazone, optimal conditions for the multiple reaction monitoring 
(MRM) scan in the negative ionization mode were: ion spray voltage, -4500 V; curtain 
gas, 35 L/h; ion source Gas1, 55 L.h-1; ion source Gas2, 50 L.h-1; temperature, 450 oC; 
collision Gas 6 L.h-1.  The MRM transitions of 6-hydroxy chlorzoxazone were m/z 
183.8→119.8 and 183.8→148.1; and those of 6-hydroxy chlorzoxazone-d2 were 
187.6 → 121.9 and 187.6 → 149.8.  The assay was also linear, precise and accurate. 
3.2.5 Determination of in vitro kinetics of HBUP formation.    
Following the determination of the concentration of HBUP in HLMs and HepaRG 
cells, the rate of formation of HBUP was calculated.  The in vitro kinetic parameters 
of HBUP formation, km (apparent Michaelis-Menten constant), Vmax (the maximal 
velocity) and CLint (intrinsic clearance), were estimated using GraphPad Prism 
version 7.0 (GraphPad Software Inc., La Jolla, CA).  The appropriateness of fit was 
assessed by the sum of squares of residuals, and the standard errors of the parameter 
estimates.   
 
110 
 
3.2.6 PBPK Simulation 
IVIVE of HBUP exposure after single and multiple doses of 150-mg oral bupropion in 
obese volunteers were performed using Simcyp® simulator version 15.1.  The 
demographic characteristics of donors Table 3.1 were used to match the donors of 
livers with respect to age, BMI and gender.  The input parameters including 
physicochemical properties of HBUP and CLint have been presented in Table 3.6.  
All other parameters were set to the Simcyp default values of SV-bupropion 
compound file.  Bupropion was used as the substrate and the CYP2B6-mediated 
formation of HBUP was added as the only metabolite.  The other pathways leading to 
the biotransformation of BUP to EB and TB were not included, hence changes in BUP 
exposure was not reflective of BUP total clearance.  Ten trials in 10 virtual subjects 
were simulated and the overall means of Tmax, Cmax and AUC compared between 
NoNAFLD and the NAFLD groups.  The first order absorption model with a full 
PBPK model was used to perform the simulations. 
 
3.2.7 Statistical Analysis 
Statistical analyses were carried out using SAS software version 9.3 (SAS Institute 
Inc., Cary, NC) and graphs were generated using GraphPad Prism version 7.0.  The 
median together with the minimum and maximum values were expressed as: median 
(minimum - maximum).  Differences between groups were evaluated using Mann-
Whitney U and Kruskal-Wallis tests for groups with two and greater than two 
categories respectively.  Both tests, which are nonparametric, were used because they 
do not require the normality distribution assumption of data required by parametric 
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approaches like T-test and ANOVA (analysis of variance).  Statistical differences 
were considered significant at the P < 0.05 level. 
 
3.3 Results 
3.3.1 Donor demographics and liver characterization.  
Table 3.1 shows the demographics of 90 donors of the liver tissues, vendor-supplied 
diabetic labels, results of the NAFLD characterization, and results of genotyping.  The 
median age and BMI were respectively 49 years and 31 kg.m-2 suggesting an obese 
adult population.  The demographic distribution was approximately equal in all 
categories of diabetes and NAFLD.  Using generally accepted algorithms for NAFLD 
classification (Kleiner et al., 2005, Kleiner and Makhlouf, 2016) the livers were 
categorized into NoNAFLD (n=29), NAFL (n=34) and NASH (n=27).  The 
NoNAFLD group was therefore designated as the control group.  The NoNAFLD 
group had steatosis level of < 5% in the hepatocytes and a median NAS score of 1, 
compared with the NAFL and NASH groups with higher hepatic content of fat and > 1 
median NAS score.  
With the aid of our previously developed logistic model, the diabetic status of the 
livers were confirmed: True nondiabetic (n = 36), True diabetic (n = 38), false 
nondiabetic (n=8) and false diabetic (n=8).  In all analyses where diabetic and non-
diabetic groups were compared, the misclassified ones were excluded.  
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3.3.2 Activity of CYP2B6 in HLM.  
The rate of formation of HBUP was used as a probe to measure the activity of 
CYP2B6.  Though other pathways like the carbonyl reductase are involved in the 
metabolism of BUP (Connarn et al., 2015), the formation of HBUP is mainly mediated 
via the CYP2B6 pathway (Faucette et al., 2000, Hesse et al., 2000) and hence used for 
phenotyping its activity.  The activity of CYP2B6 in the 90 HLMs were determined at 
10, 50, 100, 400, 800 and 1600 uM of bupropion.  Initial analysis was however done 
with the activity measures at 10, 100 and 400 uM bupropion in line with reported km 
values Table 3.7.  Activities were compared without the CYP2B6*5 and CYP2B6*6 
variants.  Though their impact on BUP disposition is not significant, this was done to 
minimize confounding by their reduced in vitro activity and to balance the proportion 
in the three NAFLD groups. 
The activity of CYP2B6 was higher in the nondiabetic group compared with the 
diabetic group.  Similarly, the false diabetic group had higher CYP2B6 activity 
compared to the false nondiabetic group (Table 3.8).  These differences were however 
not significant.  On the other hand, the activity was significantly different among the 
NALD groups (p <0.01), with the NoNAFLD group having higher activity. 
In the next step of the analyses, the HLMs with misclassified diabetes status were 
removed to prevent them from confounding the analysis.  Then the effect of NAFLD 
was compared in the diabetic and nondiabetic groups (Table 3.9). Again, activity was 
significant (p<0.03) among the NAFLD group.  The trend of decrease in activity for 
NAFLD was: NoNAFLD > NAFL > NASH in the nondiabetic group, but NoNAFLD 
> NASH > NAFL in the diabetic group.  Consequently, the highest activity was 
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observed in the nondiabetic-NoNAFLD group and lowest was found in the diabetic-
NAFL group.  This suggested that the presence of diabetes could be a potential 
aggravator of NAFLD and could confound the detection of the influence of NAFLD 
on CYP2B6.  
3.3.3 Kinetics of CYP2B6-mediated HBUP in HLMs.  
The kinetics of HBUP in the HLMs were determined using the Michaelis-Menten 
equation.  The km, Vmax and CLint were estimated. Graphical inspection showed that 
some of the HLMs did not attain saturable rates of HBUP formation as observed in 
previous study(Faucette et al., 2000).  Those HLMs had very high km values > 1000 
uM.  To improve the reliability of our analysis, a subset of the livers (Table 3.2) with 
km ≤ 2x130 uM were compared (Faucette et al., 2000).  The results of the kinetic 
analysis (Table 3.3) showed that the Vmax decreased in the fashion: 
NoNAFLD>NAFL>NASH; whereas the km increased in the order: 
NoNAFLD<NAFL<NASH.  The decrease in Vmax was not statistically significant, 
but the increase in km was (p<0.041).  The CLint therefore was approximately 2-fold 
lower in both NAFL and NASH groups.  
3.3.4 mRNA Expression of CYP2B6, CAR and PXR in HLM.  
The mRNA level of CYP2B6 decreased in the fashion: NoNAFLD > NAFL > NASH, 
but was not statistically significant (Table 3.9).  The fold change in 
NoNAFLD/NAFLD, did not correspond with the changes in the kinetic parameters. 
Similarly, changes in mRNA of CAR and PXR did not correspond with changes in 
CYP2B6 mRNA and kinetics.  This suggests that mRNA levels may not reflect 
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CYP2B6 kinetic parameters adequately and may mislead the detection of the influence 
of NAFLD on CYP2B6 if solely relied upon. 
3.3.5 HepaRG Cell Lines.  
In view of the heterogeneity of the HLMs, the HepaRG cell lines was used as a 
homogenous system to confirm qualitatively and quantitatively the effect of fat 
content on CYP2B6 expression and activity.  Steatosis was induced in the HepaRG, 
and the accumulation of fatty acids was confirmed using Oil Red O staining and UV-
spectrophotometry (Figure 3.1).  The measurement of the Total AKT/Phospho AKT 
(results not shown) showed a reduced insulin response in the FA-treated cells.  
Because CYP2E1 enzyme expression and activity is elevated under steatotic 
conditions (Chalasani et al., 2003, Aljomah et al., 2015), it was used as an endogenous 
control to confirm induction of steatosis by monitoring the formation of 6-
hydroxychlorzoxazone (6-OH CZ).  In the FA-treated cells, the chlorzoxazone 
hydroxylase activity was about 4-times higher compared to the control suggesting a 
viable steatotic tool for further investigation. 
Qualitatively consistent with the HLM data, the fatty-acid-loaded HepaRG cells 
showed significantly lower activity compared to control (Figure 3.2).  The Vmax was 
47% lower in the FA-treated group.  However, the km was 3.5-fold higher in the FA-
treated.  Consequently, CLint was 5-fold lower in the FA-treated group.  Thus, 
quantitatively, the HepaRG cells amplified the effect of steatosis in the HLMs. 
Furthermore, the mRNA expression of CYP2B6, CAR and PXR were also 
significantly reduced in fatty-acid-loaded HepaRG cells compared to control (results 
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not shown).  
 
3.3.6 Physiologically based pharmacokinetic (PBPK) Simulation. 
The simulated exposure parameters of HBUP via CYP2B6 are presented in Table 3.4 
and the concentration profiles in Figure 3.3. The Cmax was slightly higher in 
NoNAFLD group compared to NAFL and NASH. AUC of HBUP was however 
similar among groups.  Despite the limitations of our simulations (no NAFLD 
population, no data on clearance of HBUP), the results show that a completely 
different findings from our in vitro work is possible in complete human subjects. 
Hence, clinical studies in human subjects would greatly enhance our understanding on 
the influence of NAFLD on CYP2B6.   
 
3.4 Discussion 
CYP2B6 was originally considered an enzyme of minor significance.  However, 
further investigations have shown that it plays both major and minor roles in the 
metabolism of clinically relevant drugs.  Bupropion is one of its major substrates. 
Though bupropion is metabolized into erythrohydrobupropion (EB) and 
threohydrobupropion (TB) by carbonyl reductases, hydroxybupropion is the main 
metabolite and it is formed via the CYP2B6 pathway (Faucette et al., 2000, Hesse et 
al., 2000, Connarn et al., 2015).  It is used in the treatment of depression and smoking 
cessation, and to ensure safety and efficacy, various factors capable of influencing its 
pharmacokinetics like gender, polymorphisms, renal impairment and alcoholic liver 
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diseases (Turpeinen et al., 2007, DeVane et al., 1990, Ilic et al., 2013) have been 
studied.  Other groups have also studied the influence of NAFLD on the activity and 
expression of CYP2B6 in human liver tissues.  The aim of this study, however, was to 
determine the influence of NAFLD on the activity of CYP2B6 and the in vitro kinetics 
of HBUP formation.  To our knowledge, this is the first report of the influence of 
NAFLD on the in vitro kinetics of HBUP formation by CYP2B6. 
 
In this work, we used two in vitro systems, Human Liver tissues and HepaRG cell 
lines, to show that both Vmax and km of CYP2B6-mediated HBUP formation are 
altered in NAFLD.  In the HLMs, the presence of NAFLD caused a modest reduction 
in the Vmax, but a significant increase in the km.  Eventually, the CLint was about 2-
fold lower in the NASH group.  Qualitatively, the findings in the HepaRG system was 
similar to the HLM system, but alteration was more pronounced quantitatively.  This 
is not surprising as cell culture systems have the tendency to exaggerate effects. 
Notwithstanding, our work is in agreement with another study in Sprague−Dawley rats 
fed with a methionine/choline deficient (MCD) diet to induce NASH (Cho et al., 
2016).  The in vitro kinetic parameters determined using the rat liver microsomes 
showed 26 % reduction in Vmax and 2.4 fold increase in Km for the formation of 
HBUP by Cyp2b1 (rat orthologue of human CYP2B6) in the NASH group. 
Contrary to the findings in the HLMs, HepaRG, and the rat studies by Cho et al., 
2016, the differences in CLint between the NoNAFLD and the NAFLD groups did not 
translate into differences in AUC except a slight decrease after simulating single and 
multiple doses of 150-mg BUP.  CLint is one of the parameters that could change in 
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NAFLD.  However, changes in the function and structure of the heart, kidneys and 
other organs (Cassidy et al., 2015, Machado et al., 2012) may also influence the 
overall disposition of a drug.  Therefore, the combined effect of changes in the organs 
and enzymatic activity are relevant to determine the overall disposition of BUP in 
NAFLD.  Our PBPK model attempted to do that, but we did not find enough data in 
the literature to recapitulate NAFLD in the virtual population.  This did not allow us to 
account for possible changes in organs in NALF and NASH.  Notwithstanding, our in 
vitro findings highlight the potential of NALFD to alter CYP2B6-mediated HBUP 
kinetics like ALD (Toshikuni et al., 2014, DeVane et al., 1990), which is similar to 
NAFLD, but caused by significant alcohol consumption. 
In addition to the above, our work shows that the heterogeneity of NAFLD and the 
variableness of expression and activity of CYP2B6 may impair detection of the 
influence of NAFLD on CYP2B6.  Hence, the need to account for reasonable amount 
of the variability in CYP2B6.  We accounted for diabetes because it is closely 
associated with NAFLD (Anstee et al., 2013) and could potentially confound it.  
HLMs showing non-saturable kinetics were excluded from analysis to prevent 
confounding (Faucette et al., 2000).   
This work had some limitations.  Donors of HLMs were predominantly obese adults, 
so we could not evaluate the influence of NAFLD in lean subjects.  Secondly, we 
could not account for all polymorphisms in our dataset, as this was impractical. 
However, the high frequency variants with potential to alter in vitro kinetics were 
removed.  Lastly, we did not investigate the carbonyl reductase pathways for the 
formation of EB and TB, hence, the CLint determined was more relevant to the 
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CYP2B6-mediated formation of HBUP.  
In summary, we investigated the effect of NAFLD on CYP2B6 using HLMs and 
HepaRG cell lines.  We observed that the Vmax was modestly reduced, and km 
significantly increased, and CLint reduced in NAFL and NASH HLMs.  Qualitatively, 
the HepaRG findings corroborated the finding in the HLM in the NAFL group.  This 
investigation is hoped to contribute to our current knowledge on the influence of 
NAFLD on CYP2B6-mediated HBUP in vitro kinetics; and offers some basis for 
further studies in a clinical trials.  
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3.6 Tables 
 
Table 3.1 Demographic characteristics, diabetes status, liver biopsy grade.  
Demographic characteristics, diabetes status, liver biopsy grade, and CYP2B6 
genotypes of the donors of human liver tissues. 
 
Variable 
 
Category 
 
NoNAFLD 
(n=29) 
 
NAFL       
(n = 34) 
 
NASH 
(n = 27) 
 
Overall 
(n=90) 
Age N/A 49 (21-78) 53.5 (33-56) 49 (33-74) 51 (21-78) 
BMI N/A 29 (19-89) 31 (17-70) 32 (22-52) 31 (17-89) 
Gender 
Female 13 (14.4) 19 (21.1) 14 (15.6) 46 (51.1) 
Male 16 (17.8) 15 (16.7) 13 (14.4) 44 (48.9) 
Ethnicity 
Caucasian 21 (23.3) 30 (33.3) 25 (27.8) 76 (84.4) 
African American 7 (7.8) 1 (1.1) 1 (1.1) 9 (10.0) 
Hispanics 1 (1.1) 3 (3.3) 1 (1.1) 5 (5.6) 
Diabetes 
Nondiabetic 13 (14.4) 19 (21.1) 12 (13.3) 44 (48.9) 
Diabetic 16 (17.8) 15 (16.7) 15 (16.7) 46 (51.1) 
Liver 
histology 
Steatosis 0 (0-0) 1.5 (1-3) 2 (1-3) 1 (0-3) 
Lobular 
inflammation 
1 (0-2) 1 (0-2) 1 (1-3) 1 (0-3) 
Hepatocyte 
ballooning 
0 (0-1) 0 (0-2) 1 (1-2) 0 (0-2) 
NAS score 1 (0-3) 3 (1-5) 5 (3-7) 3 (0-7) 
CYP2B6*5 
*1*1 26 (28.9) 26 (28.9) 22 (24.4) 74 (82.2) 
*1*5 2 (2.2) 8 (8.9) 4 (4.4) 14 (15.6) 
*5*5 1 (1.1) 0 1 (1.1) 2 (2.2) 
CYP2B6*6 
*1*1 11 (12.2) 18 (20.0) 13 (14.4) 42 (46.7) 
*1*6 15 (16.7) 15 (16.7) 12 (13.3) 42 (46.7) 
*6*6 3 (3.3) 1 (1.1) 2 (2.2) 6 (6.7) 
Data presented as median (minimum - maximum) or frequency (percentage of total 
number of liver tissues). NAS, nonalcoholic fatty liver disease activity score. N/A, not 
applicable. 
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Table 3.2 Demographic characteristics of a subset of donor livers.  
Demographic characteristics of a subset of donor livers used to determine final in vitro 
kinetic parameters (km, Vmax, CLint) of hydroxybupropion (HBUP) formation 
CYP2B6-mediated hydroxylation of bupropion (BUP). 
 
Variable 
 
Category 
 
NoNAFLD 
 
NAFL 
 
NASH 
 
Age NA 41 (28-62) 53 (36-69) 48 (39-68) 
BMI NA 27 (19-50) 31 (17-37) 34 (26-50) 
Gender 
Female 3 (27.27) 2 (28.57) 3 (42.86) 
Male 8 (72.73) 5 (71.43) 4 (57.14) 
Ethnicity 
Caucasian 8 (72.73) 6 (85.71) 6 (85.71) 
African American 
(AA) 
2 (18.18)* 0 0 
Hispanics 1 (9.09) 1 (14.29) 1 (14.29) 
Diabetic 
Nondiabetic 3 (27.27) 5 (71.43) 2 ( 28.57) 
Diabetic 8 (72.73) 2 (28.57) 5 (71.43) 
Liver 
histology 
Steatosis 0 (0-0) 1 (1-3) 2 (1-3) 
Lobular inflammation 1 (0-2) 1 (0-2) 1 (1-3) 
Hepatocyte ballooning 0 (0-0) 0 (0-1) 1 (1-2) 
Fibrosis 1 (0-2) 1 (0-3) 0 (0-1) 
NAS score 1 (0-2) 3 (2-4) 4 (3-7) 
 
*Only the NoNAFLD group had African Americans (AA). However, removing AA 
did not alter the kinetics, maintained in the final analyses.  
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Table 3.3 In vitro kinetic parameters of CYP2B6.  
In vitro kinetic parameters of CYP2B6-mediated hydroxybupropion (HBUP) formation in human liver microsomes. 
Values reported as median (min - max).  
 
NAFLD Lesion Vmaxa Kmb* Clintc  
Fold Change in Clint 
(NoNAFLD/NASH) 
NoNAFLD (n=11) 109.2 (26.41-350.8) 142.7 (66.38-240.2) 0.77 1 
NAFL  (n=7) 89.41 (22.97-349.8) 239.3 (128.2-247.7) 0.37 2.05 
NASH  (n=7) 73.38 (18.17-172.4) 218.1 (160.9-244.2) 0.34 2.27 
* Kruskal Wallis , p-value <0.041; a, Vmax pmoles.min-1.mg microsomal protein-1;  b, Km in units of micromolar 
(uM); c, CLint = Vmax/km  in units of uL.min-1.mg microsomal protein-1  
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Table 3.4 Simulated exposure parameters of hydroxybupropion.  
Simulated exposure parameters of hydroxybupropion after single and multiple doses 
of 150-mg oral bupropion using Simcyp simulator. 
The AUC0-inf was estimated for single doses; and AUC0-504 hrs for multiple doses. 
 
 
 
 
 
 
 
 
 
 
 
Dosing Substrate   TMax (h) CMax (mg/L) AUC (mg/L.h) 
Single  Hydroxybupropion 
NoNAFLD 4.32 0.10 2.79 
NAFL 5.53 0.09 2.68 
NASH 6.03 0.09 2.67 
Multiple Hydroxybupropion 
NoNAFLD 5.50 0.19 6.52 
NAFL 8.25 0.18 6.74 
NASH 8.25 0.18 6.78 
 
130 
 
 
Figure 3.1 Lipid content of control and fatty acid (FA) loaded HepaRG cells.  
Evaluation of the lipid content of control and fatty acid (FA) loaded HepaRG cells 
(A and B) Oil Red O (ORO) staining. Intracellular lipid accumulation was not 
observed in control (A). However, because the treatment group (B) was loaded with 
palmitate and oleate (1:2), lipid accumulation was observed after ORO staining. (C) 
Spectrophotometric assessment of intracellular lipid content (** TTest, p < 0.001). 
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Figure 3.2 Representation of kinetic profile of CYP2B6.  
Representation of  kinetic profile of CYP2B6-mediated formation of hydroxybupropion:    
Upper panel: In NoNALFD, NAFL and NASH human liver microsomes (HLMs). Lower panel: In control and steatotic HepaRG cell 
lines. 
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Figure 3.3 Simulation of the plasma concentration time curve of HBUP.  
Simulation of the plasma concentration time curve of Hydroxybupropion (HBUP) in 
NoNAFLD, NAFL and NASH donors after administration of 150-mg of bupropion 
single (upper graph) and multiple (lower graph) doses. 
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3.7 Supplementary Information 
 
Table 3.5  Sequences of primers for qRT-PCR 
 
Gene Forward primer Reverse Primer 
CYP2B6 ATGGGGCACTGAAAAAGACTGA AGAGGCGGGGACACTGAATGAC 
CAR AGATGGAGCCCGTGTGGG GGTAACTCCAGGTCGGTCAGG 
PXR GCTGACAGAGGAGCAGCGGATGA CCCTGGCAGCCGGAAATTCTT 
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Table 3.6 PBPK input parameters.  
Summary of parameters for simulating exposure of Hydroxybupropion (HBUP) after administering 150-mg of bupropion (BUP).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Parameters were obtained from Drugbank: https://www.drugbank.ca/metabolites/DBMET00277 (accessed on 3/09/2018); ** Value obtained by dividing the 
default Simcyp value (74.1 L/h) by 2. This was done to obtain half-life of approximately 20 hrs for HBUP 
 
Category Parameter NoNAFLD NAFL NASH Reference 
Physicochemical 
properties (BUP) 
Molecular weight 239.74 239.74 239.74 Simcyp 
log P 3.4 3.4 3.4 Simcyp 
Compound type 
monoprotic 
base 
monoprotic 
base 
monoprotic 
base 
Simcyp 
pKa 8.02 8.02 8.02 Simcyp 
B/P 0.82 0.82 0.82 Simcyp 
Physicochemical 
properties 
(HBUP) 
Molecular weight 255.74 255.74 255.74 Drugbank* 
log P 2.22 2.22 2.22 Drugbank* 
Compound type 
monoprotic 
base 
monoprotic 
base 
monoprotic 
base 
  
pKa 7.65 7.65 7.65 Drugbank* 
B/P 0.55 0.55 0.55 Simcyp Predicted  
Absorption Absorption type 
First-order 
absorption 
model 
First-order 
absorption 
model 
First-order 
absorption 
model 
  
Distribution Distribution model 
Full PBPK 
model 
Full PBPK 
model 
Full PBPK 
model 
  
Elimination 
(Bupropion) 
CYP2B6 CLint (nL.min-1. 
mg microsomal protein-1) 
770 370 340 Experimental 
Elimination 
(HBUP) 
CLiv (L/h) 37.05 37.05 37.05 Simcyp** 
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Table 3.7 Reported kinetics of CYP2B6.  
Reported kinetics of CYP2B6-mediated formation of hydroxybupropion (HBUP) from 
bupropion (BUP) in human liver microsomes (HLM).   
 
No N Vmax Km Clint Study 
1 HLM 105±3.4 198±18 0.53 (Skarydova et al., 2014) 
2 HLM (n=105) 53.3 
 (12.8 - 333.5) 
73.4 
(17.1-393.3) 
0.77 
(0.13-5.22) 
(Gao et al., 2017) 
3 HLM 131.2±5.8 87.9±20.2 1.49 (Connarn et al., 2015) 
4 HLM (n=5) 739.5 ± 440.6 130.2±22.0 5.68 (Faucette et al., 2000) 
5 HLM (n=4) 3623±1520 89±14 40.7 (Hesse et al., 2000) 
 
n= number of human liver tissues used in study.
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Table 3.8  Summary of mRNA expression and activity of CYP2B6 (I) 
 
 
A: The diabetic group was compared.  
B: The NAFLD group was compared. * Kruskal Wallis, p-value <0.01; 
A 
Variable 
NonDiabetic (ND) 
(n=31) 
Diabetic (D) (n=34)  
False nondiabetic 
(n=6) 
False Diabetic (n=8) 
Fold change 
(ND/D) 
CYPB6 activity (10 uM) 1.18 (0.2-45.85) 0.77 (0.27-30.2) 1.04 (0.28-8.16) 1.01 (0.25-92.6) 1.53 
CYPB6 activity (100 uM) 6.49 (0.45-256.5) 4.41 (0.83-172) 6.24 (0.87-47.6) 6.69 (1.08-467.5) 1.47 
CYPB6 activity (400 uM) 14.65 (1.19-459.5) 9.98 (2.11-281) 13.85 (2.41-89.55) 17.3 (3.33-726) 1.47 
CYP2B6 mRNA 1.76 (0.04-58.15) 0.52 (0.02-47.56) 0.26 (0.08-7.9) 0.3 (0.01-68.68) 3.38 
PXR mRNA 1.49 (0.23-7.74) 1.36 (0.12-6.18) 1.89 (0.45-4.83) 1.1 (0.01-4.8) 1.10 
CAR mRNA 1.67 (0.03-4.61) 1.67 (0.04-23.48) 1.3 (0.38-4.33) 1.22 (0.01-5.99) 1.00 
B 
     
Variable NoNAFLD (n=24) NAFL (n=32) NASH (n=23) 
Fold Change 
(NoNAFLD/NASH)  
CYPB6 activity (10 uM)* 1.78 (0.33-45.85) 0.6 (0.2-10.95) 0.92 (0.28-92.6) 1.93 
 
CYPB6 activity (100 
uM)* 
11.62 (1.22-256.5) 3.41 (0.45-91.3) 5.62 (0.87-467.5) 2.07 
 
CYPB6 activity (400 
uM)* 
27.93 (2.81-459.5) 7.33 (1.19-225) 12.65 (2.41-726) 2.21 
 
CYP2B6 mRNA 1.36 (0.1-59.17) 0.63 (0.01-30.21) 0.45 (0.02-68.68) 3.02 
 
PXR mRNA 1.53 (0.16-6.18) 1.41 (0.01-7.74) 1.09 (0.12-4.83) 1.40 
 
CAR mRNA 1.98 (0.21-23.48) 1.94 (0.01-6.67) 1.11 (0.04-22.84) 1.78 
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Table 3.9 Summary of mRNA expression and activity of CYP2B6 (II).  
Values reported as median (min - max). Summary statistics of overall levels of mRNA expression and activity of CYP2B6. 
Values reported as median (min - max). 
 
  Variable NONAFLD (n=11/9) NAFL (n =13/13) NASH (n=10/9) 
Fold Change 
(NONAFLD/NASH) 
Diabetic 
CYPB6 activity (10 uM)* 1.74 (0.33-30.2) 0.46 (0.27-2.38) 1.02 (0.33-9.66) 1.71 
CYPB6 activity (100 uM)* 10.48 (1.22-172) 2.73 (0.83-15.7) 5.85 (1.72-66.7) 1.8 
CYPB6 activity (400 uM)* 22.2 (2.81-281) 5.65 (2.11-32.75) 12.7 (6.39-122) 1.75 
CYP2B6 mRNA 1.63 (0.12-47.56) 0.45 (0.03-7.98) 0.19 (0.02-4.02) 8.58 
PXR mRNA 2.02 (0.16-6.18) 1.63 (0.29-2.78) 1.09 (0.12-2.5) 1.85 
CAR mRNA 2.08 (0.46-23.48) 2.09 (0.24-6.67) 1.02 (0.04-22.84) 2.04 
Nondiabetic 
CYPB6 activity (10 uM)* 1.81 (0.36-45.85) 1.18 (0.2-10.95) 0.72 (0.41-6.22) 2.51 
CYPB6 activity (100 uM)* 12.75 (1.93-256.5) 6.49 (0.45-91.3) 4.78 (1.74-37.7) 2.67 
CYPB6 activity (400 uM) 33.65 (4.28-459.5) 14.65 (1.19-225) 12.45 (4.44-69.55) 2.7 
CYP2B6 mRNA 0.38 (0.1-58.15) 2.37 (0.05-30.21) 0.83 (0.04-5.41) 0.45 
PXR mRNA 1.04 (0.23-3.84) 1.94 (0.61-7.74) 1.46 (0.3-2.41) 0.71 
CAR mRNA 2.26 (0.21-4.61) 2.3 (0.03-4.31) 0.86 (0.29-3.63) 2.63 
 
*Kruskal Wallis, p-value <0.03 
The diabetic and NAFLD groups were simultaneously compared. 
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Table 3.10 Summary of mRNA expression and activity of CYP2B6 
Summary of mRNA expression and activity of CYP2B6 in the subset of human liver 
microsomes (HLM) used to determine the in vitro kinetics of CYP2B6-mediated 
hydroxybupropion (HBUP) formation. Values reported as median (min - max). 
 
 
 
 
Variable 
NoNAFLD 
(n=11) 
NAFL (n=7) NASH (n=7) 
Fold Change 
(NoNAFLD/NASH) 
CYPB6 activity (10 uM) 7.89 (1.43-30.2) 4.28 (0.25-10.95) 3.59 (0.92-9.66) 2.20 
CYPB6 activity (100 uM) 47.6 (8.99-172) 31.15 (1.08-91.3) 23.2 (5.11-66.7) 2.05 
CYPB6 activity (400 uM) 89.55 (17.55-281) 64.35 (3.33-225) 45.85 (11.25-122) 1.95 
CYP2B6 mRNA 3.15 (0.1-47.56) 2.37 (0.04-27.51) 0.11 (0.02-5.41) 28.64 
PXR mRNA 0.86 (0.23-4.02) 1.86 (0.29-3.32) 1.49 (0.52-2.14) 0.58 
CAR mRNA 1.65 (0.39-23.48) 2.62 (0.31-6.67) 1.36 (0.04-22.84) 1.21 
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4 MANUSCRIPT IV 
Abstract 
Background and Objectives: PF-5190457 is an inverse agonist of the growth hormone 
secretagogue receptor (hGHS-R1a), that is undergoing clinical trial for treatment of 
alcohol use disorder.  The purpose of this study was to describe the population 
pharmacokinetics (PK) of PF-5190457 and to identify clinical and demographic 
characteristics that influence its PK variability. 
Subjects and Methods. Data on drug dosage, sampling times and plasma 
concentrations were collected retrospectively from two studies: Phase 1a and Phase 
1b.  Thirty five (35) healthy volunteers were enrolled in the Phase 1a, and 12 non-
treatment seeking alcoholic subjects in the Phase 1b trial.  The log-transformed 
concentration-time points were modeled in NONMEM.  The influence of patients' 
demographic and biochemical characteristics were evaluated; and the accuracy and 
precision of the model parameters determined using bootstrapping.  The predictive 
performance of the final model was checked using percentile visual predictive check. 
Results. The pharmacokinetics of PF-5190457 was best described by a one-
compartmental model with first order absorption after oral administration.  The 
estimated typical pharmacokinetic parameters included the absorption rate constant 
(ka, 3.6 h-1), oral clearance (CL/F, 80 Lh-1) and apparent volume of distribution (V/F, 
575 L).  Body weight and serum albumin on V/F reduced the interindividual 
variability (IIV) associated with V/F by ~28%.  Increasing body weight increased V/F, 
whereas increasing serum albumin levels reduced it.  
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Conclusion. PF-5190457 is rapidly cleared from the body.  The V/F of PF-5190457 is 
influenced by body weight and albumin.  We anticipate that this model would serve as 
a guide in designing dosage regimen for future clinical trials with PF-5190457. 
 
Key words:  
Albumin, Alcoholism, Clinical trial, Ghrelin, Growth Hormone, Pharmacokinetics,  
 
Abbreviations: 
ALT: alanine aminotransferase 
 AST: aspartate aminotransferase 
AUDs: Alcohol Use Disorders  
CL/F: oral clearance 
CrCL: Creatinine clearance 
 CWRES: conditional weighted residuals  
DSGRP: Dose group 
DV: observed plasma concentration 
GAM: generalized additive model  
GH: growth hormone  
GOAT: ghrelin O-acyl-transferase  
hGHS-R1a: human growth hormone secretagogue receptor 1a 
IIV: interindividual variability 
IPRED:  individual predicted concentration 
IRB: Institutional Review Board  
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ka: absorption rate constant 
MDRD: modification of diet in renal disease 
NCA: non-compartmental analysis  
OFV: objective function value  
PK: Pharmacokinetics 
PRED: predicted plasma concentration 
UPLC-MS/MS: UPLC/tandem mass spectrometry  
V/F: apparent volume of distribution 
VPC: visual predictive check  
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4.1 Introduction 
Alcohol Use Disorders (AUDs), i.e., alcohol abuse and alcohol dependence 
(alcoholism) is a global concern [1, 2].  Despite its effects on health, economy and 
society, only few medications are approved for treatment in both the United States 
(US) and Europe.  The available medications including naltrexone, disulfiram, and 
acamprosate [3, 4] have not adequately met patients’ needs due to side effects and 
moderate efficacy.  Consequently, there is a crucial need to identify novel 
pharmacological targets to effectively treat AUDs.  
Several drugs including sertraline [5, 6], topiramate [7-9] and baclofen [10, 11] are 
under investigation for the treatment of AUD.  More recently, the ghrelinergic system 
(ghrelin receptor also known as growth hormone secretagogue receptor (hGHS-R1a), 
ghrelin, and ghrelin O-acyl-transferase (GOAT)) is studied due to its involvement in 
alcohol craving [12, 13] and offers a potential for the treatment of AUDs.  
Ghrelin is a gastrointestinal peptide hormone produced mainly in the oxyntic glands of 
the gastric fundus [14].  It serves as the endogenous agonist of the ghrelin receptor. 
The activation of this receptor by ghrelin requires the acylation of its serine-3 residue 
[15, 16] to acyl-ghrelin by GOAT.  The physiological roles of the ghrelin system in 
humans include stimulating the release of growth hormone (GH) [14], regulation of 
food intake, body weight, adiposity, and glucose metabolism [17-19].  In view of its 
roles, the ghrelinergic system is increasingly becoming an attractive pharmacological 
target not only for the treatment of drug addiction [13, 20-22]; but also diabetes [23, 
24], obesity [25], and Parkinson’s disease [26]. 
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PF-5190457, a spiro-azetidino piperidine compound, is an inverse agonist of hGHS-
R1a [27, 18].  Originally developed for the treatment of Type 2 diabetes and obesity, 
PF-5190457 is being repurposed for the treatment of alcoholism.  Due to its promising 
pharmacological and safety profile, it has advanced into human clinical trials.  To 
maximize efficacy and minimize toxicity in subsequent phases of clinical trials of PF-
5190457, a thorough understanding of the clinical PK is essential.  Therefore, the goal 
of this work was to characterize the PK of PF-5190457 in healthy and non-treatment 
seeking alcoholic subjects, and to investigate the covariates that influence PK 
variability.  We hope that the findings in this work will serve as a guide in designing 
subsequent clinical trials in humans.  
4.2 Methods 
4.2.1 Study Design and Patients 
Two Phase 1 studies, in healthy humans (Phase 1a) and in non-treatment seeking 
alcoholic subjects (Phase 1b) were conducted by Pfizer and NIH at l’Hôpital Erasme 
(Brussels, Belgium) and NIH Clinical Center (Bethesda, Maryland) respectively. 
Institutional Review Board (IRB) approval was obtained prior to the beginning of each 
study.  All participants provided written informed consent before enrolment.  Full 
details of the Phase 1a study has been described previously [28]; whereas the Phase 1b 
study has been accepted for publication (Manuscript 2017MP001300RR, Mol. 
Psychiatry). 
Phase 1a was a randomized, double-blind, placebo-controlled study of four cohorts of 
single and divided doses of PF-5190457 or placebo: Cohorts 1 and 2 (9 subjects each) 
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participated in a three-sequence crossover dose-escalation leg with doses of 2, 10, 50, 
100, 300 mg and placebo substitution; Cohort 3 (8 subjects) underwent a standard 
two-sequence crossover investigating gastric emptying after a single 150 mg dose or 
placebo; and Cohort 4 (9 subjects) underwent a two-period, three-sequence incomplete 
block receiving 40 or 300 mg divided dose regimens (with breakfast, 2 h post 
breakfast, with dinner, and 2 h post dinner)  [28].  In the dose-escalating, single-blind, 
placebo-controlled, crossover Phase 1b study, 12 subjects received b.i.d doses of PF-
5190457 (placebo, 50 and 100 mg b.i.d) for 3 days.  PF-5190457 was administered as 
oral suspension in both studies. 
4.2.2 Inclusion and Exclusion criteria for patient enrollment 
A total of 47 adult subjects (age ≥ 18 years) with no clinically relevant abnormalities 
identified in medical history, physical examinations, vital signs, electrocardiograms or 
clinical laboratory tests were selected for both studies. Enrolled subjects in the Phase 
1a study were healthy whereas those in Phase 1b were non-treatment seeking 
alcoholics.  Women enrolled in the studies were non-childbearing.  
4.2.3 Data Collection 
Patient data collected included demographics (e.g., age, race, sex, and body weight) 
and relevant laboratory findings (e.g., alanine aminotransferase, aspartate 
aminotransferase, serum albumin, serum creatinine, total bilirubin).  Additional study 
related characteristics like dose group (DSGRP), alcohol and nicotine use status of 
subjects were included as covariates.  Creatinine clearance was determined from 
serum creatinine using the MDRD (modification of diet in renal disease) equation [29] 
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which accounts for racial and gender differences in serum creatinine levels. 
4.2.4 PK sampling schedule and PF-5190457 Assay 
Plasma concentration samples were collected up to 48 h (non-steady state PF-5190457 
concentrations) for the Phase 1a study; and up to 73.5 h (Steady state PF-5190457 
concentrations) from day 1 to 3 (immediately prior to dosing, 1-2 h. after dosing, and 
approximately 30 mins after day 2) for Phase 1b.  Each sample was quantified using a 
validated UPLC/tandem mass spectrometry (UPLC-MS/MS) method described 
previously.  The limit of quantification of the two assays was 1 ng/mL [28, 30].   
4.2.5 Population PK modeling 
PopPK analysis of the concentration-time data of PF-5190457 was performed using 
the computer program NONMEM (Version 7.3; ICON Development Solution, MD). 
NONMEM allows the implementation of mixed effects (fixed and random) non-linear 
regression models to estimate population means and variance of the population 
pharmacokinetic parameters.  PLTTOOLS (Version 5.5.1, San Francisco, CA) was 
used as an interface throughout the entire modeling process and covariate selection; 
while R (version 3.4.0) and R Studio (Version 1.0.153) were used for graphical 
evaluations.  A stepwise procedure was used to find the model that adequately fit the 
data.  Parameter estimation was done with first order conditional estimation with 
interaction (FOCE -I).  Natural logarithmic-transformed data were used for the 
analysis.  Both one-compartment (ADVAN2, TRANS2); and two-compartments 
(ADVAN4, TRANS4) structural models with or without lag-time were explored.  
Inter-individual variability was modeled using exponential error model: 
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Pi = TVP*EXP(ETA(i)) ..................... (1); 
Where Pi represents the parameter estimate of the ith subject, and TVP is the typical 
parameter estimate in the population, and ETA(i) the random inter-individual 
variability (IIV) in the parameter for the ith participant.  
Residual variability was modeled using an additive proportional log error model: 
$ERROR 
PRED=F  
IPRED=0 
IF(F.GT.0) IPRED=LOG(F) 
Yij = IPRED +SQRT(THETA(4)**2 + THETA(5)**2/F**2)*EPS(1)  
 
Where Yij is the observed jth concentration in the ith subject; F is the model 
prediction for jth concentration on the ith subject; and EPS(1) is the random residual 
effect for the jth concentration; THETA(4) and THETA(5) are fixed effect additive 
and proportional components of the error model respectively. 
4.2.6 Covariate analysis 
Candidate covariates presented in Table 4.1 were selected based on the trial design, 
graphical inspection, significant change in OFV, changes in variance of IIV, and 
physiological plausibility.  The influence of covariates were conducted sequentially 
using forward selection followed by backward elimination by comparing changes in 
objective function value (OFV) of base and covariate models.  Continuous covariates 
 
148 
 
were centred to their median (med) values and modeled using additive (3), 
multiplicative (4) and exponential (5) models in PLTTOOLS:  
TVPi = ((THETA(i) + (THETA(x)-1) * (COV-medCOV)) * EXP(ETAi) ......(3) 
TVPi = ((THETA(i) * (1+THETA(x)-1) * (COV-medCOV)) * EXP(ETAi) ...(4) 
TVPi = ((THETA(i) * (COV/medCOV) * *(THETA(x)-1) * EXP(ETAi) .......(5) 
 
Where COV is the covariate, medCOV is the median value of that covariate; and  
 x = 1 + (the number of THETAs in the $THETA block in the control stream). 
 
4.2.7 Model Selection and evaluation 
Comparison among the structural models as well as models containing covariates was 
based on the OFV, goodness-of-fit plots, estimates of parameters, and visual 
predictive checks.  A p < 0.01, representing a decrease in OFV greater than 6.635 was 
considered statistically significant (degrees of freedom = 1) for selection of a 
structural model and covariates.  The basis of the critical values for model and 
covariate selection is derived from the approximate χ2 distribution of the difference 
between the OFV of two models.  
The statistical significance and accuracy of the model parameters were assessed using 
bootstrapping. Bootstrap datasets (n=1000, stratified by study population) were 
generated by random sampling with replacement from the original dataset; and 
parameters were estimated from each dataset.  A 95 % confidence interval (2.5th and 
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97.5th percentile) of each parameter distribution was then computed. 
Finally, percentile visual predictive check (VPC) was conducted to examine adequacy 
of the model in predicting the original data.  We simulated 1000 replicates of the 
original dataset, and compared the lower quartile, median and upper quartiles of the 
observed and simulated data.  
 
4.3 Results 
4.3.1 Study Population 
Forty-seven subjects were enrolled in both studies.  All subjects in Phase 1a trial were 
males (Caucasian = 90%); whereas in Phase 1b, 90 % were males (Black = 90%).  
Body weight differed significantly between the two studies (t-test, p-value < 0.04), but 
age did not.  The demographic details of all subjects are summarized in Table 4.1. 
Alcohol consumption per week and serum albumin concentration were significantly 
higher in Phase 1b subjects (Mann Whitney, p <0.001).  There was no major 
differences in the distribution of other laboratory tests Table 4.1 between study 
subjects. 
4.3.2 Pharmacokinetic Population Model 
A total of 1354 data points were included in the analysis. A one-compartment model 
with first-order absorption from the gastrointestinal tract adequately described the 
data.  Addition of a two-compartment model did not improve fit (increased OFV > 
6.635).  The overall model fitting to the data was satisfactory (r2=0.95, p-value < 
0.001), as shown in Figure 4.1.  The best-fit population PK parameter estimates and 
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the bootstrap median (95 % confidence intervals) of the base model are shown in 
Table 4.2.  The oral clearance was ~80 Lhr-1, oral volume of distribution 575 L, and 
t1/2 approximately 5 h.  The inter-individual variability (IIV) of CL/F and Vd/F were 
less than 30%.  The rate of absorption was however imprecise because few 
concentration data points were available during the absorption phase of PF-5190457. 
4.3.3 Covariate Analysis 
The influence of each covariate on the PK parameters was tested.  Based on the trial 
design, the sex covariate was not considered though it appeared significant.  This is 
because the study population was predominantly males (~98 %).  Also, since the 
Phase 1a study was carried out in healthy subjects (who were predominantly white); 
and Phase 1b in non-treatment seeking alcoholic subjects (who were predominantly 
blacks), RACE was not considered as a potential covariate due to the possible 
confounding by the differences in alcohol consumption by the two groups.  
Graphical inspection and evaluation using a generalized additive model (GAM) 
showed a significant association (p < 0.03) between interindividual variability (ETAs 
of CL/F, V/F and Ka), body weight (WEIGHTKG) albumin (ALBUMIN) (Figure 
4.2).  In a univariate analysis, DSGRP on V/F significantly reduced the OFV (ΔOFV = 
30) along with ALBUMIN and body WEIGHTKG (Supplementary Table 4.4 : 
Table 4.6).  Further evaluation of covariates resulted in no significant change in OFV 
after addition of ALBUMIN and WEIGHTKG (on V/F) to the base model (with 
DSGRP on V/F).  The final covariate model based on forward selection was DSGRP, 
ALBUMIN and WEIGHTKG on V/F. Backward elimination and examination of 
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changes in IIV showed that a base model with ALBUMIN and WEIGHTKG on V/F 
significantly reduced the OFV and the IIV associated with V/F by ~28% compared to 
one containing DSGRP which changed OFV significantly, but reduced the IIV on V/F 
by ~21% (Supplementary Table 4.7).  In addition, since the covariates (WEIGHTKG 
and ALBUMIN) were physiologically relevant to V/F, this model was selected as the 
final covariate model and presented below (model 6):  
V
F  = THETA2 ∗ +
WEIGHTKG
78.3 
0.85 + ALBUMIN4.32 
−4.48; … … … … … … . . 6 
 
Where V/F is the apparent volume of distribution (L); THETA(2) is 279.53 L; 
WEIGHTKG is body weight in kg; and ALBUMIN is serum albumin in g/dL. The 
final PK parameters for the full model are presented in Table 4.3. 
This model suggests that the typical value of V/F of a median weight (78.3 kg) 
individual with median albumin level of 4.32 g/dL is 559 L.  This value will increase 
with increase body weight (when albumin is 4.32 g/L).  On the other hand, the V/F 
will decrease with increasing serum albumin levels (when body weight is 78.3 kg). 
4.3.4 Model Evaluation 
The goodness of fit plots for the base and full models are shown in Figure 4.1.  The 
plot of predicted (PRED) and observed (DV) shows symmetry of points about the line 
of unit slope.  The relative tightness of points was improved when individual predicted 
values (IPRED) were plotted against DV.  The conditional weighted residuals 
(CWRES) [31] were approximately distributed around CWRES=0, but showed a 
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slight trend towards an additional compartment. Notwithstanding, the one-
compartmental model was adequate for the model.  
The median estimates and nonparametric 95 % CIs from the bootstrap analyses for 
fixed effect and IIV parameters were in a 1:1 ratio indicating that the parameter 
estimates in the final models were accurate, precise and statistically significant.   
The results from the VPC evaluations Figure 4.3 suggested that there was good 
agreement on the time course and central tendency (median) between distributions of 
observed and simulated data.  The lower quartile, median and upper quartile of the 
observed concentration data were in agreement with the simulated data.  
4.4 Discussion 
PF-5190457 is an inverse agonist of the growth hormone secretagogue receptor 
(hGHS-R1a), believed to reduce alcohol craving.  The purpose of this study was to 
describe the population pharmacokinetics of PF-5190457 and to identify clinical and 
demographic patient characteristics that influence PK variability. 
Two studies (Phase 1a and Phase 1b) have been conducted recently to characterize the 
pharmacokinetics of PF-5190457 in healthy and alcoholic subjects separately [28].  In 
both studies, non-compartmental analysis (NCA) was employed to estimate the 
pharmacokinetic parameters.  NCA is relatively fast and does not require any 
assumption of compartments.  However, it has the tendency to under-estimate the 
ascending absorption phase of the plasma-concentration time curve after oral 
administration, or over-estimate the descending elimination phase, especially where 
the sampling interval is larger than the half-life of the drug [32].  Population 
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pharmacokinetics on the other hand, is model-based and is dependent on assumptions 
that drugs move into hypothetical body compartments and permits the incorporation of 
influential covariates on the PK parameters.  PopPK is thus superior and used for 
comprehensive characterization of the PK profile of a drug.  To the best of our 
knowledge, this is the first PopPK work for PF-5190457.  This work presents an early 
characterization of the PK profile of PF-5190457 using combined data from both 
healthy and alcoholic subjects.  
A one-compartment model with first-order absorption from the gastrointestinal tract 
adequately described the data.  Though the CWRES showed a slight trend towards an 
additional compartment, a two-compartmental model did not improve the goodness of 
fit.  This is because the sampling interval between 57 and 72 h was large for the Phase 
1b study, and introduced a pseudo compartment.  The typical PopPK estimates of the 
base model (CL/F, Vd/F,  Ka and t1/2: 80 Lhr-1, 559 L, 3.7 hr-1 and 5 hrs respectively) 
were in agreement with the bootstrap values; thus indicating the stability of the model 
under 1000 bootstrap data sets.  The reported half-life from the previous works 
however was higher (5.5 - 9.8 hrs) [28].  In NCA, the estimation of the half-life is 
heavily dependent on 3-4 observations which determines the terminal slope. 
Notwithstanding, visual inspections of the concentration-time curves 
(Supplementary) shows that plasma concentration falls by 50 % approximately every 
~5 hours.  Overall, PF-5190457 is rapidly absorbed and rapidly cleared from the body, 
supporting a washout period of 72 hrs for the removal of the parent drug from the 
body during a crossover clinical trial.  
We evaluated patient demographics (e.g., age, race, sex, and body weight) and 
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relevant laboratory findings (e.g., alanine aminotransferase, aspartate 
aminotransferase, serum albumin, serum creatinine, total bilirubin) on the PK-
parameters.  Though initially many covariates came important; after further 
optimization of the model, body weight (kg) and serum albumin (g/dL) remained 
significantly important predictors on V/F.  An increase in body weight will result in 
increase in V/F; but an increase in serum albumin will decrease V/F.  This implies 
that, with oral clearance of ~80 Lh-1 and body weight of 78.3 kg, a subject with serum 
albumin level of <3.5 gdL-1 (hypoalbuinemia) will have a V/F > 997 L and a t1/2 of > 
8.6 hrs.  Thus, the V/F may change from 559 L to more than 990 L in 
hypoalbuminemic subjects weighing 78.3 kg.  In future trials and use of PF-5190457, 
it may be necessary to dose subjects based on body weight and serum albumin levels; 
and monitor patients for conditions that could alter serum albumin levels.  This may be 
more necessary in alcoholic individuals with alcoholic liver disease where serum 
albumin level may be altered.   
One limitation of this work was the absence of data points between 57 and 72 hrs for 
the Phase 1b study.  This resulted in a pseudo bi-exponential profile. Also, because the 
studies were carried out in mainly males (98% of subjects), we could not evaluate the 
differences in PK between males and females. Lastly, since the distribution of race 
wasn't uniform in both studies, we could not evaluate the influence of race without 
confounding from alcohol consumption. 
Despite the limitations, our work provides the first PopPK characterization of PF-
5190457 and adequately shows that body weight and serum albumin are important 
predictors of V/F.  We anticipate that our model would serve as a guide in designing 
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dosage regimen for participants of future clinical trials with PF-5190457. 
 
Acknowledgement 
We gratefully acknowledge support from the National Center for Advancing 
Translational Sciences (NCATS) grant UH2/UH3-TR000963 (PIs: Drs Lorenzo 
Leggio and Fatemeh Akhlaghi). We also acknowledge the help of Drs. Ayman El-
Kattan and Santos Carvajal-Gonzalez (Pfizer, Cambridge, MA) and Melanie Schwandt 
(NIH/NIAAA, Bethesda, MD) for their help in providing the data. We are thankful for 
the suggestions of contributors to NONMEM discussions on NMUsers 
(http://www.cognigencorp.com/nonmem/nm/99apr232002.html).  
 
156 
 
4.5 References 
1. Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE et al. 
Global burden of disease attributable to mental and substance use disorders: 
findings from the Global Burden of Disease Study 2010. The 
Lancet.382(9904):1575-86. doi:10.1016/S0140-6736(13)61611-6. 
2. Room R, Babor T, Rehm J. Alcohol and public health. The Lancet.365(9458):519-
30. doi:10.1016/S0140-6736(05)17870-2. 
3. De Sousa A. The Pharmacotherapy of Alcohol Dependence: A State of the Art 
Review. Mens Sana Monographs. 2010;8(1):69-82. doi:10.4103/0973-
1229.58820. 
4. Lee MR, Leggio L. Combined pharmacotherapies for the management of 
alcoholism: rationale and evidence to date. CNS drugs. 2014;28(2):107-19. 
doi:10.1007/s40263-013-0137-z. 
5. Hien DA, Levin FR, Ruglass LM, López-Castro T, Papini S, Hu M-C et al. 
Combining seeking safety with sertraline for PTSD and alcohol use disorders: 
A randomized controlled trial. Journal of consulting and clinical psychology. 
2015;83(2):359.  
6. Pettinati HM, Volpicelli JR, Kranzler HR, Luck G, Rukstalis MR, Cnaan A. 
Sertraline treatment for alcohol dependence: interactive effects of medication 
and alcoholic subtype. Alcoholism: Clinical and Experimental Research. 
2000;24(7):1041-9.  
 
157 
 
7. Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K et 
al. Oral topiramate for treatment of alcohol dependence: a randomised 
controlled trial. The Lancet. 2003;361(9370):1677-85.  
8. Sylvia LG, Gold AK, Stange JP, Peckham AD, Deckersbach T, Calabrese JR et al. 
A randomized, placebo‐controlled proof‐of‐concept trial of adjunctive 
topiramate for alcohol use disorders in bipolar disorder. The American Journal 
on Addictions. 2016;25(2):94-8.  
9. Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K et al. 
Topiramate for treating alcohol dependence: a randomized controlled trial. 
Jama. 2007;298(14):1641-51.  
10. Addolorato G, Leggio L. Safety and efficacy of baclofen in the treatment of 
alcohol-dependent patients. Current pharmaceutical design. 2010;16(19):2113-
7.  
11. Garbutt JC, Kampov‐Polevoy AB, Gallop R, Kalka‐Juhl L, Flannery BA. Efficacy 
and safety of baclofen for alcohol dependence: a randomized, double‐blind, 
placebo‐controlled trial. Alcoholism: Clinical and Experimental Research. 
2010;34(11):1849-57.  
12. Jerlhag E, Egecioglu E, Landgren S, Salome N, Heilig M, Moechars D et al. 
Requirement of central ghrelin signaling for alcohol reward. Proceedings of the 
National Academy of Sciences of the United States of America. 
2009;106(27):11318-23. doi:10.1073/pnas.0812809106. 
13. Leggio L, Zywiak WH, Fricchione SR, Edwards SM, de la Monte SM, Swift RM 
et al. Intravenous Ghrelin Administration Increases Alcohol Craving in 
 
158 
 
Alcohol-Dependent Heavy Drinkers: a Preliminary Investigation. Biological 
psychiatry. 2014;76(9):734-41. doi:10.1016/j.biopsych.2014.03.019. 
14. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a 
growth-hormone-releasing acylated peptide from stomach. Nature. 
1999;402(6762):656-60.  
15. Gutierrez JA, Solenberg PJ, Perkins DR, Willency JA, Knierman MD, Jin Z et al. 
Ghrelin octanoylation mediated by an orphan lipid transferase. Proceedings of 
the National Academy of Sciences. 2008;105(17):6320-5.  
16. Sakata I, Yang J, Lee CE, Osborne-Lawrence S, Rovinsky SA, Elmquist JK et al. 
Colocalization of ghrelin O-acyltransferase and ghrelin in gastric mucosal 
cells. American Journal of Physiology-Endocrinology and Metabolism. 
2009;297(1):E134-E41.  
17. Porteiro B, Diaz-Ruiz A, Martinez G, Senra A, Vidal A, Serrano M et al. Ghrelin 
requires p53 to stimulate lipid storage in fat and liver. Endocrinology. 
2013;154(10):3671-9. doi:10.1210/en.2013-1176. 
18. Bhattacharya SK, Andrews K, Beveridge R, Cameron KO, Chen C, Dunn M et al. 
Discovery of PF-5190457, a Potent, Selective, and Orally Bioavailable Ghrelin 
Receptor Inverse Agonist Clinical Candidate. ACS medicinal chemistry letters. 
2014;5(5):474-9. doi:10.1021/ml400473x. 
19. Tschöp M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature. 
2000;407(6806):908-13.  
20. Dickson SL, Egecioglu E, Landgren S, Skibicka KP, Engel JA, Jerlhag E. The role 
of the central ghrelin system in reward from food and chemical drugs. 
 
159 
 
Molecular and cellular endocrinology. 2011;340(1):80-7. 
doi:10.1016/j.mce.2011.02.017. 
21. Stevenson J, Francomacaro L, Bohidar A, Young K, Pesarchick B, Buirkle J et al. 
Ghrelin receptor (GHS-R1A) antagonism alters preference for ethanol and 
sucrose in a concentration-dependent manner in prairie voles. Physiology & 
behavior. 2016;155:231-6.  
22. Addolorato G, Capristo E, Leggio L, Ferrulli A, Abenavoli L, Malandrino N et al. 
Relationship between ghrelin levels, alcohol craving, and nutritional status in 
current alcoholic patients. Alcoholism, clinical and experimental research. 
2006;30(11):1933-7. doi:10.1111/j.1530-0277.2006.00238.x. 
23. Rudolph J, Esler WP, O'Connor S, Coish PD, Wickens PL, Brands M et al. 
Quinazolinone derivatives as orally available ghrelin receptor antagonists for 
the treatment of diabetes and obesity. Journal of medicinal chemistry. 
2007;50(21):5202-16. doi:10.1021/jm070071+. 
24. Yada T, Dezaki K, Sone H, Koizumi M, Damdindorj B, Nakata M et al. Ghrelin 
regulates insulin release and glycemia: physiological role and therapeutic 
potential. Current diabetes reviews. 2008;4(1):18-23.  
25. Asakawa A, Inui A, Kaga T, Katsuura G, Fujimiya M, Fujino MA et al. 
Antagonism of ghrelin receptor reduces food intake and body weight gain in 
mice. Gut. 2003;52(7):947-52.  
26. Andrews ZB, Erion D, Beiler R, Liu ZW, Abizaid A, Zigman J et al. Ghrelin 
promotes and protects nigrostriatal dopamine function via a UCP2-dependent 
mitochondrial mechanism. The Journal of neuroscience : the official journal of 
 
160 
 
the Society for Neuroscience. 2009;29(45):14057-65. 
doi:10.1523/jneurosci.3890-09.2009. 
27. Cameron KO, Bhattacharya SK, Loomis AK. Small molecule ghrelin receptor 
inverse agonists and antagonists. Journal of medicinal chemistry. 
2014;57(21):8671-91.  
28. Denney WS, Sonnenberg GE, Carvajal-Gonzalez S, Tuthill T, Jackson VM. 
Pharmacokinetics and pharmacodynamics of PF-05190457: The first oral 
ghrelin receptor inverse agonist to be profiled in healthy subjects. British 
journal of clinical pharmacology. 2017;83(2):326-38. doi:10.1111/bcp.13127. 
29. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate 
method to estimate glomerular filtration rate from serum creatinine: a new 
prediction equation. Modification of Diet in Renal Disease Study Group. 
Annals of internal medicine. 1999;130(6):461-70.  
30. Ghareeb M, Leggio L, El-Kattan A, Akhlaghi F. Development and validation of an 
UPLC-MS/MS assay for quantitative analysis of the ghrelin receptor inverse 
agonist PF-5190457 in human or rat plasma and rat brain. Anal Bioanal Chem. 
2015;407(19):5603-13. doi:10.1007/s00216-015-8730-2. 
31. Hooker AC, Staatz CE, Karlsson MO. Conditional Weighted Residuals (CWRES): 
A Model Diagnostic for the FOCE Method. Pharmaceutical Research. 
2007;24(12):2187-97. doi:10.1007/s11095-007-9361-x. 
32. Gabrielsson J, Weiner D. Non-compartmental Analysis. In: Reisfeld B, Mayeno 
AN, editors. Computational Toxicology: Volume I. Totowa, NJ: Humana 
Press; 2012. p. 377-89. 
 
161 
 
 
4.6 Tables 
 
Table 4.1 Demographic and biochemical covariates of subjects 
 
Characteristics Subjects (N) Median Range 
Sex (Male/Female)       
Overall 46/1 
Study 1 35/0 
Study 2 1-Nov 
Race(White/Black/Others) 
Overall 33/13/1 
Study 1 32/2/1 
Study 2 1/11/2000 
Age (YEARS)  
Overall 47 37 19-58 
Study 1 35 37 19-55 
Study 2 12 40 23-58 
Weight (kg) 
Overall 47 78.3 56.60-120.50  
Study 1 35 75.8 56.60-98.20 
Study 2 12 82.9 58.10-120.50 
BMI (kg/m2) 
Overall 47 25.6 18.60 - 38.03 
Study 1 35 25.4 18.60 - 30.30 
Study 2 12 26.09 21.60 - 38.03 
ALT (IU/L) 
Overall 20.165 Jul-59 
Study 1 19.75 9.5 - 59 
Study 2 21.165 7 - 56.67 
ALBUMIN (g/dL) 
Overall 4.32 3.76 - 4.90 
Study 1 4.23 3.76 - 4.79 
Study 2 4.65 4.00 - 4.90 
AST (IU/L) 
Overall 21.665 11.33 - 43 
Study 1 21 12.5 - 43 
Study 2 24.5 11.33 - 41 
Serum Creatinine (mg/dL) 
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Overall  0.9 0.53 - 1.2 
Study 1 0.88 0.68 - 1.18 
Study 2 0.945 0.53 - 1.20 
CRCL (mL/min) 
Overall 125.528 73.97 - 246.64 
Study 1 130.761 76.15 - 172.27 
Study 2 119.884 73.97 - 246.63 
Total Bilirubin (mg/dL) 
Overall 0.64 0.27 - 1.55 
Study 1 0.7 0.3 - 1.55 
Study 2 0.515 0.27 - 1.03 
Alcohol per week (Glass) 
Overall 5 0 - 136.60 
Study 1 3 0 - 12 
Study 2 65.8 37.87 - 136.36 
Nicotine Use 
Overall 1 0 - 6 
Study 1 1 1 - 6 
Study 2   2 0 - 6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
163 
 
   
Table 4.2 Population pharmacokinetic parameter estimates of the base model for PF-
5190457 
 
Parameter Estimate (Final 
Model) 
Bootstrap:  
median (95 % CI) 
Fixed Effects    
CL/F (L/hr) 79.53 79.80 (73.47 - 131.17) 
V/F (L) 575.00 577.00 (521.38 - 985.83) 
Ka (hr-1) 3.62 3.65 (2.58 - 28.70) 
Theta(4); additive component 0.31 0.31 (0.28 - 0.33) 
Theta(5); proportional component 0.56 0.56 (0.43 - 0.85) 
   
Inter-individual Variability (IIV)    
IIV  CL/F, % 26.00 26.18 (18.46 - 54.78) 
IIV  V/F, % 29.00 29.12 (18.96 - 67.74) 
IIV  Ka, % 102.00 102.00 (74.11 - 454.78) 
   
Residual Variability (Epsilon)   
EPS (σ1), % 1, FIXED  
 
CL/F, apparent clearance; V/F, apparent volume of distribution; Ka, absorption rate constant; 
Theta(4), additive component of error model; Theta(5), proportional component of error 
model weighting factor in the residual error; σ1is the residual error variability. 
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Table 4.3 Population pharmacokinetic parameter estimates of the full model 
(base+covariate) for PF-5190457 
 
 
Parameter Estimate (Final 
Model) 
Bootstrap:  
median (95 % CI) 
Fixed Effects    
CL/F (L/hr) 79.58 80.00 (73.49 - 101.00) 
Theta(2)  279.53 280.77 (257.36  - 497.32) 
Ka (hr-1) 3.60 3.66 (2.56 - 19.11) 
Theta(4) 0.31 0.31 (0.28 - 0.33) 
Theta(5) 0.56 0.56 (0.43 - 0.84) 
Theta(6); on body weight (WT) 0.85   
Theta(7); on serum albumin (ALB) -4.48  
   
Inter-individual Variability (IIV)    
IIV  CL/F, % 26.05 26.24 (18.42 - 67.34) 
IIV  V/F, % 21.00 21.27 (13.37 - 82.21) 
IIV  Ka, % 104.19 103.50 (76.13 - 192.38) 
   
Residual Variability (Epsilon)   
EPS (σ1), % 1, FIXED  
   
Covariate model   
V/F (L) Theta(2)*[(WT/78.3)**0.85 + (ALB/4.32)**(-4.48)] 
 
CL/F, apparent clearance; V/F, apparent volume of distribution; Ka, absorption rate 
constant; Theta(4), additive component of error model; Theta(5), proportional 
component of error model weighting factor in the residual error; σ1is the residual error 
variability. 
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4.7 Figures 
 
 
Figure 4.1 Goodness of fit plots for base (top panel) and full model (bottom panel) 
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Figure 4.2 Relationship between ETAs and covariates: Body weight (WEIGHTKG) and 
serum albumin. 
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Figure 4.3 Percentile visual predictive checks. 
Percentile visual predictive checks for base (left hand side) and full (right hand side) 
models. The lower quantile, median and upper quantile of observations (solid lines) 
and simulations (dashed lines) of all data (top panel), data corresponding to 100 mg 
dose in STUDY 1 (middle panel), and data corresponding to 100 mg dose in STUDY 
2 (bottom panel). 
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4.8 Supplementary 
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Figure 4.4 Graphs showing the plasma concentration-time plot of PF-5190457 
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Figure 4.5 Graphs showing the relationship between ETAs and all covariates. 
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Covariate selection (forward selection) based on change in OFV and 
improvement in variance associated with interindividual variability.  
 
Table 4.4 Step 2: Base model + single covariate 
 
Covariate Parameter OF ΔOF CutOff OM-VAR1 OM-VAR2 OM-VAR3
Functional 
Form
p-value
BASE -1071.89 0.00 0.069 0.084 1.046
DSGRP V/F -1101.93 30.04 > 6.63 0.068 0.087 1.051 Exponential 0.00
DSGRP ka -1086.79 14.90 > 6.63 0.068 0.084 0.872 Exponential 0.00
ALBUMIN V/F -1085.55 13.66 > 6.63 0.069 0.063 1.103 Multiplicative 0.000
ALBUMIN V/F -1085.55 13.66 > 6.63 0.069 0.063 1.103 Additive 0.000
STUDY ka -1081.23 9.34 > 6.63 0.067 0.087 0.693 Additive 0.002
STUDY ka -1081.23 9.34 > 6.63 0.067 0.087 0.693 Exponential 0.00
STUDY ka -1081.23 9.34 > 6.63 0.067 0.087 0.693 Multiplicative 0.002
BMI ka -1080.99 9.10 > 6.63 0.055 0.085 1.040 Exponential 0.00
ALBUMIN CL/F -1080.09 8.20 > 6.63 0.055 0.085 1.040 Additive 0.004
ALBUMIN CL/F -1080.09 8.20 > 6.63 0.055 0.085 1.040 Multiplicative 0.004
ALCOHOLPERWEEK CL/F -1080.05 8.16 > 6.63 0.057 0.084 1.050 Additive 0.004
DSGRP V/F -1079.45 7.56 > 6.63 0.069 0.086 1.051 Additive 0.006
AGEYRS V/F -1079.43 7.54 > 6.63 0.068 0.071 1.012 Exponential 0.01
WEIGHTKG V/F -1079.33 7.44 > 6.63 0.068 0.071 1.012 Additive 0.006
STUDY CL/F -1078.45 6.56 < 6.63 0.059 0.084 1.054 Exponential 0.01
STUDY CL/F -1078.45 6.56 < 6.63 0.059 0.084 1.054 Additive 0.010
STUDY CL/F -1078.45 6.56 < 6.63 0.059 0.084 1.054 Multiplicative 0.010
DSGRP ka -1078.38 6.49 < 6.63 0.068 0.083 0.869 Additive 0.011
ALCOHOLPERWEEK V/F -1077.91 6.02 < 6.63 0.069 0.072 1.069 Additive 0.014
CRCL_MDRD ka -1077.88 5.99 < 6.63 0.068 0.085 1.103 Multiplicative 0.014
AGEYRS V/F -1076.34 4.45 < 6.63 0.068 0.075 1.044 Additive 0.035
STUDY V/F -1076.34 4.45 < 6.63 0.069 0.076 1.067 Multiplicative 0.035
STUDY V/F -1076.34 4.45 < 6.63 0.069 0.076 1.067 Additive 0.035
AGEYRS CL/F -1076.20 4.31 < 6.63 0.062 0.084 1.047 Exponential 0.04
WEIGHTKG CL/F -1075.98 4.10 < 6.63 0.062 0.084 1.047 Multiplicative 0.043
WEIGHTKG CL/F -1075.98 4.10 < 6.63 0.062 0.084 1.047 Additive 0.043
TOTBILIRUB V/F -1075.85 3.96 < 6.63 0.068 0.085 1.066 Exponential 0.05  
OF is objective function; ΔOF is change in OF; OM-VAR variance associated with 
CL/F (1), V/F (2), and Ka (3); DSGRP is dose group. Covariate was considered for the 
next step of the analysis if p-value < 0.01. 
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Table 4.5  Step 3. Base model + DSGRP on V/F + single covariate 
 
Covariate Parameter OF ΔOF Cut off OM-VAR1 OM-VAR2 OM-VAR3
Functional 
form
P-value
Base -1101.93 0.00 < 6.63 0.068 0.087 1.051 Exponential 1.000
ALBUMIN V/F -1112.56 10.63 > 6.63 0.069 0.067 1.090 Additive 0.001
WEIGHTKG V/F -1111.56 9.63 > 6.63 0.068 0.070 1.012 Exponential 0.002
WEIGHTKG V/F -1111.44 9.51 > 6.63 0.068 0.070 1.011 Additive 0.002
ALBUMIN CL/F -1110.69 8.76 > 6.63 0.055 0.088 1.048 Multiplicative 0.003
ALBUMIN CL/F -1110.69 8.76 > 6.63 0.055 0.088 1.048 Additive 0.003
ALCOHOLPERWEEK CL/F -1109.70 7.77 > 6.63 0.057 0.088 1.055 Additive 0.005
DSGRP CL/F -1108.81 6.88 > 6.63 0.069 0.088 1.055 Exponential 0.009
WEIGHTKG CL/F -1106.68 4.75 < 6.63 0.062 0.087 1.050 Exponential 0.029
WEIGHTKG CL/F -1106.47 4.54 < 6.63 0.062 0.087 1.050 Additive 0.033
ALCOHOLPERWEEK V/F -1106.39 4.46 < 6.63 0.069 0.078 1.070 Additive 0.035
DSGRP CL/F -1102.09 0.16 < 6.63 0.069 0.087 1.052 Additive 0.688
ALCOHOLPERWEEK CL/F 1166.90 -2268.83 < 6.63 0.072 0.284 1.515 Multiplicative
ALBUMIN V/F -924.68 -177.25 < 6.63 0.109 0.798 20.458 Multiplicative
ALBUMIN CL/F -911.14 -190.78 < 6.63 0.106 1.636 26.595 Exponential
ALBUMIN V/F -859.56 -242.37 < 6.63 0.112 1.303 39.615 Exponential
WEIGHTKG V/F -865.94 -235.99 < 6.63 0.038 0.130 137.206 Multiplicative
WEIGHTKG CL/F -486.88 -615.05 < 6.63 0.003 4.543 620.837 Multiplicative
DSGRP CL/F -759.80 -342.13 < 6.63 0.039 0.642 203346.000 Multiplicative  
OF is objective function; ΔOF is change in OF; OM-VAR variance associated with 
CL/F (1), V/F (2), and Ka (3); DSGRP is dose group. Covariate was considered for the 
next step of the analysis if p-value < 0.01. 
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Table 4.6 Step 4. Base model + DSGRP on V/F + Body weight on V/F + single covariate 
 
Covariate Parmeter OF ΔOF Cutoff OM-VAR1 OM-VAR2 OM-VAR3
Functional 
Form
p-value
Base -1102.6 0 < 6.63 0.068 0.072 1.035 1
ALBUMIN V/F -1124.8 22.21 > 6.63 0.067 0.043 1.085 Exponential 0.0000
ALBUMIN V/F -1123.3 20.65 > 6.63 0.067 0.045 1.094 Multiplicative 0.0000
ALBUMIN V/F -1123.3 20.65 > 6.63 0.067 0.045 1.094 Additive 0.0000
ALBUMIN CL/F -1111.5 8.89 > 6.63 0.055 0.073 1.032 Exponential 0.0029
ALBUMIN CL/F -1110.7 8.09 > 6.63 0.055 0.073 1.031 Additive 0.0044
ALBUMIN CL/F -1110.7 8.09 > 6.63 0.055 0.073 1.031 Multiplicative 0.0044
ALCOHOLPERWEEK CL/F -1110.4 7.79 > 6.63 0.056 0.073 1.038 Additive 0.0052
ALCOHOLPERWEEK V/F -1109.8 7.16 > 6.63 0.068 0.060 1.059 Additive 0.0074
WEIGHTKG CL/F -1107.5 4.85 < 6.63 0.061 0.071 1.035 Exponential 0.0276
WEIGHTKG CL/F -1107.2 4.64 < 6.63 0.061 0.071 1.036 Additive 0.0313
DSGRP CL/F -1103.2 0.60 < 6.63 0.067 0.072 1.035 Additive 0.4391
ALCOHOLPERWEEK CL/F -985.01 -117.61 < 6.63 0.053 0.081 1.131 Multiplicative
WEIGHTKG CL/F -984.83 -117.78 < 6.63 0.054 0.078 1.145 Multiplicative
DSGRP CL/F -980.46 -122.15 < 6.63 0.062 0.079 1.148 Exponential
DSGRP CL/F -979.76 -122.85 < 6.63 0.062 0.080 1.150 Multiplicative
ALCOHOLPERWEEK V/F -851.57 -251.04 < 6.63 0.504 0.125 4.051 Multiplicative  
 
OF is objective function; ΔOF is change in OF; OM-VAR variance associated with 
CL/F (1), V/F (2), and Ka (3); DSGRP is dose group. Covariate was considered for the 
next step of the analysis if p-value < 0.01. 
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Covariate selection (backward elimination) based on change in OFV and 
improvement in variance associated with interindividual variability of V/F 
(ETA(2)).  
 
Table 4.7 Backward elimination 
 
Covariate OF ΔOF DF IIV [ETA(2)] p-value
BASE MODEL -1071.89 0 0 29
WEIGHT+ALBUMIN -1098.15 26.26 2 21 > 0.0001
DSGRP+WEIGHTKG -1102.55 30.66 2 27 > 0.0001
DSGRP+ALBUMIN -1105.14 33.25 2 25 > 0.0001
DSGRP+WEIGHTKG+ALBUMIN -1109.44 37.55 3 23 > 0.0001  
WEIGHTKG is body weight in kg; DSGRP is dose group; IIV [ETA(2)] is 
interindividual variability associated with volume of distribution (V/F). 
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5  CONCLUSION 
 
This work demonstrates the utility of in vitro drug metabolism and population 
pharmacokinetics to elucidate the sources of pharmacokinetic variability. 
 
In the first part of this work (Manuscripts I, II and III), we demonstrated that NAFLD 
influences the in vitro kinetics of CYP2B6-mediated hydroxylation of bupropion.  It 
reduced the Vmax by ~32% and increased the km by ~2 fold.  Consiquently, the 
intrinsic clearance was reduced in NASH human liver microsomes (HLM) by 2.3 fold 
compared to the NoNAFLD HLM.  The HepaRG system, together with available 
findings in Sprague-Dawley rats corroborrated the findings in the HLM.  However, the 
Simcyp simulation suggested a possibly different scenario in vivo.  This may be due to 
lack of an appropriate NAFLD population model for PBPK simulation.  A well-
controlled clinical trial may therefore be necessary to confirm the findings of this 
study. 
In the second part of this work (Manuscript IV), we used population pharmacokinetics 
to characterize PF-5190457, and to identify potential covariates that influence the PK 
variability of PF-5190457.  A one-compartmental model with first order absorption 
after oral administration best described the PK profile of PF-5190457.  The estimated 
typical PK parameters of the base model, including the absorption rate constant (3.6 h-
1), oral clearance (79.53 Lh-1) and apparent volume of distribution (575 L), suggested 
that PF-5190457 is rapidly absorbed and rapidly cleared from the body.  Additionally, 
body weight  and serum albumin reduced the IIV associated with V/F by ~28%.  Body 
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weight and serum albumin were thus identified to be potential sources of PF-5190457 
PK variability.  
We believe this work presents new insights into the influence of NAFLD on CYP2B6-
mediated hydroxylation of bupropion.  Similarly, it gives new information about the 
PK of PF-5190457.  It is hoped that the information will be useful for future studies 
involving CYP2B6 and NAFLD.  We also anticipate that our model for PF-5190457 
would serve as a guide in designing future clinical trials with PF-5190457. 
. 
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6 APPENDIX 
6.1 NONMEM codes for Manuscript IV 
BASE MODEL 
;PF-05190457 was given as oral suspension 
 
$PROBLEM 1CMT WITH ABSORPT PF-05190457 (BASE MODEL) 
 
$DATA 
C:/Users/ENOCH/Documents/4_PKPD_Model/step_5_final_models/DATAFILES/Fi
nalData_PK_COV_ALLSUBJ_V2_orem1a.csv IGNORE=C  
 
$INPUT C SUBJID=DROP ID=PTID TIMEMNS=DROP TIME=TIMHRS ODV 
DV=LNDV MDV CMT EVID AMT=AMTNG ADDL II DSGRP STUDY COHORT 
CPEVENT ALBUMIN ALT AST SCr=DROP CRCL_CG=DROP CRCL_MDRD 
TOTBILIRUB MALE1 AGEYRS WEIGHTKG BMI RACEW 
ALCOHOLPERWEEK NICTINUSE 
 
$SUBROUTINE ADVAN2 TRANS2  
 
$PK 
 
  TVCL = THETA(1) ; specifying the clearance 
  CL = TVCL*EXP(ETA(1)); exponential IIV 
 
   
  TVV = THETA(2)  
  V = TVV*EXP(ETA(2)) exponential IIV 
 
  TVKA = THETA(3) ; specifying the absorption rate constant 
  KA = TVKA*EXP(ETA(3)) ; exponential IIV 
 
  S2=V ; scale paramenter of 1 
 
 
$ERROR (OBSERVATIONS ONLY) 
        PRED=F  
 IPRED=0 
 IF(F.GT.0) IPRED=LOG(F) 
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 Y= IPRED +SQRT(THETA(4)**2 + THETA(5)**2/F**2)*EPS(1)   
    
 
$THETA 
  (0.1,6000,);initial estimate for CL [CL]  
  (0.1,50000,); initial estimate for Vd [V]  
  (0.01,1,) ; initial estimate for KA [KA] 
  (0, 0.1); 
  (0, 0.1); 
 ;(,0.01,); 
 
 
$OMEGA 0.1 0.1 1; diagonal matrix for variance of omegas 1, 2, and 3  
 
$SIGMA 1 FIX 
 
 
$ESTIMATION 
        METHOD=1        PRINT=1         MAXEVALS=9999    NOABORT 
        SIGDIGITS=6     POSTHOC         INTER           MSFO=MSFO.OUTPUTFILE 
 
$COVARIANCE 
$TABLE  ID  EVID  AMT TIME DSGRP STUDY IPRED CWRES NOPRINT 
FILE=ALLRECORDS.TXT 
$TABLE  ID  DSGRP  STUDY  CL V KA ETA1 ETA2 ETA3 FIRSTONLY 
NOPRINT NOAPPEND FILE=FIRSTRECORDS.TXT 
 
 
FULL MODEL (Base + Covariates) 
 
;PF-05190457 was given as oral suspension 
 
$PROBLEM 1CMT WITH ABSORPT PF-05190457 (Full model) 
 
$DATA 
C:/Users/ENOCH/Documents/4_PKPD_Model/step_5_final_models/DATAFILES/Fi
nalData_PK_COV_ALLSUBJ_V2_orem1a.csv IGNORE=C  
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$INPUT C SUBJID=DROP ID=PTID TIMEMNS=DROP TIME=TIMHRS ODV 
DV=LNDV MDV CMT EVID AMT=AMTNG ADDL II DSGRP STUDY COHORT 
CPEVENT ALBUMIN ALT AST SCr=DROP CRCL_CG=DROP CRCL_MDRD 
TOTBILIRUB MALE1 AGEYRS WEIGHTKG BMI RACEW 
ALCOHOLPERWEEK NICTINUSE 
 
 
$SUBROUTINE ADVAN2 TRANS2  
 
 
$PK 
 
  TVCL = THETA(1) ; specifying the clearance 
  CL = TVCL*EXP(ETA(1)); exponential IIV 
 
 TVV = (THETA(2) * (WEIGHTKG / 78.3) ** (0.85)) + (THETA(2) * (ALBUMIN / 
4.32) ** (-4.48))  
  V = TVV*EXP(ETA(2)) exponential IIV 
 
  TVKA = THETA(3) ; specifying the absorption rate constant 
  KA = TVKA*EXP(ETA(3)) ; exponential IIV 
 
S2=V ; scale paramenter of 1 
 
$ERROR (OBSERVATIONS ONLY) 
           PRED=F  
 IPRED=0 
 IF(F.GT.0) IPRED=LOG(F) 
 Y= IPRED +SQRT(THETA(4)**2 + THETA(5)**2/F**2)*EPS(1)   
    
 
$THETA 
  (0.1,6000,);initial estimate for CL [CL]  
  (0.1,50000,); initial estimate for Vd [V]  
  (0.01,1,) ; initial estimate for KA [KA] 
  (0, 0.1); 
  (0, 0.1); 
 
 
$OMEGA 0.1 0.1 1; diagonal matrix for variance of omegas 1, 2, and 3  
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$SIGMA 1 FIX 
 
 
$ESTIMATION 
        METHOD=1        PRINT=1         MAXEVALS=9999    NOABORT 
        SIGDIGITS=6     POSTHOC         INTER           MSFO=MSFO.OUTPUTFILE 
 
$COVARIANCE 
$TABLE  ID  EVID  AMT TIME DSGRP STUDY IPRED CWRES NOPRINT 
FILE=ALLRECORDS.TXT 
$TABLE  ID  DSGRP  STUDY  CL V KA ETA1 ETA2 ETA3 FIRSTONLY 
NOPRINT NOAPPEND FILE=FIRSTRECORDS.TXT 
 
 
